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Summary 
Tuberculosis (TB) has been declared a global health emergency by the World Health 
Organisation, and consequently there is an urgency to develop improved methods of 
diagnosis and treatment. Despite the current TB epidemic, the disease can be treated 
effectively using isoniazid (INH) in combination with other antibiotics. However, INH is 
inactivated in the body by certain drug metabolising enzymes, which may reduce the 
efficacy of TB treatment. The activity of these drug metabolising enzymes, called NAT, 
are in turn reduced by nucleotide changes (SNPs) in the gene. These genetic variants 
(alleles) have been correlated with the rapid- (FA), intermediate- (IA), and slow 
acetylation (SA) enzymatic activity, and one is therefore able to investigate potential 
phenotypic effects via genotypic analyses. 
 
We investigated these genetic changes in the NAT1 and NAT2 genes in individuals from 
the local Coloured community (SAC) since this group has one of the highest TB 
incidences in the country. NAT2 is primarily responsible for the inactivation of INH, 
whilst NAT1 metabolises para-aminosalicyclic acid (PAS) which is used in the treatment 
of drug resistant TB. 
 
The NAT2 results indicated that the NAT2 alleles were not equally represented in three 
local ethnic groups studied, and subsequently the rapid, intermediate and slow acetylation 
activity reflected these differences. However, the relative frequency of these variants in 
the SAC and Caucasian groups were relatively low. These differences require further 
investigation to determine their overall relevance to the NAT2 activity differences 
between groups. 
 
In the case of the NAT1 analysis we also observed differences in the relative frequency of 
various NAT1 alleles between Caucasian and SAC individuals. However, many of these 
NAT1 SNPs and alleles have not as yet been characterised, so effects of these variants are 
currently unknown. Interestingly, the NAT1*4 and NAT1*10 alleles were the most 
prevalent NAT1 alleles in both Caucasians and SAC. The NAT1*4 allele exhibits the rapid 
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NAT1 activity, whilst the activity of the NAT1*10 allele is currently subject to ongoing 
debate. In this respect, the analysis of NAT1 continues to be a topic for ongoing research. 
 
These results, observed for the NAT genes, underscore the importance of doing genetic 
analyses in local ethnic groups, since these differences may vary significantly between the 
groups. 
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Opsomming 
Tuberkulose (TB) is deur die Wêreldgesondheidsorganisasie (WGO) tot 'n globale 
gesondheidsnood verklaar en derhalwe is dit noodsaaklik dat nuwe, verbeterde 
diagnostiese metodes ontwikkel word, wat tot meer effektiewe behandeling kan lei. Ten 
spyte van die huidige TB-epidemie, kan die siekte doeltreffend behandel word deur 
middel van isoniasied (INH), in kombinasie te met ander antibiotika. INH kan egter 
geïnaktiveer word deur sekere ensieme in die liggaam, met die gevolg dat INH nie meer 
effektief is nie in die behandeling van TB. Die aktiwiteit van hierdie ensiem, die 
sogenaamde NAT2 (Arielamien N-asetieltransferase 2) ensiem, word op sy beurt 
beïnvloed deur sekere nukleotied veranderings (SNPs) in die geen. Hierdie genetiese 
veranderings gekorreleer met ensiemaktiwiteitsveranderings (geklassifiseer as vinnig 
(FA) Intermediêr (IA) en stadig (SA)), wat mens in staat stel om potensiële fenotipiese 
effekte te ondersoek deur middel van genotipiese analise. 
 
Ons het hierdie genetiese veranderings ondersoek in die NAT1 en NAT2 gene in individue 
van die Kleurling-gemeenskap (SAC) omdat díe bevolkingsgroep die hoogste voorkoms 
van TB in die land het. NAT2 is primêr verantwoordelik vir die inaktivering van INH, 
terwyl NAT1 para-amienosalisilaat (PAS) inaktiveer, wat gebruik word in die 
behandeling van midel-weerstandige TB. 
 
Die NAT2 resultate dui daarop dat die allele van die NAT2 geen nie eweredig 
verteenwoordig wasin die drie etniese groepe nie en derhalwe word die vinnige (FA), 
intermediêre (IA) en stadige (SA) ensiemaktiwiteite deur hierdie verskille weerspieël. 
Hoewel die teenwoordigheid van hierdie variante relatief laag was in die SAC en 
Koukasiër gemeenskappe, is verdere studies nodig om die omvang van hierdie verskille te 
bepaal ten onsigte van NAT2 aktiwiteit tussen groepe. 
 
In die geval van die NAT1 analise het ons verskille waargeneem in die voorkoms van 
verskeie NAT1 allele tussen Koukasiese en SAC individue. Baie van hierdie NAT1 SNPs 
is egter nog nie gekarakteriseer nie, en derhalwe is die effek van hierdie NAT1 variante 
Stellenbosch University  http://scholar.sun.ac.za
 Page | v  
 
onbekend. Die NAT1*4 en NAT1*10 allele was die prominentste NAT1 alleel in beide 
Koukasiërs en SAC. Die NAT1*4 is betrokke by vinnige NAT1 aktiwiteit, terwyl die 
effek van die NAT1*10 alleel nog onderhewig is aan aktiefwe debat. In hierdie verband, is 
die studie van NAT1 steeds 'n onderwerp vir toekomstige navorsing. 
 
Hierdie resultate, wat vir die NAT gene waargeneem is, beklemtoon die belangrikheid 
van verdere genetiese analises in plaaslike etniese groepe, aangesien hierdie verskille 
beduidend kan wees tussen die verskillende groepe. 
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CHAPTER  1 
Introduction 
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1.1 General background to Tuberculosis 
Tuberculosis (TB) is the principal cause of death in adults, when seen in the 
context of the global health of individuals. Reports of the World Health Organisation 
(WHO) suggest that no less that one-third of the world’s population is host to or have 
been exposed to the causative agent, Mycobacterium tuberculosis (Mtb). Subsequently it 
is projected that at least 8 million of these infected individuals will develop active TB, 
resulting in an annual death rate in excess of 2 million individuals (WHO Reports, 2006 
onwards). This is all the more disconcerting since TB is a curable disease, and effective 
anti-tuberculous treatment has been available for more than 40 years [1]. However, due to 
several factors, such as social stigma and poor patient compliance, and a lack of 
investment in a concerted TB control programme, the pandemic has been a global health 
emergency for more than a decade (WHO Report, 2007). The combined effect of these 
and other factors has also led to the increasing emergence of multi-drug resistant (MDR), 
and even more recently, extensively drug resistant (XDR) Mtb strains [2]. Therefore, it 
would appear that the pandemic is still escalating, and in some regions of the world, most 
notably sub-Saharan Africa and South East Asia, it is fuelled by a synergy with the 
Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome 
(HIV/AIDS). 
The global population is presently estimated to be in the region of 6.7 billion people, of 
whom approximately 700 million reside in the developed countries of the world 
(http://www.census.gov/ipc/www/). This demographic is alarming, since it is the 
developing countries that also have the highest burden of TB disease (WHO Report 
2007). South Africa is currently listed as a country with one of the highest TB incidences 
(WHO Report, 2008), and as such, the situation is indicative of a developing country: - it 
has a high burden of TB disease, coupled to an increasingly expanding population. Recent 
statistics released by the Health Systems Trust, a local non-governmental organization 
(http://www.hst.org.za/healthstats/161/data) cite the national TB incidence as 722.4 per 
100 000 population, with the highest TB incidence recorded in the Western Cape and 
KwaZulu-Natal provinces (in excess of 1000 per 100 000 population). The lowest TB 
incidences were recorded in Limpopo and Mpumalanga provinces, at 305.2 and 463.4 per 
100 000 population respectively. 
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In South Africa, the treatment success rate has unfortunately been relatively low in the 
past, reaching only 68% in 2002 (http://www.worldlungfoundation.org/map_SA.php). 
This indicates that many patients are lost to follow-up health care, and subsequent 
monitoring for treatment compliance, thereby possibly worsening the local epidemic. 
Despite these obvious operational difficulties, reasons behind the skewed disease 
demographics in South Africa as well as other developing countries of the world are still 
actively debated, given the higher recorded incidences of disease within certain localised 
areas of these countries. 
This debate is furthermore fuelled by the often quoted tenet which holds that only 
approximately 5-10% of Mtb-infected individuals become clinically ill with disease, in 
the absence of confounding factors, like malnutrition, and/or immunosuppressive 
conditions such as HIV/AIDS. These confounding factors notwithstanding, this tenet 
implies that the majority of infected individuals are able to mount some level of 
“resistance”, sufficient to preclude the development of clinically overt disease. On the 
other hand, Mycobacterium tuberculosis strain analysis from different regions of the 
world has given rise to the idea of strain evolution within (and potentially along with) 
certain niche populations [3, 4]. Under the precepts of this hypothesis it is envisaged that 
this host-pathogen interaction could contribute to the selective prevalence of certain Mtb 
strains within these population groups [5-7]. 
Investigations of the mummified remains of ancient human populations from both Egypt 
and Peru [8, 9] indicate that TB is an age-old disease. TB palaeomicrobiology, as this 
branch of the research is known, strives to unravel the evolution of Mtb in its co-existence 
with humankind. An additional impetus was provided by the deciphering of the Mtb 
genome [10], and subsequently, several publications have investigated the global 
dissemination of Mtb strains in different populations [5, 11, 12]. These molecular 
techniques have assisted in the establishment of modern day TB research practises, which 
encompasses the development of new TB vaccines, the improvement of the existing drugs 
and treatment regimens, as well as analysing the factors underlying the pathogenesis and 
global dissemination of Mtb. [13] 
Despite this long co-existence with humankind, Mtb is still a powerful parasite of its 
human host, and it can be controlled within populations by the complementary strategies 
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of early disease detection, (rapid diagnosis) and patient compliance during the full course 
of treatment. Of these, it is poor patient compliance to treatment that is often highlighted 
as an important factor contributing to the continuation of the pandemic, and the 
subsequent emergence of MDR-and XDR-TB [2]. Whilst it is generally accepted that 
there is a need to improve upon the current practices for disease detection and diagnosis, 
poor compliance is not fully understood and/or investigated. This is all the more 
important in the light of the synergy between TB and HIV/AIDS, since an individual 
afflicted with the dual infections of TB/HIV is required to adhere to a long, onerous 
therapeutic regimen. 
 
 
1.2 Isoniazid: An important frontline Antibiotic 
Isoniazid, or isonicotinic-acid hydrazine (INH), has been an integral component of 
all forms of TB therapy since the early 1950s [14]. The continued use of INH is supported 
by its proven therapeutic efficacy [15], as well as for its role in precluding the 
development of resistance to co-administered TB drugs in Mtb [16]. INH is inexpensive 
to manufacture, due to its simple chemical structure, and is highly active at easily 
attainable concentrations that are non-toxic to most individuals [17]. Furthermore, it also 
exhibits a good overall distribution in a wide range of human tissues, which is very 
important for counteracting disseminated TB. However, notwithstanding its proven 
efficacy as an anti-TB drug, humans have the inherent ability to diminish the activity of 
INH, via an acetylation reaction catalysed by the enzyme arylamine N-acetyltransferase 2 
(NAT2) [18, 19]. This apparent dichotomy may contribute to the factors confounding the 
global TB pandemic. 
The majority of Mycobacteria are sensitive to INH concentrations of greater than 1µg/ml 
[15]. Most strains of Mtb however, are even more sensitive to INH, generally ranging 
between concentrations of 0.02 µg/ml and 0.06 µg/ml [20]. At present, it is not 
understood why Mtb exhibits such an extreme INH sensitivity in comparison to the other 
Mycobacteria, and numerous attempts have been made to explain the mechanisms for the 
antimycobacterial action of INH [21-23]. The current consensus proposes that INH is 
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activated in the mycobacterial cell via an oxidative reaction catalysed by the catalase-
peroxidise enzyme, katG [24]. Subsequently the activated-INH, which is bactericidal, 
inhibits the synthesis of mycolic acid, the major cell wall component [25]. 
In contrast to the above, it has recently been shown that Mtb is also capable of 
inactivating INH by an acetylation reaction catalysed by its own inherent arylamine N-
acetyltransferase (NAT) gene [26, 27]. This gene is highly homologous to the human 
NAT2 gene [28, 29], and its presence has also been demonstrated in Mycobacterium 
smegmatis [26] as well as in Mycobacterium bovis BCG [30]. The significance of the 
mycobacterial NAT gene is as yet poorly understood. Nevertheless it appears that the 
gene is located within an operon that is essential for the survival of this organism within 
the macrophages of the human host [31]. 
At the structural level, the human and mycobacterial NAT enzymes both possess a 
conserved triad of amino acids within the active site pocket of the enzyme, with highly 
conserved domains situated proximal to this site [27, 32, 33]. Furthermore, initial 
investigations indicate that prior acetylation of INH by Mtb-NAT protects the organism 
against the activated-INH formed by the katG gene product [34]. 
 
 
1.3 The Arylamine N-acetyltransferases 
1.3.1 The Human Acetylation Phenotype 
The first reports describing the metabolic fate of INH in humans were published in 
1953 [18], and whilst these studies proclaimed the effectiveness of INH as an anti-TB 
drug, they also indicated that TB patients differed in their capacity to metabolise INH. 
During this metabolism a proportion of INH is converted into acetylated-INH, which is 
ineffective against the tubercle bacillus [19]. Subsequently, a number of studies in healthy 
individuals, as well as family-based analyses, suggested that the acetylation phenomenon 
was bimodally distributed in the Caucasian population, indicating that two major alleles 
are responsible for this acetylation phenotype [28, 35, 36]. In an early analogous study of 
Stellenbosch University  http://scholar.sun.ac.za
 - 6 - 
Oriental subjects however, the acetylation phenotype was shown to follow a trimodal 
distribution curve [37-39], indicating that the two alleles could be co-dominant. These 
early studies served to highlight possible ethnic differences in the acetylation reaction, 
and facilitated further research into the mechanism of drug metabolism via acetylation 
[40]. 
The early investigations employed several xenobiotic compounds to probe the mechanism 
of acetylation in humans, and phenotypic studies using sulfamethazine (SMZ) [41] 
procainamide (PRO) [42], and caffeine [43], have confirmed this inter-individual 
variation in the rate of acetylation. However, similar studies using 4-aminosalicylic acid 
(4AS) and para-aminobenzoic acid (PABA) as probe substrates observed an invariant 
monomorphic acetylation phenotype [44]. Thus, human beings have the capability to 
exhibit both a monomorphic (invariant) as well as a polymorphic (variable) acetylation 
capacity, depending upon the probe substrate used (Fig. 1.1). These results suggested that 
separate enzymes, with quite different substrate specificities, could be responsible for the 
different acetylation phenotypes. 
 
 
 
Figure 1.1 Analysis of human acetylation phenotype using procainamide 
(a) and para-Aminobenzoic Acid (b) as probe substrates. The results 
indicate the polymorphic (a) and monomorphic (b) acetylation frequency 
distribution. The y-axis represents number of individuals assayed [45]. 
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1.3.2 Monomorphic versus Polymorphic Acetylation 
The acetylation reaction has subsequently been shown to be catalysed by the 
arylamine N-acetyltransferase enzymes (NATs), under the Enzyme Commission 
Classification of E.C. 2.3.1.5 [46]. The NATs are class II drug metabolising enzymes 
(DME) occurring primarily in the hepatic cell cytosol [47, 48], where they catalyse the N-
acetylation, O-acetylation, as well as the N-O-transacetylation of xenobiotic compounds 
possessing a primary aromatic amine or hydrazine substituent group [49-52]. Biochemical 
analyses indicate that the acetylation reaction proceeds via a two step “ping–pong Bi-Bi” 
reaction mechanism [53-55], resulting in the transfer of the acetyl moiety from the 
cofactor acetyl coenzyme A (CoA) to specific reactive groups within the arylamine 
substrates. The course of the reaction proceeds via the initial formation of a short-lived 
enzyme-thio-ester intermediate (acetyl-NAT), followed by the subsequent transfer of the 
acetyl group from the acetylated-NAT to the primary amine nitrogen of the substrate (Fig. 
1.2). 
 
 
Figure 1.2 The “ping-pong” reaction mechanism for NAT-catalysed 
acetylation. The acetyl moiety from CoA is initially transferred to a cysteine 
residue in the active site of the enzyme (acetyl-NAT intermediate), before 
being transferred to the arylamine substrate (acetylated arylamine) [55-57]. 
 
Depending upon the particular arylamine substrate, and whether it undergoes N-
acetylation, O-acetylation or N-,O-transacetylation, the metabolites formed during this 
reaction are either inert by-products, which are readily excreted from the body, or are 
converted into toxic and highly reactive acetoxy and N-acetyl-acetoxy esters [58]. These 
latter substrates undergo spontaneous decomposition into DNA-or protein-binding 
nitrenium ions [59], which can initiate carcinogenic and mutagenic changes [58, 60, 61]. 
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These early in vitro studies also established that a range of different compounds are 
metabolised via the acetylation mechanism, including therapeutic agents (dapsone, 
hydralazine, isoniazid, procainamide, sulfamethazine), important industrial chemicals (2-
aminofluorene, benzidine), and environmental toxins such as 4-aminobiphenyl, a 
constituent of tobacco smoke (Fig. 1.3). 
On the basis of the in vitro polymorphic acetylation of compounds such as isoniazid and 
sulphamethazine, individuals can be characterised as either Rapid or Slow acetylators [46, 
62], or as Rapid- (RA), Intermediate- (IA), or Slow acetylators (SA) [63-65]. In contrast 
to these results, acetylation analyses using substrates such as 4-aminosalicylic acid (4AS) 
and para-aminobenzoic acid (PABA), could only demonstrate a relatively small 
difference in acetylation capacity between individuals, and subsequently these latter 
substrates are unable to distinguish between the polymorphic categories (of fast, 
intermediate or slow), as seen with INH [44, 45]. This difference in acetylation capacity is 
now known to be due to the presence of two separate enzymes, NAT1 and NAT2, which 
respectively catalysed the selective monomorphic and polymorphic acetylation of 
substrates seen in man [28, 66-68]. 
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Figure 1.3 Structures of some compounds that undergo NAT-specific acetylation. 
Compounds are abbreviated as follows:- aniline (ANL), para-aminobenzoic acid 
(PABA), 4-bromoaniline (BRA), 4-chloroaniline (CLA), 4-iodoaniline (IOA), 4-
aminosalicylic acid (4AS), 5-aminosalicylic acid (5AS), 2-aminofluorene (2AF), 
para-aminobenzoyl-L-glutamic acid (PABAGlu), procainamide (PRO), 
sulphamethazine (SMZ), isoniazid (INH), 4-chlorobenozoic hydrazide (CBZ), 
hydralazine (HDZ) and phenylhydrazine (PHZ). 
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This early notion of monomorphic versus polymorphic acetylation has since been refuted 
by several studies, which indicated that NAT1 acetylation in leucocytes [69], liver tissue 
[70, 71], and whole blood [72], also exhibits an inter-individual variation in acetylation. 
Several additional studies have confirmed this polymorphic acetylation capacity of the 
NAT1 enzyme [73-77]. Currently the consensus amongst researchers seems to be that 
both the NAT1 and NAT2 enzymes are polymorphic [68], due to the presence of several 
single nucleotide polymorphisms (SNPs) within these genes, that specifically alter the 
activity of the enzyme. Subsequently, numerous epidemiological studies have sought to 
elucidate the role of human NAT acetylation in relation to susceptibility to infectious and 
malignant diseases [78-81]. However, the overall clinical significance of this apparent 
difference in the human acetylation capability is still unclear. 
The acetylation of therapeutic agents such as INH, dapsone (used in the treatment of 
leprosy, and certain forms of malaria [82]), and procainamide (used in the therapy of 
cardiac arrhythmias [42]), impacts upon the therapeutic treatment of the patient. 
Subsequently it has been established that some patients are prone to the development of 
adverse drug reactions (ADR) and chemically induced toxicity caused by their inherent 
metabolism of these drugs. This can require that the drug(s) be withdrawn from treatment, 
which could imply subsequent less effective treatment. Secondly, in the case of TB and 
leprosy, such partial exposure to the drugs, could facilitate the development of drug 
resistance in the disease-causing organism. Hence it is important to develop an 
understanding of the metabolism of these compounds with respect to acetylation, because 
the drugs in question feature prominently in the treatment regimens for these diseases. 
 
 
1.3.3 The Human NAT Genes 
Three NAT genes have been detected and characterised in humans, namely, NAT1, 
NAT2, and NATP [83]. These genes occur on chromosome 8, in the region of 8p22 [84-
86]. All three genes occur relatively close together, within a 360 kilobase pair (kb) 
domain (Fig. 1.4), with the chromosome-specific marker D8S261 situated telomeric to the 
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NAT1 gene [86]. Functional NAT enzymes are derived from single open reading frames 
(ORF) of 870 nucleotides in length [70]. These protein coding domains share a nucleotide 
sequence identity of 87%, and code for proteins of 34 kiloDaltons (kDa) containing 290 
amino acids which are 81% identical [83]. 
Early studies using hepatic tissue indicated that the messenger RNA (mRNA) transcripts 
for NAT1 have an exact co-linearity with a single exon locus, implying that the protein 
transcript is entirely derived from this exon. On the other hand, the NAT2 mRNA 
transcript consists of sequences from the primary protein-coding exon, as well as 
sequences from a small non-coding exon, located 8.65 kb upstream of it [87] (Fig. 1.4). In 
contrast, the NATP locus contains numerous stop codons, and neither immunoreactive 
protein nor acetylation activity could be detected in NATP in vitro transfection 
experiments [83]. Consequently, NATP is believed to be a pseudo-gene. 
 
 
Figure 1.4 The organisation of NAT gene loci on Chromosome 8 [86]. 
 
 
Both in vivo and in vitro studies have established that the expression of NAT1 occurs 
independently of NAT2 [88], which indicates that these genes are under the control of 
separate promoters. There is however, a paucity of published information on the 
mechanism(s) controlling the expression of the NAT genes. Nevertheless, it has been 
established that NAT1 is expressed in diverse tissues, such as liver [70], leukocytes [69], 
bladder [89], erythrocytes [90], placenta [91], foetal tissue [92], and intestinal epithelium 
Stellenbosch University  http://scholar.sun.ac.za
 - 12 - 
[77]. The NAT2 gene also exhibits a diverse tissue expression profile, but generally at a 
relatively lower rate of transcription compared to NAT1, in most tissues. A higher level 
of NAT2 expression has however been found in the liver, colon and small intestine [93, 
94]. This relatively high level of NAT2 expression in these tissues, traditionally regarded 
as sites of initial drug metabolism, may support the hypothesis that NAT2 is primarily 
involved in the metabolism of various drugs. On the other hand, the wide-spread 
expression of NAT1 in human tissue suggests that NAT1 may fulfil an inherently 
endogenous role within the body. 
The significant structural similarity between NAT1 and NAT2 [95] suggests that these 
enzymes could also exhibit an overlapping substrate selectivity, and this has been shown 
using various probe substrates [96]. A recent publication [97], investigating the substrate 
specificity of the human NAT enzymes has provided support for the overlapping substrate 
hypothesis, by observing that, whilst many of the probe substrates tested exhibit a clear 
NAT1- or NAT2-acetylation specificity, some of the compounds were equally acetylated 
by both enzymes (Fig. 1.5). Despite this overlapping substrate specificity, it is still not 
known whether NAT1 and NAT2 act co-operatively and/or sequentially within the same 
or disparate acetylation pathways. 
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Figure 1.5 Substrates screened for NAT1 and NAT2-specific acetylation via 
acetyl-coA hydrolysis. Abbreviations for the different compounds are:- aniline 
(ANL), para-aminobenzoic acid (PABA), 4-bromoaniline (BRA), 4-
chloroanaline (CLA), 4-iodoaniline (IOA), 2,4-dichloroaniline (2,4DCA), 3,4-
dichloroaniline (3,4DCA), 4-ethoxyaniline (EOA), 4-butoxyaniline (BOA), 4-
aminosalicylic acid (4AS), 5-aminosalicylic acid (5AS), 2-aminofluorene 
(2AF), para-aminobenzoyl-L-Glutamic acid (PABAGlu), procainamide (PRO), 
Sulphamethazine (SMZ), isoniazid (INH), 4-chlorobenzoic hydrazide (CBZ), 
Hydralazine (HDZ), and phenylhydrazine (PHZ). Adapted from [97]. 
 
 
1.3.4 Structure and Functional Studies of NAT Proteins 
The NAT proteins constitute a highly conserved family of enzymes that are well 
represented amongst both prokaryotic and eukaryotic organisms, including humans [93], 
chickens [98], rabbits [99, 100], rats [101], cats [102] and various bacterial species [26, 
103]. Interestingly, dogs and other canids do not exhibit any N-acetyltransferase activity 
[104]. This substantial body of early knowledge has facilitated our understanding of the 
NAT acetylation mechanism. Across species comparisons of the NATs have identified a 
number of highly conserved amino acids, as well as functionally important structural 
motifs (Fig. 1.6). Due to this conserved sequence identity amongst the NATs, a number of 
model organisms have been developed to study human acetylation. In this context, studies 
of bacterial NAT [52] have shown that these enzymes contain a catalytic triad of amino 
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acids (Cys
69–His107–Asp122) as the primary feature of the enzyme’s active site pocket [32, 
33]. In human NAT, this structurally and functionally analogous feature is depicted by the 
Cys
68
-His
107
-Asp
122
 triad [105, 106]. 
 
 
 
 
Figure 1.6 A sequence alignment of NAT proteins from several different 
species to show the overall structural similarity between them - mostly -
helical (cylindrical) and - sheet (arrow bar) conformations. The magenta 
colour (for example in the 10 and 7 domains) indicate regions specific to 
human NATs. Highly conserved amino acids are indicated in red; Acetyl CoA-
binding amino acids are indicated as red triangles, whilst substrate-binding 
amino acids are indicated with blue triangles (taken from Wu et al [107]). 
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Despite the similarities in overall structure, crystallographic experimentation and 
computational analyses have revealed the presence of two additional structural features in 
the human enzymes:- a 17-residue inserted domain (amino acids 167-183), and a domain 
at the carboxy terminus which assumes a random coil conformation [107, 108]. These 
domains are not present in other Eukaryotic species, nor have they been found in any of 
the bacterial NATs thus far studied (Fig.1.7). It is currently speculated that these domains 
may feature prominently in the catalytic activity of the human enzymes, since the 17-
residue inserted domain is orientated in such a way as to interact with several of the –
sheet and –helical domains in the native enzyme structure, thereby contributing to the 
overall stability of the human proteins (Fig.1.7). 
 
 
 
Figure 1.7 Ribbon diagrams of the overall structure for human and bacterial NATs, 
showing the domains of difference (magenta) prevalent in human NATs (ref. 
[107]). 
 
The carboxy-terminal region assumes an extended structural conformation, and stretches 
across the opening of the catalytic site pocket, effectively shielding the pocket and 
restricting access to this site. This orientation furthermore promotes the initial interaction 
between human NAT and acetyl-CoA, during the formation of the characteristic 
acetylated enzyme-substrate intermediate [109]. Furthermore, this carboxy-terminal 
domain, specifically from amino acid 274 onward, is oriented into the interior of the 
molecule, and is thus effectively shielded from interacting with the aqueous outer 
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environment [109]. In contrast, the carboxy terminal domain in Prokaryotes occurs on the 
periphery of the enzyme molecule, away from the catalytic site pocket [32]. Despite the 
overall structural similarities between the Eukaryotic and Prokaryotic NAT enzymes, the 
significance of these latter structural differences have yet to be determined. 
 
Studies investigating the substrate binding selectivity of NAT1 and NAT2 observed that 
the carboxy terminal domain of the protein, along with residues 124 to 129, facilitates the 
interactions of the substrate with the active site of the enzymes [110, 111]. According to 
Wu et al [107], the amino acids at position 93, 125, 127 and 129 feature prominently in 
the substrate selectively of the human enzymes by affecting the interactions within the 
catalytic site pocket. In the case of NAT2, the amino acid serine occurs at positions 125, 
127 and 129. In contrast to this, the NAT1 protein has phenylalanine, arginine and 
tyrosine at these respective positions [107]. These authors also show that the bulky side 
chain groups of arginine-127 and tyrosine-129 protrude into the NAT1 active site pocket, 
effectively reducing the substrate binding volume by 40% with respect to the NAT2 
substrate binding pocket. Consequently, the NAT1 substrates are relatively small, 
compared to NAT2-specific substrates (see Fig.1.3, PABA vs SMZ). Furthermore, the 
amino acid valine occurs at position 93 in NAT1, whereas phenylalanine occurs at 
position 93 in NAT2. This difference affects the binding capacity within the substrate 
binding pocket of NAT2 specifically, making it more conducive for the interaction with 
hydrophobic substrates, due to the flat planar surface of the benzene ring structure in the 
side chain group of phenylalanine. 
The substrate binding specificity of the human NATs also appears to be largely 
influenced by the identity of the amino acid at position 125. In a series of substitution 
experiments conducted by Goodfellow et al [111], the substitution of phenylalanine-125 
with serine in the NAT1 enzyme, abrogated the usual NAT1-specific interaction with 
PABA, and resulted in a NAT1 enzyme that specifically interacted with SMZ, a NAT2-
specific substrate. 
Besides the significance of particular amino acid residues within these enzymes, the 
importance of the catalytic site triad (Cys-His-Asp) cannot be over emphasised. 
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Homology modelling studies have shown that these three amino acids are conserved in all 
known NAT enzymes, and that the cysteine residue in particular, is crucial for the 
acetylation reaction [52, 105]. As indicated earlier, this cysteine residue is the site of 
initial acetylation of the enzyme with acetyl CoA, prior to the acetylation of the substrate. 
The significance of this aspect of the reaction is borne out by the observation that the 
acetylated NAT moiety is more stable than an un-acetylated enzyme. Moreover, prior 
acetylation of the substrate rather than the enzyme, leads to the rapid degradation of the 
enzyme via the ubiquitin-proteasome pathway [112]. Hence, whilst the substrate 
selectivity may be prescribed by the volume of the catalytic pocket, as well as by 
interactions with particular amino acid residues, the overall rate of the acetylation reaction 
may be specified by the initial interaction between acetyl CoA and the enzyme moiety. 
 
 
1.3.5 NAT Expression Studies 
The human NAT genes, despite their similarities, appear to have very distinct 
functional roles, based upon their observed expression profiles in different tissues, and 
during the developmental stages of the organism. These expression profiles demonstrate 
apparent tissue selectivity. 
Recently, a NAT knockout mouse model [113] was used to broadly investigate NAT 
expression, as well as deduce the role of these enzymes in Eukaryotes during embryonic 
development. The murine and human NAT proteins are highly analogous [114], and map 
to syntenic regions on chromosome 8 in both species [115-117]. These factors make the 
mouse a particularly useful model system for studying acetylation, with murine Nat1 
exhibiting a substrate specificity equivalent to human NAT2, whilst murine Nat2 is 
equivalent to human NAT1. Loehle et al [118], in using this Nat2 knockout mouse model, 
found no significant difference in relative expression levels (mRNA) for both Nat genes, 
assayed via quantitative polymerase chain reaction analysis, in the murine hepatic and 
extrahepatic tissue compared to the wild type strain. This result was consistent with 
similar studies in human tissues [116, 119]. Secondly, using specific probe substrates to 
assess the acetylation activity – INH for Nat1 and PABA for Nat2 – these authors were 
able to show that the reduction in Nat2 catalytic activity was caused by the consequential 
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reduction in Nat2 protein. Interestingly, Nat1 transcription (mRNA) and catalytic activity 
(protein) did not reflect a compensatory adjustment as a result of the loss of Nat2 in the 
knockout strain. Taken together, these results indicate that the NAT acetylation reaction 
fulfils important and similar endogenous roles in the xenobiotic biotransformation 
mechanism in Eukaryotic tissue.  
 
 
1.3.5.1 NAT1 Gene Expression 
The in silico analysis of expressed sequence tags (ESTs) for the human contig 
NT_030737 (http://www.ncbi.nlm.nih.gov/nuccore/51466871) has indentified several 
putative splice variants for the NAT1 gene. Subsequently, various NAT1 mRNA 
transcripts, differing only in the 5’-untranslated region (5’-UTR), have been reported 
[120-123]. On the whole, the 5’-UTR contains 8 separate exons, giving rise to multiple 
putative mRNA transcripts, consisting of various combinations of these exons conjoined 
to the single protein coding exon, exon 9 (Fig. 1.8). 
 
Studies of the human NAT1 gene locus have identified at least two promoter domains, one 
of which is located approximately 12 kb upstream of exon 9, called NATb [120, 123], and 
another, NATa, located 51.5 kb upstream of this protein coding exon [121]. The most 
proximal promoter domain, NATb, occurs just upstream of exon 4. It contains a putative 
binding site for the Activator Protein 1 (AP-1) transcription factor, flanked by a –TCATT 
repeat motif. In addition, a functional transcription factor binding site for Stimulatory 
protein 1 (Sp1) has also been identified within this NAT1 transcriptional domain. Since 
the Sp1 transcription factor is ubiquitously found in association with house-keeping genes 
[124], it is believed that the NATb promoter region drives the constitutive expression of 
NAT1 [123]. The second promoter, NATa, appears to facilitate a higher level of NAT1 
expression in lung, liver, kidney and tracheal tissues, and hence, may function at a more 
tissue-specific level. Thus the expression of NAT1 proceeds from two separate promoters, 
which appear to exhibit differential activity in different tissues, supporting the idea that 
the expression of NAT1 is both inducible [125], and/or constitutive [123]. 
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Figure 1.8 Diagram depicting the genomic arrangement for the human NAT1 locus, 
adapted from Minchin et al [126]. Several mRNA splice variants (A to E, X and Y), 
arising from the separate promoters NATa and NATb (red arrows), have been 
described. The NAT1 protein coding sequence is derived exclusively from exon 9 
[114, 126]. Putative poly-adenylation sites are also indicated (black arrows). 
 
 
1.3.5.2 NAT2 Gene Expression 
In the case of the NAT2 gene, a different restricted expression profile is observed, 
with the highest level of expression occurring in the liver, colon and small intestine [127]. 
In their study of full length mRNA splice variants from 29 different tissue types, Husain 
et al [127] observed baseline expression levels only in the remainder of the human tissues 
analysed. They also observed that the majority of these mRNA transcripts were expressed 
from a single promoter, located 8.7 kb upstream of the NAT2 open reading frame (ORF) 
(Fig. 1.9) [87]. In addition, the NAT2 transcription start site (TSS) was located just 
upstream of the non-coding NAT2 exon, within a 100 nucleotide domain [120]. 
In contrast to these observations, Boukouvala and Sim [116] found that NAT2 transcripts 
may also be initiated from a second promoter, located immediately 5’ to the NAT2 ORF. 
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The general importance of the latter promoter has yet to be established, since its 
prominence has thus far only been demonstrated in NAT2 transcripts from liver tissue, 
and not in extra-hepatic tissue [127]. Interestingly, the very low level of NAT2 expression 
observed in the other tissues analysed by Husain et al [127], may well indicate that NAT2 
expression could be under the influence of a relatively weak promoter in these tissues, 
thereby lending support to the findings of Boukouvala and Sim [116]. The different 
expression profiles that have been observed may require the additional intervention of 
tissue-specific transcription factors. 
A comparison of the 8.7 kb NAT2 promoter domain with the corresponding region in the 
paralogous NAT1 gene has shown that they share an 85% sequence homology. Despite 
this significant similarity, the NAT2 transcription start site (TSS) domain does not contain 
the binding site for the Sp1 transcription factor [127]. These observations indicate that the 
expression of the NAT2 gene is inducible rather than constitutive, thereby supporting the 
findings of differential NAT2 expression in diverse human tissue. 
Generally speaking there is a limited amount of information available on the 
mechanism(s) affecting the regulation of NAT2 gene expression. However in silico 
analysis of the reported genome sequences have identified several other putative 
transcription factor binding sites in the 5’-UTR of NAT2, as well as tandem 
polyadenylation sites in the 3’-UTR of the gene [114, 116, 128]. The functional 
importance of these binding sites has yet to be analysed, and therefore the mechanistic 
role of the 5’-UTR in NAT2 gene expression is as yet undefined. In a recent study of 
NAT2 polymorphisms in the Indonesian population, several novel SNPs were reported in 
the 5’-UTR of the gene [129]. However similar observations in other population groups 
have not been reported, and hence the importance of these SNPs in the regulation of 
NAT2 expression has yet to be established. 
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Figure 1.9 The genomic arrangement for the human NAT2 gene locus. A single 
non-coding exon (NCE) is located approximately 8.7kb upstream of the open 
reading frame (ORF) of the protein coding exon. Open triangles indicate two 
putative poly-adenylation signalling sites (A1, A2). 
 
 
NAT2 mRNA is differently polyadenylated in the 3’-UTR in various vertebrate species 
[100, 130-132], thereby affirming the presence of the tandem polyadenylation sites. In the 
case of the paralogous NAT1 gene, the A2 adenylation site (Fig.1.9) appears to be the 
preferred site for mRNA polyadenylation [116], since in silico analyses of NAT1 ESTs 
have indicated that the polyA tail originates at the polyA2 site. The preferential utilisation 
of this polyA site could imply that the subsequently formed mRNAs may be more stable. 
Whilst the mechanism for the post-transcriptional regulation of NAT2 has yet to be 
elucidated, it is likely that a similar mechanism ensures the differential polyadenylation of 
the NAT2 mRNAs. 
Alternative splicing of mRNA transcripts is a general property of the cell’s translational 
processes, and is believed to be a feature of cell specific gene expression and regulation 
[133, 134]. As such, the alternative splicing of the NAT mRNA transcripts is not peculiar 
to the human species, and has also been demonstrated in hamsters [130], rabbits [99], and 
rats [131]. However, the aspect of alternative splicing in intronless genes may be worthy 
of further investigation, given that less than 5% of all genes in the higher order 
Eukaryotes are believed to be intronless [135]. 
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1.3.6 Human NAT Acetylation Polymorphisms 
Many investigations have attempted to establish whether there is a causative 
association between various diseases and the individual’s acetylation capacity with 
respect to one or both of these enzymes (NAT1 and NAT2). For example, NAT 
acetylation has been investigated in a variety of different cancers, such as bladder [136], 
breast [137], colon [138], and prostate [139]. Currently the basis for the acetylation 
polymorphism is ascribed to numerous activity-altering SNPs that have been identified 
within the NAT genes. These SNPs have been widely investigated in various studies for 
their contributory effects towards the differential acetylation of drugs and xenobiotics [28, 
78, 128, 140]. 
 
1.3.6.1 The NAT1 Acetylation Polymorphism 
At least 25 variant alleles have been characterised in the NAT1 gene. By 
convention, the reference allele, NAT1*4, confers the “wild-type” acetylation activity 
observed for the enzyme (http://louisville.edu/medschool/pharmacology/consensus-
human-arylamine-n-acetyltransferase-gene-nomenclature/). A total of 32 different 
nucleotide changes distinguish these 25 vaiant alleles from NAT1*4 (Table 1.1). Many of 
these changes occur as individual SNPs, defining separate alleles (for example as in 
NAT1*3 and 1*17), or occur as combination-SNPs, characteristic of allele clusters or 
haplotypes (NAT1*11A, 11B, 11C, and 1*18A, 18B). 
Eighteen different SNPs are localised to the protein coding region of the gene (exon 9, 
Fig. 1.8), whilst the remaining 14 nucleotide changes occur within the UTRs. Extant 
information regarding the effect of these polymorphisms on the NAT1 phenotype is, at 
best incomplete, and the acetylation capacity for at least 9 of these variants namely, 
NAT1*5, 1*11C, 1*16, 1*18A, 1*18B, 1*26A, 1*26B, 1*28 and 1*29, has still to be 
determined. 
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Table 1.1. Single nucleotide polymorphisms associated with various NAT1 alleles. 
Nucleotide 
change(s) 
Amino Acid 
Change 
Defining NAT1 Allele(s) 
5’UTR 
-344C>T None 1*11A, 1*11B, and 1*11C 
-40A>T None 1*11A, 1*11B, and 1*11C 
Exonic Region 
21T>G Synonymous 
(L7L) 
1*27 
97C>T R33Stop 1*19 
190C>T R64W 1*17 
350G>C, 351G>C R117T 1*5 
402T>C Synonymous 
(P134P) 
1*20 
445G>A V149I 1*11A and 1*11B 
459G>A Synonymous 
(T153T) 
1*11A, 1*11B, and 1*11C 
497-499G>C R166T; E167Q 1*5 
559C>T R187Stop 1*15 
560G>A R187Q 1*14A and 1*14B 
613A>G M205V 1*21 
640T>G S214A 1*11A, 1*11B, and 1*11C 
752A>T D251V 1*22 
777T>C Synonymous 
(S259S) 
1*23 and 1*27 
781G>A E261K 1*24 
787A>G I263V 1*25 
3’UTR 
884A>G None 1*5 
976 None 1*5 
1025 None 1*29 
3 between 1065-
1087 
None 1*18A 
3 between 1065-
1090 
None 1*18B 
(AAA) after 1091 None 1*16 
(TAA) insert 
between 
1065-1090 
None 1*26A and 1*26B 
(TAATAA) 
deletion  
between 1065-
1090 
None 1*28 
9 between 1065-
1090 
None 1*11A, 1*11B, and 1*11C 
88T>A  1*10, 1*14A, 1*18A, 1*29 
1095C>A None 1*3, 1*10, 1*11A, 1*11C, 1*14A, 1*16, 
1*18A, 1*26A, and 1*29 
1105 None 1*5 
See List of Abbreviations for explanation of single letter Amino acid abbreviations. 
Table adapted from NAT website 
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A limited number of alleles have however been investigated, of which, only a relatively 
small subset (most notably, NAT1*3, NAT1*4, NAT1*10, NAT1*11, and NAT1*14), have 
been shown to exhibit differences in phenotype, in mostly Caucasian cohort studies [141-
144] (see Table 1.2 below). Despite this knowledge from early in vitro acetylation 
studies, there is still a limited understanding of the NAT1 genotype-phenotype inter-
relationships. Thus, acetylation studies based on strictly phenotypic analyses may not be 
able to characterise a particular NAT1 variant locus. Therefore it is important to develop 
improved and more robust experimental methodologies to define the SNP frequencies 
within populations, in order to accurately define the acetylation phenotype conferred by 
these SNPs. 
 
 
1.3.6.1.2. Functional Impact of NAT1 Polymorphisms 
The acetylation phenotypes for various NAT1 haplotypes are depicted in Table 
1.2. It is interesting that the alleles with an acetylation phenotype “greater than” NAT1*4, 
show polymorphisms that occur within the UTRs of the gene. Moreover, the NAT1*10 
allele encodes a greater acetylation capacity than NAT1*3 [116], and it would appear that 
this difference may be solely due to the additional SNP at position 1088. The significance 
of the 1088T>A polymorphism may be further extrapolated, based upon the observation 
that the 1095C>A SNP on its own does not appear to substantially affect the acetylation 
capacity, since the NAT1*3 phenotype is observed to be equivalent to that of the reference 
allele, NAT1*4. However, these alleles have not been studied in diverse populations, and 
the contribution of these SNPs (and alleles) to the overall acetylation phenotype is 
unknown. Hence, further investigations are necessary to substantiate these results 
obtained from Caucasian cohort studies [141-144]. In general, the role postulated for 
NAT1 in the metabolism of xenobiotic compounds has been developed from early studies 
using validated animal models (reviewed by Sim et al, 2008 [128]), and subsequently 
many investigations have attempted to define a causative association between NAT1 
acetylation polymorphisms and malignant disease susceptibility [145, 146]. 
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Table 1.2 Deduced acetylation phenotypes for polymorphic NAT1 Haplotypes. 
Acetylation 
Phenotype 
NAT Allele 
(Haplotype) 
Nucleotide Change Deduced Amino Acid 
Change 
Reference NAT1*4 Reference None (Reference 
Sequence) 
Equivalent to 
1*4 
NAT1*3 1095C>A  
NAT1*20 402T>C P134P
‡
 
NAT1*21 613A>G M205V 
NAT1*23 777T>C S259S
‡
 
NAT1*24 781G>A E261K 
NAT1*25 787A>G I263V 
NAT1*27 21T>G; 777T>C L7L
‡
; S259S
‡
 
Greater than 
1*4 
NAT1*10 1088T>A; 1095C>A  
 -344C>T; -40A>T  
 445G>A V145I 
NAT1*11A 459G>A T153T
‡
 
 640T>G S214A 
 9 between 1065-1090  
 1095C>A  
 -344C>T; -40A>T  
 445G>A V145I 
NAT1*11B 459G>A T153T
‡
 
 640T>G S214A 
 9 between 1095-1090  
Lower than 1*4 
NAT1*14A 
560G>A R187Q 
1088T>A; 1095C>A  
NAT1*14B 560G>A R187Q 
NAT1*15 559C>T R187Stop 
NAT1*17 190C>T R64W 
NAT1*19 97C>T R33Stop 
NAT1*22 752A>T D251V 
‡
 = Synonymous amino acid change conferred by SNP. Table adapted from 
the official NAT website. 
 
 
These latter studies have reported some association, yet the overall results have been 
tenuous, due mainly to the low resolving power inherent in genetic studies employing a 
small number of participants, and the difficulty in replicating the results in other cohorts. 
Furthermore, only some of the NAT1 alleles have thus far been investigated in a limited 
number of population cohorts [141-144]. Nevertheless, a seemingly regular association 
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has been demonstrated between several types of cancers and the NAT1*10 allele [76, 147-
149]. These latter results are of particular interest since the SNPs defining NAT1*10 all 
occur in the 3’-UTR of the gene, and by popular convention are not considered to have 
any effect on the activity of the enzyme [150, 151]. 
Recent studies employing micro-array technologies have shown an association between 
an increased NAT1 expression and oestrogen receptor positive breast cancer cells, which 
would indicate the involvement of a hormone response element, presumably present 
within the promoter domain of this gene [152, 153]. Thus the study of the polymorphic 
NAT1 alleles will continue to contribute valuable insights into the pharmacogenetics of 
acetylation. 
 
 
1.3.6.1.3 Ethnic distribution of NAT1 polymorphisms 
Several studies have investigated the frequency distribution for the various NAT1 
alleles, however the existing information is not as comprehensive as for the NAT2 gene. 
This imposes a major limitation upon comparative studies investigating the contributory 
effects of the acetylator polymorphisms in different populations. Furthermore, many of 
the earlier studies utilised a PCR-RFLP analytical protocol exclusively, which facilitated 
the investigation of a targeted subset of NAT1 alleles only, mainly, 1*4, 1*3, 1*10 and 
1*11 [76, 154-156]. In other instances, the complete NAT1 sequence domain was 
investigated via genetic sequencing [157-159], which indicated that some NAT1 alleles 
are rare (occurring at a frequency of 1% or less) or absent in these extant populations. 
Table 1.3 summarises the NAT1 allele frequencies in different populations. 
Despite these limitations, both in the alleles investigated, and in the limited number of 
ethnicities analysed, it is apparent that the profile of NAT1 alleles found in Caucasians 
compared to Asians is sufficiently diverse to account for the observed differences in 
NAT1 acetylation status for these groups [75, 158]. In this respect, the ethnic African 
populations have to a large extent been neglected in these analyses, and therefore it is 
difficult to reach a consensus on the status of the NAT1 acetylation within the latter 
groups. It is however extremely important to address this limitation since this group 
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appears to exhibit allele frequencies that are similar to both Caucasians and Asians, as 
indicated in Table 1.3. 
 
Table 1.3. The distribution of NAT1 alleles as reported for various ethnic groups. 
 
Ethnic 
Group 
No. Of 
Alleles 
tested 
(n) 
Allele frequency expressed as percentage  
(%) 
Reference 
1*4 1*3 1*10 1*11 1*14 Other

 
Caucasians 
British 224 73.7 3.6 18.7 3.1 0.9 0 [155] 
French  540 74.4 2.8 17.8 0 3.7 1.3 [144] 
German 628 70.9 3 20.1 3.3 2.2 0.5 [76] 
African 
Lebanese
¥
 84 56 3.6 10.7 0 23.8 n.d. [156] 
S.A. Black  202 48.5 1 50.5 0 0 0 [155] 
Asian 
Indian 280 51 30 17 2 n.d. n.d. [154] 
Malay 244 30 29 39 2 n.d. n.d. [154] 
Thai 466 50.4 3.4 43.8 2.4 0 n.d. [157] 
Han 
Chinese  
280 49.6 8.2 40 2.2 n.d. n.d. [158] 
Taiwanese 342 54 3.2 42 6 n.d. n.d. [160] 
Japanese  98 56.2 1.0 40.6 0 0 5.7
†
 [161] 
n.d. = Alleles not determined by the experimental assay; 

 = combined frequencies of alleles, such as, 1*15, 1*17, etc. usually <1%. 
¥
 Cohort consisted of second generation Lebanese individuals living in the United 
States of America at the time of the study 
† Figure represents the sum of frequencies specifically for the NAT1*18 alleles 
only; no other NAT1 alleles were found in this study. 
 
The importance of elucidating how NAT1 genotypes affect the acetylation phenotype is 
also apparent from contrasting results obtained by separate phenotypic studies [75, 110, 
141, 158]. Studies by Hughes et al [75] and Payton & Sim [110] found the acetylation 
activity of the NAT1*10 allele to be similar to that of the 1*4 allele, using PAS and 
PABA as activity probes respectively. On the other hand, Bell et al [141] and Zhangwei 
et al [158], using PABA to probe for NAT1 acetylation, observed an elevated acetylation 
activity for the NAT1*10 allele in homozygous as well as heterozygous genotypes. This 
apparent discrepancy could be ascribed to differences in study design, in that Hughes et al 
[75] and Payton & Sim [110] investigated NAT1 acetylation in Caucasian individuals, 
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whilst Zhangwei et al [158] analysed Chinese individuals, and Bell et al [141] conducted 
an in vitro study of bladder and colon tissue samples. Interestingly, the mean NAT1 
activity in bladder tissue was 8 times lower than in the colon samples, yet a higher 
NAT1*10 activity was observed in bladder samples relative to colon tissue [141]. Taken 
together, these results accentuate the importance of elucidating the NAT1 genotype-
phenotype inter-relationship with further studies. 
 
1.3.6.2 NAT2 Polymorphisms 
The classic “isoniazid acetylation polymorphism” has been unequivocally linked 
to the human NAT2 genetic locus [28, 36, 46, 50]. Historically, the acetylation reaction 
has been more frequently studied and characterised with respect to the NAT2 gene and its 
well-defined polymorphisms [37, 162-167]. Several of these polymorphisms encode 
NAT2 proteins exhibiting a reduced enzyme activity [71, 83, 168], giving rise to the Slow 
acetylator (SA) phenotype. These particular SNPs, namely, 191G>A, 341T>C, 590G>A, 
and 857G>A, are characterised by complete genotype-phenotype concordance, and have 
become the defining polymorphisms for the 2*14, 2*5, 2*6, and 2*7 allele clusters 
(haplotypes), respectively [169-173] (Table 1.4). Subsequently, a number of additional 
activity-altering SNPs have been described, namely 190C>T (2*19), 364G>A (2*12D), 
411A>T (2*5I), 434A>C (2*17), and 499G>A (2*10). However the effect of these 
particular SNPs on the overall NAT2 acetylation status in different populations has yet to 
be investigated comprehensively. 
A total of 27 different SNPs, defining 52 NAT2 alleles, have thus far been described 
(http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-
acetyltransferase-gene-nomenclature/). Combinations of 1-4 SNPs, are classified into 
several haplotype groupings (allele clusters), which by popular convention, are usually 
classified via one of the reduced-activity SNPs defined above. However, as indicated in 
table 1.4, some of these SNPs also occur in differently defined haplotypes, for example 
the 341T>C SNP, whilst others, such as the 364G>A and 411A>T SNPs, occur solely in 
particular haplotypes. Hence these SNPs may be confounding factors during NAT2 
acetylation analyses, both when assigning the particular NAT2 genotype, as well as when 
defining the overall acetylation phenotype. 
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Table 1.4. NAT2 haplotypes and their defining-SNPs conferring reduced 
enzyme activity. 
 
NAT2 
Haplotype 
Defining 
SNP 
Amino 
Acid 
change
§
 
Alleles containing the 
haplotype-defining SNP 
2*5 341T>C I114T 2*5A – 2*5M; 2*14C, 2*14F 
2*6 590G>A R197Q 2*6A – 2*6L; 2*5J, 2*14D 
2*7 857G>A G286E 2*7A - 2*7B; 2*6I, 2*6J 
2*10 499G>A E167K 2*10 
2*14 191G>A R64Q 2*14A – 2*14H; 
2*17 434A>C Q145P 2*17 
2*19 190C>T R64W 2*19 
2*5I 411C>T L137F 2*5I 
2*12D 364G>A D122N 2*12D 
§
 = See List of Abbreviation for amino acid abbreviations. 
Table constructed from the information found in the official NAT 
website. 
 
The 27 known NAT2 SNPs are listed in Table 1.5. The majority of these SNPs (22/27) 
code for non-synonymous amino acid changes, whilst the remainder, namely, 111T>C, 
282C>T, 345C>T, 481C>T, and 759C>T, encode synonymous amino acids, which by 
convention, are considered to impart an enzyme activity equivalent to the NAT2*4 allele. 
However, Cascorbi et al [174], using caffeine as the probe substrate, found that the 
282C>T SNP caused a reduced acetylation activity in a cohort of German individuals, 
thereby highlighting the significance of SNP validation, both genetically and 
phenotypically. Interestingly, the majority of the SNPs depicted in Table 1.5 are present 
in alleles that form sub-categories of the central NAT2 haplotypes (2*5, 2*6, 2*7, and 
2*14), yet the effect on the NAT2 acetylation status for many of these SNPs is still 
undefined. 
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Table 1.5. NAT2 SNPs and their effect on the Acetylation Phenotype. 
Nucleotide 
Change 
Amino Acid Change Acetylation Phenotype Defining Alleles 
None Reference Sequence Rapid 2*4 
29C>T I10T Unknown 2*12J 
70T>A L24I Unknown 2*5L 
111T>C F37F
§
 Unknown 2*6D 
152G>T G51V Unknown 2*6M 
190C>T R64W Slow 2*19 
191G>A R64Q Slow 2*14 
203G>A C68Y Unknown 2*5O 
228C>T Y76Y Unknown 2*12I 
282C>T Y94Y
§
 Rapid 2*13 
341T>C I114T Slow 2*5 
345C>T D115D
§
 Unknown 2*6L 
364G>A D122N Slow 2*12D 
403C>G L135V Unknown 2*12H 
411A>T L137F Slow 2*5I 
434A>C Q145P Slow 2*17 
458C>T T153I Unknown 2*21 
472A>C I158L Unknown 2*5N 
481C>T L161L
§
 Rapid 2*11 
499G>A E167K Slow, substrate dependant 2*10 
518A>G K173R Unknown 2*6G 
578C>T T193M Unknown 2*5P; 2*12E; 2*13B 
590G>A R197Q Slow 2*6 
600A>G E200E
§
 Unknown 2*20 
609G>T E203D Unknown 2*12G 
622T>C Y208H Unknown 2*12F 
638C>T P213L Unknown 2*6K 
683C>T P228L Unknown 2*14H 
759C>T V53V
§
 Unknown 2*5F 
766A>G K256E Unknown 2*6H 
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Nucleotide 
Change 
Amino Acid Change Acetylation Phenotype Defining Alleles 
803A>G K268R Rapid 2*12 
838G>A V280M Unknown 2*5M; 2*6I 
845A>C K282T Rapid 2*18 
859Del S287 Frameshift Unknown 2*5H; 2*11B 
857G>A G286E Slow 2*7 
Table 1.5 continued…. adapted from 
http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-
acetyltransferase-gene-nomenclature 
 
§ - 
indicates Synonymous amino acid changes, most of which have yet to be 
characterised phenotypically. 
SNPs highlighted in colour represent the activity altering SNPs most often 
analysed in NAT2 genotyping studies. 
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1.3.6.2.1 Functional impact of NAT2 Polymorphisms 
The 191G>A, 341T>C, 590G>A, and 857G>A SNPs, reduce the acetylation 
activity of the NAT2 enzyme, resulting in the slow acetylation (SA) phenotype [168, 
175]. In vitro expression studies indicate that none of these SNPs alter the level of mRNA 
transcribed from these alleles [168, 176, 177], thereby indicating that they do not affect 
the rate of gene expression. However, the level of protein derived from the 191A, 590A, 
and 857A alleles was significantly reduced, whereas in the case of the 341A allele it was 
not [176]. Furthermore, only the 857A polymorphism exhibited an increased affinity 
towards the probe substrate (SMZ), as well as a decreased affinity for the cofactor 
acetyCoA. This latter finding supports the results of Hickman et al [178], who also 
reported that the 857G>A SNP exhibited an increased affinity for some substrates (SMZ 
and dapsone) but not others (INH and 2AF). 
Similar in vitro functional characterisation of the other SNPs conferring the SA 
phenotype, namely, 190C>T (2*19), 364G>A (2*12D), 411A>T (2*5I), 434A>C (2*17), 
and 499G>A (2*10), also confirmed that their reduced acetylation capacity was due to the 
decrease in the level of the active protein, rather than to a change in the level of mRNA 
expressed from these NAT2 alleles [175, 177, 179, 180]. In the case of the 2*12D 
(364G>A and 803A>G SNPs) and 2*5I (341T>C, 411A>T, 481C>T and 803A>G SNPs) 
alleles, the presence of the 364A and 411T SNPs respectively, affected the overall 
acetylation, resulting in undetectable levels for the corresponding proteins, when assayed 
via Western Blot analysis [180]. Thus the rapid acetylation phenotype, conferred by the 
481C>T and 803A>G SNPs [168, 181] is completely abrogated in these alleles. 
These authors also found that the 499G>A and 857G>A SNPs caused a moderate 
reduction in enzyme activity, approximately 40% lower than that observed for the 
reference 2*4 allele. In addition, the 499G>A SNP appears to affects the stability of the 
protein without compromising the kinetic activity of the 2*10 allele, with respect to the 
substrate and the cofactor acetyl-CoA. It would therefore appear that separate 
mechanisms may prevail in influencing the slow acetylator activity at the NAT2 protein 
level. This would imply that there could be different rates of slow acetylation activity, 
intrinsic to a particular SNP or haplotype, expressed via aberrant or improper protein 
folding, or inherently unstable proteins, that undergo an accelerated degradation within 
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the cellular environment. This kind of differential phenotypic activity has been 
demonstrated for the 2*6A, 2*7B and 2*14A alleles, which exhibited a lower activity than 
found for the 2*5A, 2*5B and 2*5C alleles [174, 182]. The activity of these 2*5 alleles 
was reduced by approximately 25% when compared to the 2*4 allele, whereas the 
activities for the 2*6A, 2*7B and 2*14A alleles were reduced by more than 70% with 
respect to 2*4 over the same time period. 
The determination of the individual’s NAT2 acetylation status generally focuses on an 
analysis of the following 7 SNPs as the means of defining the acetylation status, namely 
191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, and 857G>A [168, 175, 177]. 
Whilst there is some contention surrounding the activity conferred by the 282C>T SNP, 
its inclusion is based upon the observation that it often occurs in linkage equilibrium, as 
part of the 2*5, 2*6, 2*7 and 2*14 allele clusters (haplotypes). Similarly, the 803A>G 
SNP is seldom observed as an individual SNP, and also forms part of the above 
haplotypes, where, by convention, they are considered to play a secondary role to the 
activity-altering SNP defining these clusters [177]. 
Furthermore, the 341T>C, 590G>A, and 857G>A SNPs also form part of the 2*14C, 
2*5J and 2*6I alleles respectively, where their role in the overall acetylation status is still 
obscure, since the phenotype of these alleles has not, to our knowledge, been determined 
via in vitro expression analyses. In addition, many reports in the literature genotype the 
481C>T SNP as a proxy for the 341T>C SNP, since these SNPs are considered to be in 
linkage disequilibrium [62, 164, 183, 184]. However, this type of assay would yield 
erroneous results, since the 481C>T SNP is not present in several of the alleles classified 
among the NAT2*5 haplotypes, such as for example, 2*5C, 2*5D, 2*5E. These results 
therefore highlight the importance of investigating the contribution of the various NAT2 
SNPs both individually, as well as within the context of their respective alleles, in order to 
assay the accurate acetylation phenotype within individuals. This could be particularly 
important since the different SNPs may not be equally distributed within different 
individuals and/or populations. 
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1.3.6.2.2 Ethnic Distribution of NAT2 Polymorphisms 
Analysis of the acetylation status in different populations indicate that the 
frequency of occurrence of fast and slow acetylators differs between population groups 
[185-187]. The phenotypic fast acetylation is conferred by the homozygous wild type F 
allele (FF; usually 2*4, but increasingly 2*12 and 2*13 are also included as the genotypic 
equivalent), and slow acetylation by the homozygous S allele (SS; combinations of either 
of the 2*5, 2*6, 2*7, or 2*14 genotypic alleles). 
Genetic analyses on the other hand, also suggests a heterozygous FS genotype, equated to 
an intermediate acetylation status in studies of certain population groups [38, 63, 173]. 
However, in studies of Caucasian populations the FS genotype is often considered to 
confer the FA phenotype [62, 171]. This bi- and trimodal acetylation classifications have 
persisted in the literature, despite the statement by Weber that “acetylation is determined 
by two major alleles without dominance.” [46]. Secondly, the NAT2 gene has been 
mapped to chromosome 8p22 [84, 86], and no epigenetic effects, such as an altered 
methylation status, have been reported for NAT2 alleles. Hence it is more likely that these 
alleles are equally expressed in the cell. Thus, there is very little support for the idea that 
the F allele is the dominant allele, thereby arguing against the assignment of the FS 
genotype to a FA rather than an IA status. 
Table 1.6 depicts the NAT2 allele frequency reported for different population groups. 
Currently the number and type of alleles investigated in most populations is incomplete, 
and several of the interesting NAT2 alleles are often not determined. For example the 
191G>A SNP (2*14 allele) is often omitted from the analysis since it is considered to be 
an “African” allele [164]. However it has also been found in Brazilians [188], Caucasians 
[174], Emiratis [189], and Hispanics [185], as well as ethnic individuals from South India 
[172], thereby suggesting that it would be erroneous to omit it from the population 
analysis based upon the physical appearance of the subjects in the cohort. 
The general trend seen in Table 1.6 indicates that the FA genotype frequency is 20-25% 
in Caucasians, compared to 60-70% in Oriental populations [190]. In other parts of the 
world, the picture is difficult to interpret since the extant information often consists of 
phenotype-derived data only. Patin et al [167, 190], in reporting on the evolutionary 
history of the NAT genes, indicate an extended spectrum of NAT2 acetylation phenotypes 
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across the world, and importantly, within the African continent. They compared the 
results of studies in Eskimos, Koreans, Japanese, Papua New Guineans, and Pygmies, 
which indicate that the frequency of slow acetylators in these populations is very similar, 
at approximately 20%. In Germans and Russians on the other hand, the frequency of slow 
acetylators is 50-60%, similar to that reported for Zimbabweans [191], and some South 
African population groups [155]. 
Studies of African populations also indicate a wide spectrum of slow acetylation, ranging 
from 40% in Yorubas in Nigeria [192], 10-18% in Pygmies, and 70% in Somalis [193], to 
greater than 80% in northern Sudanese [194]. This data therefore indicates that an 
acetylation study of “African individuals” should not be extrapolated to include Africans 
in general, since there is a clear shift in the frequency of SA within the continent, from 
west to east, and even from north to south. This observation may be of particular 
importance with regard to the global TB pandemic, given that Sub-Saharan African is one 
of the regions of the world that experiences the highest burden of TB disease (WHO 
Report, 2007). Given this inter-relatedness between the individual’s inherent capacity for 
metabolising INH and the very high burden of TB disease within the region, there may be 
considerable merit to the suggestion that INH treatment should be individualised to 
achieve the greatest treatment efficacy. 
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Table 1.6 NAT2 Allele (Haplotype) frequencies in different population groups 
Population 
Allele Frequency (%) 
Citation 
NAT2*4 NAT2*5 NAT2*6 NAT2*7 NAT2*14 
European       
British 26 45 27 1.6 n.d. [62] 
Scottish 20 49 27 3.6 n.d. [195] 
German 23 47 28 1.3 n.d. [174] 
French 18 52 25 1 n.d. [192] 
Spanish 25 39 27 1.4 n.d. [196] 
Portuguese 21 43 33 2.7 n.d. [197] 
Turkish 46 27 23 4 n.f. [184] 
North American       
Caucasian (USA) 25 45 28 2 n.f. [164] 
African-American 36 30 22 2 9 [164] 
Asian       
Chinese 62 5 19 14 n.d. [198] 
Korean 60 2 23 15 n.f. [199] 
Japanese 61 1.8 25 10 n.f. [161] 
Indian 23 37 32 1.5 n.f. [200] 
Thai 38 4 33 20 n.d. [201] 
South American       
Embera
a
 63 10 4 23 n.d. [202] 
Ngwabe
a
 74 2.5 0 23 n.d. [202] 
Amerindians
b
 51 25 6 20 n.d. [203] 
Brazilian 20 38 26 4 3 [188] 
African       
Egyptian 21 50 26 3 n.d. [171] 
Iranian 43 32 19 6 n.f. [204] 
Gabonese 27 41 22 2 8 [192] 
Dogons 13 30 47 3 7 [192] 
Tanzanian 30 34 21 3 12 [191] 
Zimbabwean 28 31 21 6 14 [191] 
Venda 23 39 22 5 11 [191] 
Xhosa 60 20 15 2 3 [205] 
Coloured 54 25 11 3 5 [205] 
n.d. = not determined by experimental assay; n.f. = not found in cohort studied 
a
 = Native American tribes resident within Panama and Colombia 
b
 = Native American tribes resident within Argentina and Paraguay 
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1.4 NAT Acetylation and TB treatment Efficacy 
It is feasible that INH is exclusively inactivated by the NAT2 acetylation 
reaction, since NAT1 has not yet been shown to be involved in the acetylation of INH 
[97]. However, given the significant structural similarity between these enzymes [83], it is 
not inconceivable that NAT1 and NAT2 are isoenzymes, with the capacity to act 
synergistically. In this context, it is interesting to note that in 1951 Mark et al [206] 
reported that PABA (a NAT1-specific substrate) is formed during the metabolism of PRO 
(a NAT2-specific substrate), thereby respectively implicating both NAT2 and NAT1 in 
this metabolic pathway. However, the recent in vitro analyses by Kawamura et al [97] 
indicated that NAT1 and NAT2 exhibit a dissimilar substrate-specificity towards PABA. 
On the other hand, Fretland [207] et al showed that 4-aminobiphenyl (ABP) is acetylated 
by both Nat1 and Nat2, the murine homologues of human NAT2 and NAT1, respectively. 
 
A study by Mitchell and Warshawsky [125] showed that the upstream promoter domains 
of both these genes contains promoter sites which are induced in a tissue-specific rather 
than substrate-specific manner. in vitro tests in a liver cell line, indicated that both PAS 
(NAT1-specific substrate) and SMZ (NAT2-specific substrate) induce similar rates of 
expression for both NAT1 and NAT2 enzymes, whereas in bladder cells, both these 
substrates only affected NAT1 expression. This is an interesting result, since it is 
commonly accepted that SMZ is a NAT2-specific substrate, which is not metabolised by 
NAT1 [97], and therefore the question remains as to whether these genes, given their 
close proximity, and similarity as isoenzymes, act exclusively and/or co-operatively in the 
acetylation metabolism. In a study conducted in Caucasians, Smelt et al [208] reported 
that the prevalence of the NAT1*10 and NAT2*4 haplotype occur 3.5 times more 
frequently than expected by chance association. Subsequent studies [147, 209] have 
reported a similarly higher occurrence for the NAT1*10 allele in Caucasians genotyped as 
NAT2 FA. The significance of any linkage disequilibrium between NAT1 and NAT2 is 
unknown, and has yet to be tested with respect to these and other NAT haplotypes in 
various diseases, if we are to develop a better understanding of the involvement of NATs 
in the overall acetylation reaction. 
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1.4.1 Optimising the INH Dosage 
Over the past 50-60 years the treatment of TB has been refined to the current 
internationally standardised DOTs (directly observed treatment, short course) protocol, in 
which patients are treated for a period of six months, with a defined drug regimen 
containing INH. An essential component of the DOTs protocol is a well-structured 
programme to manage ambulatory patients, many of whom are socially disadvantaged. 
This requires that the strategy for optimal large-scale therapy be adapted to a single most 
suitable regimen for this type of programmatic care, since there is a logistical and 
economic advantage to this standardised care. At present the uniform INH dosage 
recommended by the World Health Organisation (WHO) is 5 mg/kg body weight, with a 
range of 4–6 mg/kg [210]. However, an argument can be made for individualised 
treatment, based upon the uptake and metabolic characteristics of individual patients, 
given the apparent localisation of the burden of disease in some parts of the world. 
In developing countries such as South Africa, individualized treatment may not be 
practicable owing to very limited resources, and large numbers of patients. In this 
situation an equitable balance needs to be achieved between treatment efficacies on the 
one hand, and drug toxicity on the other. Adverse drug reactions (ADRs) are a well 
known feature of the TB treatment regimens, and it has been established that INH causes 
toxic side effects in a number of TB patients [211, 212]. In this respect the two primary 
forms of toxicity are peripheral neuropathy and hepatotoxicity. Hepatotoxicity, although 
not common amongst TB patients, can be fatal, and has been suggested to occur more 
frequently in slow acetylator (SA) individuals [213]. 
Treatment efficacy therefore, is dependant upon the combined effects of the anti-
bactericidal activity occurring at a particular INH dosage, together with the individual’s 
metabolism of INH. INH pharmacokinetic studies indicate that the maximum early 
bactericidal activity (EBA) of the drug occurs at 2 hours post dose, at a concentration of 
2-3 µg/ml [173]. However, because the individual’s inherent acetylator status would 
ultimately influence this response, it has been suggested that FA and IA adult individuals, 
due to their relatively rapid rate of acetylation, would exhibit a sub-optimal INH anti-
bactericidal activity, when given the WHO-recommended doses of 250-300 mg of total 
INH. Therefore these individuals should arguably be given a larger dosage of INH to 
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achieve an optimal EBA, as well as reduce the risk of developing drug resistant Mtb 
strains [214, 215] resulting from doses of INH which may be sub-lethal for these 
mycobacteria. Whilst the clinical importance of these observations with regard to 
individuals who are fully compliant with the treatment regimen has been questioned 
[216], the deficiencies of FA and IA individuals may become more pertinent, since the 
lower INH concentrations may translate into treatment failure or development of mono-
resistance, as well as progression to multi-drug resistance, and hence persistence of 
disease [217, 218]. 
When compared to RA individuals, SA take approximately twice as long to metabolise an 
equivalent amount of INH (Parkin, DP (1996) Ph.D. Dissertation. 
http://hdl.handle.net/10019.1/1267), and should probably be given a smaller INH dosage 
to reduce the risk of the development of drug-induced hepatotoxicity [211, 219], since it 
has been suggested that the SA may be more susceptible to this adverse effect [213]. 
Drug-induced hepatotoxicity (DIH) leads to serious deleterious consequences for the 
efficacy of TB treatment, since it necessitates interrupting the treatment regimen, and 
consequently the treatment period is prolonged. In additional, the interruption of 
treatment may also increase the risk for the development of drug-resistant organisms, 
which are more difficult to treat, and require the use of less effective, yet more toxic 
“second-line” anti-tuberculosis drugs. 
The relationship between the acetylator status and the development of DIH is still 
controversial, mainly because the incidence of DIH is often idiosyncratic and difficult to 
predict [220]. However, some reports in the literature postulated that RA individuals 
would be more prone to DIH due to the rapid accumulation of toxic intermediates formed 
during the metabolism of drugs such as INH [221]. More recently SA have been 
implicated as being more prone to the development of ADR [213, 222]. This apparent 
contradiction suggests that the role of the individual’s acetylation status requires further 
investigation to fully elucidate the contribution of RA and SA to DIH. 
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1.4.2 The role of TB drugs in Hepatotoxicity 
The WHO recommended treatment for drug susceptible TB consists of a drug 
regimen of isoniazid, rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) 
maintained for a period of at least 6 months (WHO, Treatment of Tuberculosis; 
guidelines for national programmes, 2009). Despite the effectiveness of this regimen in 
curing more than 95% of patients of their tuberculosis [223], it is well-known that DIH 
occurs within the first 2 - 4 months of treatment, which can severely reduce efficacy of 
treatment [224]. Anti-TB drugs are usually co-administered in combination therapy, and 
whilst the contribution of individual drugs to the development of DIH is still controversial 
[225], it has been shown that INH, RIF and PZA are potentially hepatotoxic [226, 227]. In 
this regard most of the data involves the well known metabolism of INH, since this drug 
is widely used as a single drug regimen for the prophylactic treatment of latent TB [228]. 
Currently it is believed that the drug-induced hepatotoxicity is caused by toxic 
metabolites formed during the metabolism of INH (Fig. 1.10). 
 
Figure 1.10. Proposed route of isoniazid metabolism in the human liver. 
Drug metabolising enzymes involved in the pathway are indicated in text 
boxes, whilst the major catalytic pathways are highlighted by solid lines. 
Potential, subsequent reactions are indicated by dotted lines. Hepatotoxic 
compounds are indicated by the asterisk. 
Adapted from Yew et al, (2006) [229] and Tostman et al, (2008) [225]. 
NAT = arylamine N-acetyltransferases; CYP = Cytochrome P450 enzymes; 
GST = Glutathione S-transferase  
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The primary hepatotoxic intermediates formed during INH metabolism have been 
identified as acetylhydrazine and hydrazine [226] formed via the metabolic pathways 
outlined in Fig.1.10. Initially INH is acetylated by NAT2 to form acetylisoniazid, which 
is subsequently hydrolysed to acetylhydrazine [230]. The acetylhydrazine then undergoes 
another round of acetylation, forming the non-toxic metabolite diacetylhydrazine. In 
addition, the acetylhydrazine can be oxidised into hydrazine via an alternate pathway 
mediated by the cytochrome P450 (CYP450) family of enzymes, which appear to be 
inducible by RIF [229]. Furthermore, whilst it is believed that the NAT2-mediated 
acetylation of INH is the predominant metabolic pathway, the hydrolysis reaction to form 
hydrazine [231], indicates that RIF and INH can have a combined effect on hepatotoxicity 
[232]. This latter reaction has recently been shown to proceed via the RIF-mediated 
induction of CYP2E1 [233]. 
Thus far, the incidence of DIH has been investigated mainly in Caucasians and certain 
Asian populations, and shown to vary between 2% and 28% [225, 234]. The direct 
contribution of RIF and/or PZA to this hepatotoxicity is still largely unknown, yet PZA 
toxicity has been shown to be largely dose-related, and a low dosage of 20-30 mg/kg of 
PZA obviates the development of acute DIH [226]. The metabolism of PZA proceeds via 
xanthine oxidase, and currently the mechanism of PZA-toxicity is controversial: PZA was 
shown to inhibit CYP450 enzymes in a study of rat microsomes [235], whereas PZA had 
no effect in a similar study using human liver microsomes [236]. However, it has recently 
been shown that PZA toxicity can be induced by hydrazine in vitro [237]. This latter 
result, together with the proposed RIF-mediated formation of hydrazine, could suggest a 
potential mechanism whereby INH-induced hepatotoxicity can be exacerbated by both 
RIF and PZA during treatment. 
Mycobacterium tuberculosis is a slow growing organism, and effective anti-TB treatment 
regimens are of necessity relatively long, and often protracted. Consequently, treatment 
efficacy is constrained by the development of DIH, leading to treatment suspension or 
interruption, which further concatenates the treatment period, and could facilitate the 
emergence of drug-resistant organisms, thereby fuelling the TB pandemic. 
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1.4.3 The Effect of NAT Acetylation on Treatment Efficacy 
1.4.3.1 Acetylation Polymorphisms and Treatment Response 
TB treatment efficacy hinges upon the effective elimination of Mtb organisms 
from the human host [14], yet the activity of INH, the primary anti-TB drug, is 
diminished by the human NAT2 enzyme [18, 35, 39]. The enzyme’s activity, in turn, is 
defined by several well-characterised exonic SNPs [44, 50, 62], which collectively 
constitute the mechanism underlying the “classical” acetylation polymorphism, of fast 
(FA), intermediate (IA) and slow acetylation (SA). Hence, the overall acetylation activity 
will be differently constrained by the individual alleles defining the slow (SS), 
intermediate (FS), or fast (FF) genotype (or diplotype). This activity can primarily be 
correlated with the SNPs at 191, 341, 590 and 857, which characterise the 2*14, 2*5, 2*6 
and 2*7 alleles respectively [140, 168]. Secondly, it has been demonstrated that these 
individual SNPs, do not affect the rate of acetylation to the same degree [176, 182]. So for 
example, Grant et al [182] demonstrated that the 2*5 allele still exhibited 75% acetylation 
activity when compared to the reference 2*4 allele, whereas the activities for the 2*6A, 
2*7B and 2*14A alleles dropped to less than 22% of the 2*4’s activity over the same time 
period. Similarly, Zang et al [177] found that the enzyme encoded by the 857G>A SNP 
exhibited a greater binding affinity for acetyl-CoA, which indicates that the formation of 
the activated acetyl-NAT intermediate (Fig.1.2) is enhanced in the 2*7 allele. 
Furthermore, this particular NAT2 variant exhibited distinct binding affinities for 
different substrates. 
These results therefore suggest that the metabolism of INH would be subjected to varying 
degrees of acetylation activity, depending upon the identity of the individual SNPs and 
alleles in the genotype. Hence combinations of the “reference” allele with different 
polymorphic alleles, will give rise to differential rates of acetylator activity amongst IA 
individuals, and similarly, different polymorphic allele combinations would give rise to 
differential rates of SA activity. In the context of treatment efficacy, these differential 
rates of acetylation between FA, IA and SA individuals, could translate into 
individualised serum INH concentrations in patients resulting in degrees of treatment 
response and efficacy, which may form the basis for the varying treatment responses 
observed in patients when employing the recommended doses of INH [217, 218]. 
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As indicated previously, there is a direct concordance between acetylator genotype and 
phenotype, and the frequency of the activity-altering SNPs differs amongst population 
groups. Thus for example, the 2*5 allele predominates amongst Caucasians, the 2*6 allele 
is more prevalent in Asian populations and amongst Amerindians in South America, the 
2*7 allele predominates (see Table 1.6). Furthermore, Grant et al [182] has shown that the 
overall activity of the NAT2 proteins derived from individual SNPs, is also very 
dissimilar. For example, a comparison of the acetylation half life between the enzymes 
encoded by the NAT2*5 and NAT2*6 alleles, showed that the overall rate of acetylation 
was reduced to a greater extent in the case of NAT2*6, when compared to the wild-type 
NAT2*4 allele. Thus, depending upon the relative frequency of particular NAT2 SNPs, the 
relative rate of acetylation for substrates like INH would vary between populations. In 
this context, the overall NAT2 genotype could determine the different responses to 
treatment observed between populations, as well as between individuals with different 
genetic backgrounds within a population. 
The information available on NAT2 genotypes for populations  on the African continent  
is generally very limited, and the SNP frequencies, contributing to the acetylation 
polymorphism have not been well documented [155, 190, 191, 205]. Similarly, whilst the 
aetiology and incidence of DIH is relatively unknown, a lack of treatment efficacy due to 
DIH has variously been linked to old age [238], malnutrition [239], gender [240] and 
alcohol intake [241]. However, these research publications have also implicated the role 
of inherent genetic factors, and recently these aspects have received more attention. 
Several reports describe an association between anti-TB drugs and hepatotoxicity, 
particularly in relation to INH and its known metabolism [221, 224-226, 228]. This serves 
to underline the importance of delineating the effects of the acetylation polymorphism in 
countries with a high burden of TB disease. Thus DIH and non-compliance with 
treatment may be fuelled by the activities of the inherent drug metabolising enzymes, and 
hence act synergistically in reducing treatment efficacy, and facilitate the continued 
spread of disease. The overall effect would be an increase in the morbidity and mortality 
among patients, whilst also facilitating the emergence of drug resistant organisms. 
The polymorphic acetylation status inherent in individuals requires further investigation 
to determine its contribution to, and association with, the epidemiology of the global TB 
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pandemic, given the fact that TB is an infectious disease. In this respect, the metabolism 
of therapeutic drugs like INH may affect various aspects of treatment efficacy either 
separately and/or additively. Therefore, the general effect of acetylation in SA and RA TB 
patients in diverse populations, from high burden countries, may need to be investigated 
more comprehensively, to determine the contribution of population-specific activity-
altering SNPs, in reducing the optimal serum concentration of INH during treatment. 
Secondly, the role of the formation of toxic metabolites such as hydrazine (Fig.1.10), 
suggested to play a greater quantitatively role in the DIH in SA rather than RA [242] is 
still largely unknown, and needs further investigation, particularly in the developing 
countries in Sub-Saharan Africa, where an analysis of the frequency of NAT2 SNPs, as 
they pertain to the acetylation polymorphism has been neglected. In this context, it is 
interesting to note that the prevalence of the acetylation polymorphism conferred by the 
NAT2*6 allele in Japanese cohorts, has been associated with an increased risk of DIH in 
SA rather than RA individuals. [222, 243] 
 
During the lucrative spice-trade era between West and East, South Africa was an 
important stop-over destination, and consequently its populations have assimilated 
genetic ancestries from indigenous African, Caucasian and Asian populations. This is 
particularly evident in the local population group known as South African Coloured 
(SAC) [244, 245]. Given the current information with regard to the acetylation 
polymorphism in Caucasian and Asian populations, as well as the dearth of information in 
African populations, South African populations such as the SAC may afford a seminal 
opportunity to investigate acetylation polymorphisms against the inherent genetics in 
local population enclaves. The primary significance of such an analysis would afford a 
better understanding of the assimilated acetylation knowledge, as well as contribute to our 
understanding of the epidemiology of TB, particularly in a high burden of disease-setting, 
such as the Western Cape region of South Africa. 
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1.5 Hypothesis and aims of the study 
The Arylamine N-acetyltransferase enzymes, NAT1 and NAT2 are important drug 
metabolising enzymes because they acetylate various xenobiotics and key therapeutic 
drugs, such as p-amino-salicylate [44] and isoniazid [18], used in the treatment of 
tuberculosis [35, 39, 75]. 
These enzymes exhibit an inter-individual variation in this acetylation metabolism due to 
several well characterised genetic polymorphisms. The efficacy of anti-tuberculosis 
treatment regimens may therefore be compromised by the activity of these NAT enzymes. 
Furthermore the inter-individual variation in enzyme activity may also be effected by 
differences in the frequency distribution of these genetic polymorphisms within admixed 
populations. 
 
 
1.5.1 Aims of the study 
 To analyse the population diversity of NAT polymorphisms in adults in local 
ethnic groups. 
 To investigate NAT polymorphisms in a South African Coloured community 
experiencing a high incidence of tuberculosis disease. 
 To test the effect of NAT2 polymorphic variation in children diagnosed with 
tuberculosis disease. 
 To evaluate NAT2 acetylation polymorphisms in children to establish 
effective treatment guidelines for isoniazid dosing. 
 To evaluate the influence of the inter-individual variation in the NAT2 
acetylation capacity on the early bactericidal activity of isoniazid. 
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CHAPTER  2 
Materials and Methods 
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2.1 Chemicals and Reagents 
All chemicals utilised in the experimental procedures were of analytical grade 
quality and purchased from the British Drug House (BDH) Laboratory Suppliers (UK), 
Merck (Germany), and the Sigma-Aldrich Company (USA). 
Molecular biology reagents, restriction enzymes, and kits for the manipulation of DNA 
were purchased from Invitrogen (USA), the Promega Corporation (USA), Roche 
Molecular Diagnostics (Germany), Fermentas International Incorporated (Canada) and 
Amersham Biosciences (General Electric Healthcare, USA). 
The solutions, buffers, reagents and laboratory equipment, as well as the resources for the 
manipulation of the data, are detailed in the text when required and also at the end of this 
chapter. 
 
 
2.2 Sample Cohorts 
Unaffected and unrelated individuals from among the Caucasian, Coloured and 
Xhosa ethnic population groups, resident in the Western Cape Province of South Africa, 
were selected for inclusion in the study. These individuals were classified on the basis of 
their own self-identification with these ethnic groups, based upon the collective values 
and cultural norms ascribed to by the individual group. Individuals from the Xhosa group, 
although an established ethnicity in the Western Cape province, often still identify with a 
group cultural home-base in the Eastern Cape region of South Africa. The individuals 
drawn from the Caucasian and Coloured groups consider themselves to be an endemic 
population to this region of the country. 
Coloured and Xhosa TB patients’ samples were sourced from the Tygerberg and 
Brooklyn Chest Hospitals, as well as from suburban clinics within the Ravensmead-Uitsig 
area of the Cape Town metropolitan region. 
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2.3 Sample Preparation and Analysis 
2.3.1 DNA Purification 
Genomic DNA (gDNA) was prepared from 3-5 millilitres (ml) of peripheral whole 
blood collected from each individual, in separate EDTA-containing vacutainer tubes (BD 
Vacutainer Systems, Plymouth, UK). The blood samples were collected on ice, and 
transported to the laboratory on the same day, where they were then stored at –20 degrees 
Celsius (°C). This approach enabled us to obtain good yields of deoxyribonucleic acid 
(DNA), from each blood sample; a minimal complemented of ribonucleic acid (RNA) 
was also obtained, during each purification. 
Good quality high molecular weight gDNA was extracted using a salting out procedure 
[246]. The method entails the removal of the cellular proteinaceous material by simple 
dehydration and precipitation, which obviates the use of hazardous organic solvents. 
Each blood aliquot was diluted with 5-6 volumes of ice-cold Cell Lysis Buffer (320 mM 
sucrose, 1% Triton X-100, 5 mM MgCl2, 10 mM Tris, pH 7.6) in a sterile 50 ml 
polypropylene centrifuge tube (Corning Incorporated, USA), and then mixed vigorously 
by hand-inversion 20-30 times. Thereafter the tubes were centrifuged at 3000 revolutions 
per minute (rmp) for 15 minutes at 4°C, in an Eppendorf centrifuge, model 5810R. The 
resulting pellet was resuspended in 6 ml of Nuclei Lysis Buffer (400 mM NaCl, 10 mM 
Tris, pH 8.2, 2 mM EDTA, pH 8.2), supplemented with Sodium dodecyl sulphate (SDS) 
to a final concentration of 1%, and digested with 200 micrograms (µg) of proteinase K 
enzyme for 2 hours at 55°C (concentration of the proteinase K stock solution is 10 
milligrams per millilitre (mg/ml)). 
Thereafter, 2 ml of a saturated sodium chloride (NaCl) solution (> 6 M) was added to the 
sample tube, and the contents gently hand-mixed to homogeneity, to reduce shearing of 
the DNA. The tubes were then centrifuged at 4000 rpm for 30 minutes at 4°C, to pellet 
the proteinaceous debris. gDNA was precipitated from the supernatant by the addition of 
2.5volumes of room temperature absolute ethanol. The precipitated gDNA was allowed to 
float to the meniscus, before being spooled out with a Pasteur pipette, the end of which 
had been heat sealed. 
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The purified gDNA was washed with 70% ethanol, briefly heat dried at 37°C (15-20 
minutes), and then re-dissolved in 800 µl of sterile 0.5x TE (10 mM Tris, pH 8.0, 1 mM 
EDTA, pH 8.0) buffer [247] for 16 hours at 4°C. 
 
2.3.2 DNA Concentration and Purity 
The quantification of the purified nucleic acid solution was determined 
spectrophotometrically at 260 and 280 nanometres (nm), by measuring the absorbance 
(Abs) of a diluted sample aliquot placed in a beam of light having a 1centimetre (cm) path 
length. Under these conditions a solution of double stranded DNA with a concentration of 
50 µg/ml has A260 = 1 [247]. 
The ratio between the readings at 260 nm and 280 nm (A260/A280) - used to estimate the 
purity of the gDNA in solution - was generally found to have a value between 1.8 and 2.0, 
thereby demonstrating good deproteinisation of the samples. Solutions of pure DNA have 
an A260/A280 value of 1.8 [247]. In those samples where the value of the A260/A280 ratio 
was closer to 2, the integrity of the gDNA was evaluated by gel electrophoresis against a 
commercially supplied preparation of purified Lambda DNA (Roche, USA). A calculated 
500 ng quantity of gDNA was assessed against 500 ng of uncut lambda DNA. The 
samples were separated in 0.7% Seakem
®
 LE agarose (BioWhittaker Molecular 
Applications, USA (BMA)), stained with a fluorescent DNA dye (GelStar
®
 nucleic acid 
stain (BMA), and visualised under ultra-violet light. In all cases the gDNA appeared as a 
single high molecular weight band, comparable in size and intensity to the band of 
lambda DNA. Furthermore these samples generally exhibited a minimal complement of 
RNA, apparent as a lesser staining front lower down the gel. 
 
2.3.3 Agarose Gel Electrophoresis 
Agarose gels, utilising either Seakem
®
 LE agarose (BMA) or MetaPhor
®
 agarose 
(BMA) were used for the electrophoresis of gDNA, as well as to assess the products of 
PCR amplification. PCR product sizes were compared to commercially supplied DNA 
markers – 100 bp DNA Ladder (Promega, USA), or GeneRuler 100 bp Plus (Fermentas 
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Inc., USA). The gels were prepared in 0.5x Tris-Borate-EDTA (TBE) buffer (45 mM 
Tris, 45 mM Borate, 1 mM EDTA, (pH 8.0)), in a mini-gel apparatus (Omeg Scientific, 
South Africa) with gel dimensions of 100 mm x 65 mm x 3.5 mm, or when required for 
the analysis of many samples, in the larger GNA 200 submarine unit (Pharmacia, USA), 
with gel dimensions 200 mm x 200 mm x 4 mm. 
Sample DNA aliquots were mixed with a Blue/Orange DNA loading dye (Promega, 
USA), loaded onto the gel, and then electrophoresed at 15 volts per centimetre (v/cm), 
using 0.5x TBE as conductance medium. Thereafter the gels were stained at room 
temperature for 20 minutes, in a solution of 0.5x TBE containing the GelStar® Nucleic 
Acid stain (BMA), diluted to a 1x final concentration. The gels were visualised on the UV 
transilluminator (UVP, USA), and photographed using the Kodak Electrophoresis 
Documentation and Analysis 120 System (Kodak Digital Science, Eastman Kodak Co., 
USA). 
 
2.3.4 PCR Amplification and Analysis of the NAT2 Gene 
A fragment of the NAT2 gene (http://www.ncbi.nlm.nih.gov/nuccore/219871) was 
amplified via the Polymerase Chain Reaction (PCR) technique (Roche, USA) using the 
gene-specific primer set HuNAT14 (5’-726GACATTGAAGCATATTTTGAAAG748-3’) 
and HuNAT16 (5-
1724
GATGAAAGTATTTGATGTTTAGG
1702
-3’), previously described 
by Hickman and Sim [62]. All primers were supplied by Integrated DNA Technologies 
(www.idtdna.com). The PCR amplification reaction was performed in a total volume of 
100 µl, and consisted of 150 ng of gDNA, 20 mM Tris buffer (pH 8.4), 50 mM KCl, 0.2 
mM each of dATP, dGTP, dCTP, and dTTP, 2.5 mM MgCl2, 0.25 µM of the HuNAT14 
and HuNAT16 primers, and 1 unit of Taq DNA Polymerase I (Gibco BRL Life 
Technologies, USA). The amplification reactions were carried performed in the Gene 
Amp PCR System 2400 (Applied Biosystems, USA) which was programmed to execute 
the following temperature cycling conditions:- initial denaturation at 94°C for 5 minutes, 
followed by 35 cycles of alternating denaturation at 94°C for 30 seconds, annealing at 
56°C for 40 seconds, and polymerisation at 72°C for 80 seconds; this was followed by an 
extended polymerisation at 72°C for 10 minutes, where after the sample tubes were 
cooled to 4°C, and maintained at that temperature for 30 minutes. 
Stellenbosch University  http://scholar.sun.ac.za
 - 51 - 
A 5 µl aliquot of each sample reaction was analysed for NAT2 product specificity and 
PCR efficiency by submarine gel electrophoresis (described above) using the Omeg mini 
gel apparatus. In addition, the specificity of the PCR product was assessed by the 
restriction enzyme analysis with HindIII and HincII (Fig. 2.1). 
 
 
 
Figure 2.1 NAT1 and NAT2 amplified products restricted with HincII and HindIII 
enzymes, to indicate the specificity of the reactions. NAT1 (lane 1) is only cleaved by 
HindIII, whilst NAT2 (lane 3) is only cleaved by HincII. Lanes 2 (NAT1) and 4 (NAT2) 
represent undigested PCR product. Lane M contains the GeneRuler
TM
 100bp DNA ladder, 
(SM0321, Fermentas International Inc., Canada), with 14 bands decreasing in size from 
3000 bp, 2000 bp, 1500 bp, 1200 bp, 1000 bp, 900 bp, 800 bp, 700 bp … to 100 bp. 
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2.3.5 Restriction Endonuclease Analysis of the NAT2 gene 
A 15 µl aliquot of each 100 µl PCR sample solution were digested separately with 
the restriction endonucleases BamHI, DdeI, FokI, KpnI, MspI, and TaqI, respectively. All 
restriction endonuclease (R.E.) digestions were carried out in accordance with the 
recommendations of the specific R.E. manufacturer. BamHI, KpnI, MspI, and TaqI 
restriction enzymes were supplied by Fermentas (Canada), DdeI was supplied by Roche 
(Germany), and FokI was supplied by Amersham Biosciences (USA). 
Restriction endonuclease incubations were carried out at 37°C, - except for TaqI, which 
was carried out at 65°C for 3-4 hours utilising 1unit of enzyme per 10 ul aliquot of the 
PCR reaction volume. In the case of the FokI restriction, the digestion period was limited 
to a maximum of 2 hours, and the enzyme quantity was reduced to 0.6 units of enzyme 
per 10 µl PCR aliquot. This enzyme is prone to non-specific cleavage of the DNA in 
situations of over digestion - that is, longer than 2 hour incubation and/or a ratio of greater 
than 5 units FokI per µg DNA [248]. 
An additional restriction of the BamHI, KpnI and MspI restricted products was also 
performed using PstI. This R.E. cleaves the NAT2 PCR product twice at nucleotide 
positions 324 and 621 of the amplified sequence, generating cleavage products of 377 bp, 
324 bp and 297 bp (Fig. 2.2). These latter cleavage products provide additional 
information to score the BamHI, MspI and KpnI digestion products, respectively. 
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Amplified NAT2 gene fragment (1000bp)
MspI
PstI PstI
KpnI BamHI
146
324 297 377
BamHI
KpnI
MspI
PstI
92 232
148 149
231
 
Figure 2.2 Diagram showing the relative restriction enzyme cleavage sites in the 
NAT2 gene product. The additional cleavage with the PstI enzyme (round dotted lines) 
generates fragment lengths which facilitate the MspI (324bp), KpnI (297bp) and 
BamHI (377)-specific analysis via polyacrylamide gel electrophoresis. 
 
These double digests generate fragment profiles possessing bands of less than 500 bp in 
size, which are specific for MspI, KpnI and BamHI, respectively. This facilitates the easy 
and accurate resolution of these profiles via non-denaturing polyacrylamide gel 
electrophoresis, which improves the sensitivity of the analysis (Fig. 2.3). The PstI 
restriction sites, which occur at nucleotide positions 1050 and 1347 of the published 
NAT2 gene sequence (http://www.ncbi.nlm.nih.gov/nuccore/219871) were found to be 
conserved in all of the samples analysed, and no polymorphic sequence variation have 
been observed in our sample cohorts using this enzyme. 
In contrast to the above, the amplified NAT2 gene sequence possesses several cutting sites 
for each of the DdeI, FokI and TaqI R.E.s, generating enzyme-specific profiles that are 
also conducive to analysis via non denaturing polyacrylamide gel electrophoresis.  
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Figure 2.3 Restriction enzyme profiles for BamHI-PstI, TaqI, KpnI-PstI, MspI-
PstI, FokI, and DdeI cleavage, (panels A, B, C, D, E, and F, respectively). Lane M: 
100bp DNA molecular weight marker ladder (Promega, USA), with the 500bp size 
marker indicated by the arrow. Lanes I and II are control sample digestions for each 
particular digestion series. Lanes 1 - 6 represent the results for individual test 
samples for each digestion series.  
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2.3.6 Polyacrylamide Gel Electrophoresis 
The NAT2 DNA profiles generated with specific R.E.s were resolved in a Mini-
PROTEAN
®
 II gel electrophoresis system (BioRad Laboratories, USA) using a 5% non-
denaturing polyacrylamide gel. The gels (102 mm x 73 mm x 0.75 mm) were prepared in 
accordance with the method detailed in Current Protocols in Molecular Biology [249]. A 
commercially supplied 40% stock solution mixture of acrylamide/bis-acrylamide (19:1) 
(Sigma- Aldrich, USA) was used in the preparation of these gels. The gels were allowed 
to polymerise at room temperature for 1-2 hours prior to being used. Gels were run at 100 
volts for 1 hour using 1x TBE buffer as the electrophoretic buffer. 
After electrophoretic separation, the DNA bands were visualised and fixed by silver 
staining [250]. The gel was washed in 50ml of 7.5% acetic acid solution for 10 minutes at 
37°C, after which they were rinsed in water for 3 minutes at 37°C. This washing step was 
repeated thrice. Next the gel was stained for 20 minutes at 37°C with 50 ml of 0.1% silver 
nitrate solution, containing 0.056% formaldehyde, followed by a very brief wash in water 
for 10 seconds. The DNA band profiles were developed by incubating the gel in 50 ml of 
ice-cold 3% sodium carbonate solution, supplemented with 0.056% formaldehyde, and 
sodium thiosulphate solution, to a final concentration of 8 µM. This incubation occurred 
at room temperature to monitor the band development, which reached optimal 
development within 3-5 minutes. The reaction was then stopped by washing the gel in an 
excess of ice-cold 7.5% acetic acid for 5 minutes at room temperature, followed by 
rinsing of the gel in water at room temperature for 5 minutes. The gels were then sealed in 
a plastic sleeve and electronically recorded by scanning the image using an Epson scanner 
and supplied software (Seiko Epson, Japan). The scanned image was then captured into 
the GelCompar II (Applied Maths, Belgium) software analysis programme for recording 
and analysis of the banding profiles. The GelCompar programme also enables one to 
establish a database of profiles collated with the sample information. 
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2.3.7 Allele-Specific PCR Analysis of NAT2 
The 341T>C nucleotide change specifically identifies the NAT2*5 class of alleles. 
This polymorphic variation was assessed using the confronting primer PCR technique 
(CP-PCR) of Hamajima et al [251], and is depicted in Fig. 2.4. 
 
Panel (a) 
 
Panel (b) 
                   
Figure 2.4 Confronting Primer PCR. Two primers (T and C) target the 
allele specific nucleotide position 341T>C (dotted arrow). Primers A and B 
facilitate amplification of the 341C (product AC), and/or 341T alleles 
(product TB) respectively. Primers A and B also generate PCR product AB, 
which serves as an internal control and monitor of the amplification 
conditions. Lanes C1, C2, C3 represent the 341TT, 341CC and the negative 
PCR controls respectively Lane M is the 100bp DNA ladder molecular 
marker (Promega) Lanes 1 – 10 are test samples. 
T 
C 
Allele-specific site 
B 
A 
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Two allele-specific, confronting primers, 341T and 341C, were used in a multiplex PCR 
reaction, along with two other primers, outer-primer A and outer-primer B, (see Table 2.1 
for nucleotide sequences) to direct the specific amplification from the 341C-allele or 
341T-allele, respectively. Each 25 µl PCR reaction consisted of 20 ng of gDNA, 2.5 µl of 
a 10x PCR buffer (200 mM Tris (pH 8.4), 500 mM KCl) (Gibco BRL Life Technologies, 
USA), 0.25 mM of each of dATP, dGTP, dCTP, and dTTP, 2.5 mM MgCl2, 0.25 µM of 
each of the four primers, and 0.25 units of Taq DNA Polymerase I (Gibco BRL Life 
Technologies, USA ). PCR amplification was carried out in the Gene Amp PCR System 
9700 (Applied Biosystems, USA). 
 
 
Table 2.1 Primer sequences for Confronting Primer PCR. 
Primer 
Name 
NAT2 Primer Sequences for allele-specific 
amplification, (5’to 3’) 
Tm
†
 
(°C) 
341T 
1045
TTCTTCTGCAGGTGACCAT
1063
 57.0 
341C 
1081
ATGTAATTCCTGCCGTCAG
1063
 53.2 
Outer-Primer A 
894
CACATTGTAAGAAGAAACCGG
914
 52.8 
Outer-Primer B 
1368
AAGATGTTGGAGACGTCTGC
1349
 54.9 
Superscript numbers indicate the nucleotide positions in the gene 
sequence. The allele-specific nucleotide position (1063) is written as 
bold and underlined text. 
Tm
†
 = Primer melting point temperature as supplied by the 
manufacturer, Integrated DNA Technologies (www.idtdna.com) 
 
The course of programmed temperature cycling followed an initial denaturation step of 
94°C for 5 minutes, subsequently followed by 35 cycles of denaturation at 94°C for 35 
seconds, annealing at 58°C for 45 seconds, and polymerisation at 72°C for 60 seconds. 
This was followed by an extended period of polymerisation period at 72°C for 10 
minutes, and then cooling to 4°C for 60 minutes. 
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PCR sample aliquots (2 µl) were assessed by gel electrophoresis as already described, 
employing 2% of a high resolution agarose, MetaPhor
®
 agarose (BMA, USA), prepared 
and electrophoresed with 1x Sodium Borate (5 mM Na2B4O7.10H2O) Solution. In this 
case the gels were run at a constant 320 volts for 15 minutes, using the GNA 200 gel 
apparatus (Pharmacia, USA). Under these conditions, the final temperature of the 
conductance medium was only slightly increased to 38-40 °C, and the resolution of the 
DNA bands was significantly improved than had been previously found with TBE as 
conductance medium. 
The agarose gels were stained, and photographed as described above. 
 
 
2.3.8 Primer design and synthesis 
Optimal primers sets for the various PCR amplifications were designed using a 
freeware version of the Primer Premier primer design programme 
(http://www.PremierBiosoft.com). This programme uses the criteria of Innis and Gelfand 
[252] in the initial primer sequence selection, and subsequently also analyses each 
individual primer for hairpin formation, dimer and cross-dimer formations, as well as 
false priming within the chosen genetic domain. Use of these parameters facilitated the 
selection of optimised primer sets for each of the various PCR amplification reactions. 
The specificity of primer binding to the chosen DNA gene sequence, either NAT1 or 
NAT2, was analysed by alignment with the sequence databases at the National Center for 
Biotechnology Information (NCBI) using the BLAST algorithm (Basic Local Alignment 
Search Tool; http://www.nlm.nih.gov/blast/blast.cgi). All primers were purchased from 
Integrated DNA Technologies (IDT, Inc. USA) and were supplied as High Pressure 
Liquid Chromatography (HPLC) purified products to ensure that all primer molecules 
were of the uniform specified primer length to obviate spurious PCR product formation 
during amplification. 
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2.3.9 Analysis of NAT1 polymorphisms 
The NAT1 genetic sequence (http://www.ncbi.nlm.nih.gov/nuccore/14018355) 
was analysed using Primer Premier to design the NAT1frwd (5’-
117
AGGATACCAGTTGG-3’) and NAT1rev (5-
1585
TTCGAAAATTACAACCAAATAACAA-3’) primer set. This set of primers was 
used for the initial amplification of a 1492 bp sequence domain, spanning the major 
polymorphic sites that have been described for this gene 
(http://www.louisville.edu/medschool/pharmacology/). 
The PCR amplification reaction was carried out in a total volume of 25 µl, and consisted 
of 15 ng gDNA, 2.5 µl of 10x PCR Buffer (200 mM Tris-HCl (pH 8.4), 500 mM KCl; 
Gibco BRL Life Technologies, USA), 0.20 mM a dNTP mixture (containing dATP, 
dGTP, dTTP and dCTP), 0.25 µM of the NAT1frwd and NAT1rev primers, 2.5 mM 
MgCl2, and 0.25 units of Taq DNA polymerase I (Gibco BRL, USA). PCR amplification 
was carried out in the Perkin Elmer Gene Amp System 9700 (Applied Biosystems, USA). 
An aliquot of each sample PCR product was assessed for PCR efficiency and specificity 
via submarine gel electrophoresis in 1% Seakem
®
 LE agarose (BMA, USA) using 1x 
Sodium Borate (SB) buffer (5 mM Na2B4O7.10H2O), and a current of 250 volts for 15 
minutes in the Omeg mini-gel apparatus (Omeg Scientific, RSA). Subsequently, 
randomly chosen PCR products were also assayed for NAT1 sequence-specificity, via 
restriction endonuclease cleavage (see Fig. 2.1). DNA bands were visualised by GelStar
®
 
staining and photographed. 
 
 
2.3.10 NAT1 Genotyping via Direct Sequencing 
NAT1 genetic polymorphisms have been tabulated in Table 1.1 and 1.2. Twenty 
one SNPs, as well as several inserted and/or deleted sections within the 3’-UTR of the 
gene are located within the amplified NAT1 domain. Eighteen of these SNPs represent the 
major polymorphisms that have been thus far been delineated in the coding region of this 
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gene. We therefore decided to assay the amplified NAT1 domain by direct sequencing to 
facilitate the cost-effective analysis of these polymorphisms. 
 
2.3.10.1 Preparation of post PCR-reaction for Sequencing 
Aliquots of the NAT1 PCR-reaction product were purified to remove 
unincorporated dNTPs and primers (NAT1frwd and NAT1rev), via treatment with the 
ExoSAP-IT
®
 reagent kit (Amersham Pharmacia Biotech., USA). This kit is a propriety 
formulation of the shrimp alkaline phosphatase (SAP) and exonuclease I enzymes, 
catalytically active in most PCR reaction buffers. Furthermore, the kit treats post-PCR 
solutions in which the product size ranges from less than 100 basepairs (bp) to greater 
than 20 kilo-basepairs (kb). According to the manufacturer’s recommendations 2µl of 
ExoSAP-IT solution reacts with 5 µl of post-PCR reaction volume, degrading all 
unincorporated primers and dNPTs, with no loss of double-stranded DNA product. 
Furthermore these volumes can be scaled up proportionally as required. 
We mixed 15 µl of each NAT1 PCR product solution with 5 µl of the ice-cold ExoSAP-
IT solution, and then incubated this mixture at 37°C for 1 hour, according to the 
manufacturer’s recommendations. This was followed by a further incubation at 80°C for 
30 minutes to expedite the complete inactivate of the Exo-SAP-IT enzyme reagent, 
whereafter the solution can be stored at -20°C until required for sequencing. 
 
2.3.10.2 Sequencing of NAT1 PCR Products 
NAT1 sequencing reactions were facilitated in the ABI PRISM Genetic Analyser 
model 3130x1 (Applied Biosystems), via an automated cycle sequencing protocol, using 
the BigDye Terminator ready reaction sequencing kit, version 3.1 (Applied Biosystems), 
at the Central Analytical Facility (CAF), Stellenbosch University. The kit contains all the 
required reagents in a premixed solution, to expedite the synthesis, in a single tube, of 
reaction products labelled with fluorescent dideoxynucleotides (FddNTPs). Essentially 
the protocol entails a primer extension reaction, in which the FddNTPs are sequentially 
added to sequence-specific oligomers to form sequenced templates of varying lengths, 
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terminating with specific dideoxynucleotides. The results of each single reaction tube are 
then assayed in the genetic analyser, which separates the fragments by electrophoresis, 
and automatically identifies the separate FddNTPs in the sequenced template, based upon 
the different emission wavelengths for the fluorescent dye attached to each of the 
ddNTPs. 
One of the disadvantages of this technique evolves around the “spectral deconvolution” of 
the sequenced results, which limits the amount of nucleotide sequence data that can be 
read reliably by the software programme to 700 bp. This limitation therefore necessitated 
sequencing both DNA strands in opposite directions for each sample, to ensure the 
complete sequence analysis of the 1492 bp NAT1 PCR product. 
Each sample reaction was constituted as follows:- 4 µl of the premixed solution of the 
sequencing kit, 3 µl of primer (sense or antisense) at a concentration of 1.1 µM, and 3 µl 
of ExoSAP-IT-treated PCR template solution, and 1.5 µl of dimethyl sulfoxide (DMSO) 
solution. The latter reagent is added to facilitate the unwinding of potential DNA 
secondary structure formation in the PCR template. Individual sequencing reactions were 
carried out in a 96-well plate format, containing both positive and negative control sample 
reactions randomly spaced among the test samples. All pipetting reactions were executed 
using the Tecan Evo 150 automated liquid handling workstation (Tecan Group Ltd., 
Switzerland). The positive control sample template consisted of pGEM plasmid DNA and 
the M13 primer oligomer, both of which are supplied in the kit. Negative control sample 
contained no DNA template. 
Each thus-prepared 96-well plate is cycle-sequenced in a Gene Amp PCR system 9700 
(Applied Biosystems, USA) using a temperature cycling programme, consisting of 1 
cycle at 95°C for 5 minutes, followed by 25 cycles of alternating temperatures of 95°C for 
45 seconds, 55°C for 4 minutes; the process is terminated with a final incubation at 4°C. 
These PCR products are then subjected to another clean-up phase, utilising CENTRI-SEP 
columns (Princeton Separations, USA), to remove buffer salts, unused FddNTPs and 
oligonucleotide primer via gel exclusion filtration. The use of the CENTRI-SEP 96-well 
plate facilitates the processing of these reaction samples in keeping with the above multi-
well format. 
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Briefly, CENTRI-SEP Sephadex gel columns are reconstituted and equilibrated by 
centrifugation at 3000 rpm for 2 minutes in a Heraeus megafuge 11 (Thermo Fischer 
Scientific, USA). SDS-treated cycle-sequenced PCR products are loaded onto each 
column in the 96-well plate, and collected by centrifugation at 3000 rpm for 2 minutes as 
above. Next the reaction products are vacuum dried for 15 minutes at 60°C in a heated 
vacuum drier (Labconco Corportaion USA), and resuspended in Hi-Di solution (Applied 
Biosystems, USA). Prior to electrophoresis in an automated sequence analyser the 
solution is heat-denatured for 2 minutes at 95°C, and then chilled on ice for 5 minutes. 
These samples are applied to the ABI-PRISM DNA analyser platform for analysis via a 
50 cm long multi-capillary array, employing the Performance Optimum Polymer 7 
(POP7), along with the sequencing analysis software (version 5.2) supplied with the 
instrument (Seq_Z_36_POP7 and Analysis Protocol 3130POP7_BDTv3-KB-
Denovo_v5.2). All results were quality controlled by the staff at CAF, and the sequence 
alignment analysis was carried out by the researcher, using Sequencher, version 4.10.1 
(http://www.genecodes.com). 
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Reagents and Solutions 
(All solutions were prepared using reagent grade water prepared via the Synergy 
Water Purification System (Millipore Corporation, USA)) 
Acrylamide/bis-Acrylamide 40% Stock Solution (19:1 ratio) purchased from supplier. 
Silver Nitrate  5% solution (w/v):- dissolve 5 g of AgNO3 salt into a  
 total volume of 100 ml sterile water. 
Cell Lysis Buffer (1L) 320 mM Sucrose (109.54 g/L) 
 1% Triton X-100 (10 ml of stock/L) 
 5m M MgCl2 (5 ml of 1M stock) 
 10m M Tris, pH 7.6 (10 ml of 1M stock) 
EDTA (5ooml) Ethylene-Diamine-Tetra-Acetate/acetic acid 
0.5 M solution:- dissolve 93.06 g EDTA and 10 g NaOH 
pellets in 400 ml of sterile water. Adjust to pH 8.0, using 
10 M NaOH solution, and top-up to volume. Sterilize by 
filtration using a 0.2 micron filter unit. 
Nuclei Lysis Buffer (1L) 400 mM NaCl  
 10 mM Tris, pH 8.0  
 2 mM EDTA, pH 8.0 
Proteinase K Solution 10 mg/ml stock solution 
 Dissolve 10 mg in 10 ml of sterile water. 
Tris  Tris (Hydroxymethyl) Aminomethane 
1 M Tris, pH 7.6/8.0:- dissolve 121.1 g of crystals (Tris 
base) in 800 ml of sterile water; adjust to pH using 
concentrated HCl, and top-up to the desired volume 
mark. Sterilise by autoclaving. 
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Sodium Dodecyl Sulphate SDS 
 10% Solution (w/v):- dissolve 10 g of crystals in 100 ml 
of sterile water. 
Sodium Chloride NaCl 
Saturated NaCl (> 6 M):-dissolve an excess of crystals in 
500 ml of sterile water until the salt no longer goes into 
solution. Sterilise by autoclaving. 
Sodium Carbonate Na2CO 
6% solution (w/v):- dissolve 60 g of the salt in 1000 ml of 
sterile water. 
Sodium Thiosulphate Na2O3S2.5H2O 
40 mM solution:- dissolve 496.37 mg of salt per 50 ml of 
sterile water. 
Sodium Borate Na2B4O7.10H2O 
50 mM solution:- dissolving 19.07 g per 1000 ml of sterile 
water. This constitutes a 10x stock solution. 
TBE Solution Tris-Borate-EDTA (A 5x stock solution consists of  
 0.45 M Tris-Borate/0.01 M EDTA per 1000 ml) 
Dissolve 55 g Tris base, and 27.5 g boric acid per 800 ml 
sterile water. Add 20 ml of 0.5 M EDTA solution, and top-
up to 1000 ml. 
TE Solution Tris-EDTA (1x stock solution consists of 10 mM Tris, 
 2 mM EDTA) 
Add 1 ml of 1 M Tris, pH 8.0, plus 0.4 ml of 0.5 M EDTA 
to 98.6 ml of sterile water to constitute 100 ml of TE 
solution. 
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Equipment 
PCR Machines Gene Amp 2400 and 9700 PCR Systems 
 (Applied Biosystems, USA) 
Submarine Gel Apparati Omeg Mini Gel 
 (Omeg Scientific, Claremont, South Africa 
 GNA 200 Submarine Unit 
 (Amersham Pharmacia Biotech., USA) 
Polyacrylamide Gel Apparatus Mini Protean II Electrophoresis Cell 
 (Bio-Rad Laboratories, Inc. USA) 
Power Supply Consort Electrophoresis Supply Unit, 
 model E844 
UV Transluminator 3UV Transilluminator, model LMS-26E 
  (UVP, USA) 
Heaters/Incubators Techne DB 3A, Dri Block 
  (Techne, Cambridge, UK) 
Centrifuge Eppendorf model 5810R 
  (Eppendorf, Hamburg, Germany) 
Microfuge Eppendorf, model 5415D 
  (Eppendorf, Hamburg, Germany) 
Shaking Incubator Hybaid Midi Dual 14 
  (Hybaid, Ltd. Middlesex, UK) 
Scanner Epson Perfection 1670, model J141A 
  (Seiko Epson, Japan) 
Photo Documentation Kodak Digital Science Electrophoresis 
 Documentation and Analysis 120 System 
  (Eastman Kodak Company, USA) 
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CHAPTER  3 
Population diversity of NAT2 Alleles in 
South African Ethnic Groups 
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3.1 Introduction 
The “classic” NAT2 acetylation polymorphism, initially determined via 
phenotypic analyses, has highlighted several issues pertinent to the understanding of 
xenobiotic metabolism via acetylation. One such aspect concerns the polymorphic 
acetylation activity within human populations, variably described as either bimodal [35, 
253], or trimodal [37, 38, 222]. Previous acetylation studies have established that the 
frequency of occurrence of the rapid (F) and slow (S) alleles differs substantially between 
populations (discussed in Chapter 1), and this would account for the observed variation in 
overall acetylation. In addition, studies have shown that the frequency of several activity-
altering SNPs, characterising the S allele also differ between populations [188, 196, 198]. 
These variations would subsequently impact upon the frequency of slow acetylators 
between different populations. Furthermore, it has been well established that the NAT2 
enzyme can abrogate the activity of isoniazid (INH) [35]. These factors, along with the 
increasing global TB/HIV pandemic affecting some counties more than others, have 
facilitated a renewed interest into the effects of acetylation on the epidemiology of TB 
and HIV [211, 243, 254-256]. 
Globally, the greatest burden of TB disease occurs in 22 countries (Fig. 3.1), 
predominantly located in Sub-Saharan Africa and Southeast Asia (WHO Factsheet No. 
104, 2010). A few studies have investigated acetylator polymorphisms in these regions 
[167, 191, 194, 234, 257, 258], but the impact of this variation on drug metabolism and 
TB epidemiology is largely unknown. Therefore it may be important to examine the 
NAT2 polymorphisms to assess whether this impacts on anti-TB therapy. South Africa is 
ranked fifth amongst the countries with the highest burden of TB disease, and due to the 
limited information available in the literature on the NAT2 acetylation polymorphism in 
South Africa, we decided to investigate the acetylation genotypes within local ethnic 
populations of the Western Cape region of South Africa. 
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Figure 3.1 A map showing the 22 countries with the highest burden of TB 
disease globally. India (8), China (5), and Indonesia (9) are ranked first, 
second and third respectively, whilst South Africa (17) is ranked fifth. 
Numbers indicate the alphabetical listing for these countries:- Afghanistan 
(1), Bangladesh (2), Brazil (3), Cambodia (4), China (5), Democratic 
Republic of Congo (6), Ethiopia (7), India (8), Indonesia (9), Kenya (10), 
Mozambique (11), Myanmar (12) Nigeria (13), Pakistan (14), Philippines 
(15), Russian Federation (16) South Africa (17), United Republic of Tanzania 
(18), Thailand (19), Uganda (20), Viet Nam (21) and Zimbabwe (22). 
(http://www.stoptb.org/countries/tbdata.asp) 
 
 
 
3.2 Study cohorts 
The predominant ethnicities in the Western Cape Province are Caucasian (18.4%), 
Black African (Xhosa) (30.1%), and the group officially classified as South African 
Coloured (SAC) (50.2%) (http://www.statssa.gov.za/publications/P0301). The incidence 
of TB in this region has been recorded at greater than 1000 per 100 000 of the population 
[259]. Furthermore, TB surveillance studies of an urban community in Cape Town, 
namely, residents of the Ravensmead-Uitsig housing estate (R/U), have shown a 
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consistent increase in the notification rate for smear-positive TB since 1994 [260, 261], 
despite having a low prevalence of HIV in the area [262]. 
The R/U housing estate covers an area of 2.4 km
2
 and has a population of 36 334 
individuals, 98% of whom are of the SAC ethnic population (Statistics South Africa: 
Census 2001 http://www.statssa.gov.za). The high burden of TB disease in this area, and 
the singularity of ethnicity [245, 263], makes this area an ideal study area and cohort for 
investigations of TB disease. These projects have been approved by the Institutional 
Research Ethics Committees of Stellenbosch University, and Tygerberg Hospital. 
In order to develop a greater understanding of the role of the NAT2 acetylation 
polymorphism, we randomly recruited non-TB diseased (no active TB), adult individuals 
from the ethnic groups within the Cape Town Metropolitan region. This collection 
consisted of 60 Caucasians, 55 Xhosa and 108 SAC individuals. The Caucasian, Xhosa 
and SAC individuals self-reported their respective ethnicities. The SAC individuals were 
recruited from the R/U community, and consisted of 46 males and 62 females, with a 
median age of 34 years (range 18 to 64). The Caucasian group consisted of 24 males and 
36 females, with a median age of 74 years (range 39 to 86). These individuals were 
recruited from the Ophthalmology general clinic at Tygeberg Hospital as the control 
group for a study investigating age-related macular degeneration (AMD). None of these 
individuals reported any systemic disease symptoms. The Black African (Xhosa) 
individuals were randomly selected from healthy volunteers provided from a cancer 
research study, done by the Medical Research Council (MRC) of South Africa. 
 
 
3.3 Results and Discussion 
3.3.1 NAT2 SNP and Allele frequencies within cohorts 
The NAT2 acetylation polymorphism was characterised by analysis of the 
191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G and 857G>A SNPs, in the 
individuals from the local cohorts. All SNPs were tested for Hardy Weinberg Equilibrium 
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(HWE), using HaploView version 4.2 (http://www.broadinstitute.org/mpg/haploview). In 
both the Caucasian and Xhosa cohorts all of the genotypes were in HWE, indicating 
panmixia within these specific cohorts. In the case of the SAC only the 803A>G genotype 
was not in HWE (p = 0.0318), indicating a departure from the panmictic status with 
respect to this polymorphism. Since a similar disequilibrium was not observed in either of 
the Caucasian or Xhosa cohorts for this particular SNP, it is unlikely that this departure 
from HWE in the SAC cohort is due to error or bias in the experimental assay. 
The predominant or major NAT2 allele at each of the respective SNP positions was 
classified as the wild-type (WT) allele, whilst the polymorphic variant, is classified as the 
minor allele (MA) (Table 3.1). The NAT2 allele frequency observed in the SAC and 
Xhosa cohorts appear very similar, and there are no significant differences between these 
two groups. The Caucasian cohort on the other hand appears to constitute a different 
group, in which the MA frequencies for 4 of the 7 SNPs assayed were generally higher 
than observed in either the SAC or Xhosa groups. In addition, the 191A allele was not 
found in the local Caucasian population. 
The relevance of the various SNPs depends upon the phenotypic effect conferred by that 
polymorphism. In the case of the 282C>T and 481C>T polymorphisms, the acetylation 
activity of the enzyme is supposedly not impaired, since these SNPs encode the 
synonymous amino acids tyrosine and leucine at positions 94 and 161 respectively. 
However, silent or synonymous polymorphisms in the Multidrug Resistance 1 (MDR1) 
gene have recently been shown to affect the substrate specificity of the enzyme, without 
concomitant changes in the expression levels of MDR1 mRNA or protein [264, 265]. In 
this context, the significance of the above observations with respect to the 282C>T and 
481C>T NAT2 SNPs should be further investigated, to assess their affect on INH 
metabolism, particularly in these local ethnic groups, given the observed allele frequency 
for these two SNPs. However, this was not investigated at this time. 
A Pearson Chi square (2) analysis of the allele frequency for these particular SNPs 
indicates a significant difference between the three cohorts (Table 3.1), which was also 
found when comparing the Caucasian and SAC groups only. In the latter case the Chi 
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square test rendered P-values of 0.0178 for the 282C>T polymorphism, and 0.0190 for 
the 481C>T polymorphism, respectively. 
Similarly, the 803A>G polymorphism, which also confers rapid acetylation (RA) status, 
changes lysine to arginine at position 268. In the case of this SNP a comparison between 
the Caucasian and SAC cohorts revealed an allele frequency difference of borderline 
significance only (P-value of 0.0408). 
 
 
Table 3.1 Prevalence of the NAT2 alleles in local Ethnic groups 
Prevalence of NAT2 Alleles P - Value
§
 
NAT2 
allele 
Caucasian 
(n=120) 
Xhosa 
(n=110) 
SAC 
(n=216) 
Caucasian 
/ Xhosa / 
SAC
Δ
 
Caucasian / 
Xhosa
Δ
 
Caucasian / 
SAC
Δ
 
191 
G
†
 100 0.98 0.95 
0.0358 0.1379 0.0172 
A 0 0.02 0.05 
282 
C
†
 0.67 0.70 0.78 
0.0375 0.6942 0.0178 
T 0.33 0.30 0.22 
341 
T
†
 0.62 0.73 0.70 
0.1733 0.0749 0.1564 
C 0.38 0.27 0.30 
481 
C
†
 0.64 0.78 0.76 
0.0250 0.0195 0.0190 
T 0.36 0.22 0.24 
590 
G
†
 0.73 0.86 0.87 
0.0025 0.0151 0.0011 
A 0.27 0.14 0.13 
803 
A
†
 0.58 0.46 0.46 
0.0874 0.0678 0.0408 
G 0.42 0.54 0.54 
857 
G
†
 0.97 0.97 0.96 
0.8010 0.7892 0.7161 
A 0.03 0.03 0.04 
† = Wild type or major allele. 
§
 = P-values determined by Pearson Chi-square (2) analysis; a P-value of 
less than 0.05 indicates statistical significance. 
Δ
 Statistical comparisons of the NAT2 alleles between the various ethnic 
groups 
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The 191G>A, 341T>C, 590G>A and 857G>A polymorphisms reduce the acetylation 
activity of the NAT2 enzyme to varying degrees [168, 182]. In this respect the 341T>C 
and 857G>A alleles did not show any substantial differences between the cohort groups 
investigated. The most significant differences were however observed for the 191G>A, 
and 590G>A alleles. In the SAC population group, the 191A allele was 2.5-fold more 
prevalent than in the Xhosa; however, this difference was not found to be statistically 
significant by Pearson Chi square (2) analysis (P-value = 0.207). 
The most significant differences between the three groups was observed for the NAT2 
590G>A polymorphism, which showed an even greater significance in the comparison 
between the Caucasian and SAC cohorts (P = 0.0011). Furthermore, the prevalence of the 
590A allele varies between 13% and 27% in the three cohorts investigated, which 
indicates that this SNP would make a relatively significant contribution to the variation in 
the inherent acetylator activity observed in these cohorts. The significance of the observed 
allelic differences between the two most divergent groups (Caucasians and SAC) is 
provocative, but only translates into a relatively low probability of having an impact on 
the acetylation differences between these groups, given the relatively small sample size 
(only a 168 individuals). Consequently, assuming a power of 80% (probability to detect 
an effect), it would be necessary to investigate a much larger cohort of individuals 
(approximately 1100) in order to determine whether these allelic differences could have a 
significant effect on the acetylation differences between these groups. 
 
A comparison of the NAT2 genotypes defined by these seven SNPs corroborates the 
results observed for their NAT2 alleles (Table 3.2). In this context the 282C>T and 
481C>T genotypes are found to be significantly different between the Caucasian and 
SAC cohorts, whilst the 803A>G genotype is not (Table 3.2). Furthermore, the 191GG 
and 191GA genotypes were significantly different between the Xhosa and SAC cohorts, 
thereby indicating that a variation in the slow acetylation status between these cohorts 
could be attributed to this particular polymorphism. However, the impact of this variation 
upon the overall acetylation metabolism warrants further investigation, since the allele 
and genotype frequencies for the 191G>A SNP is less than 10% in these cohorts. 
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The genotypes conferred by the 590G>A polymorphism again showed the most 
significant variation between the cohorts. This indicates that this SNP would confer the 
greatest impact on the acetylation status between the different cohorts (P-value = 0.008), 
with an even greater significant difference between the Caucasian and SAC cohorts as 
assessed by the Fischer’s exact test (P-value = 0.002). Given the observed prevalences for 
the 590G>A polymorphism between these cohorts, it is clear that this particular SNP 
would exert the greatest influence upon the overall phenotypic acetylation status. 
Therefore the variation in the minor allele frequencies and genotype for this particular 
SNP may have a significant bearing upon the acetylation status in different ethnic groups. 
 
Table 3.2 Comparison of the NAT2 genotypes in three local ethnic groups. 
NAT2 
SNP 
NAT2 Genotype Frequencies (%) P – Value 
Caucasian 
(n = 60) 
Xhosa 
(n = 55) 
SAC 
(n = 108) 
Caucasian / 
Xhosa / 
SAC
§
 
Caucasian 
/ Xhosa
‡
 
Caucasian 
/ SAC
‡
 
191 
GG 100 96.4 90.7 
0.033 0.228 0.016 GA 0 3.4 9.3 
AA 0 0 0 
282 
CC 43.3 45.5 57.4 
0.089 0.778 0.02 CT 46.7 49.1 40.7 
TT 10 5.4 1.9 
341 
TT 38.3 49.1 50.9 
0.204 0.0922 0.19 TC 46.7 47.3 38.0 
CC 15 3.6 11.1 
481 
CC 43.3 58.2 59.3 
0.053 0.021 0.023 CT 41.6 40.0 34.3 
TT 15 1.8 6.4 
590 
GG 55 74.6 74.1 
0.008 0.016 0.002 GA 35 23.6 25.0 
AA 10 1.8 0.9 
803 
AA 30 21.8 15.7 
0.119 0.086 0.053 AG 55 49.1 61.1 
GG 15 29.1 23.2 
857 
GG 93.3 94.5 91.7 
0.794 0.100 1.000 GA 6.7 5.5 8.3 
AA 0 0 0 
‡
 = Fischer’s exact Test, two-tailed analysis. 
§
 = Pearson chi-square (2) analysis. 
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3.3.2 NAT2 Genotypes and Acetylation within local cohorts 
Individual NAT2 genotypes were reconstructed in accordance with a common 
convention in the literature, in which rapid acetylation (RA) is represented by two wild-
type alleles (F), characterised by a combination of any 2 of the haplotype combinations 
delineated by the following NAT2 alleles:- NAT2*4, NAT2*11, NAT2*12 and NAT2*13. 
The reference allele is defined as NAT2*4, and confers the WT rapid acetylation capacity. 
The NAT2*11, NAT2*12 and NAT2*13 alleles and genotypes also confer the RA status, 
but are defined by polymorphisms at positions 481, 803 and 282 respectively. Similarly, 
slow acetylation (SA) status is conferred by two S alleles, characterised by the NAT2*5, 
NAT2*6, NAT2*7 and NAT2*14 haplotypes and alleles, (see table 1.4 in Chapter 1). The 
intermediate acetylation (IA) status and genotype by comparison, is represented by the 
heterozygous FS allele assignment. 
The final NAT2 genotypes were deduced from the sum of the polymorphisms observed 
for the 7 NAT2 SNPs, according to Agúndez et al (2008) [266]. This classification scores 
the polymorphic variation at each individual SNP as zero (0) for no polymorphism (WT 
allele), 1 for SNP heterozygosity, and 2 for SNP homozygosity. Secondly, the SNPs are 
arranged sequentially, in accordance with their occurrence in the coding region of the 
NAT2 gene, namely 191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G and 
857G>A. Thus the NAT2*4/2*4 genotype, in which no polymorphisms occur at any of the 
above SNP positions, is assigned the “0000000” classification for the genotype 
(combined diplotype) (Table 3.3). 
According to this classification, some of the observed “diplotypes” describe various 
deduced genotypes, differing in their combinatorial assignment for the 7 NAT2 SNPs. 
This ambiguity is a consequence of the genotyping methods currently used, in that both 
the paternal and maternal alleles are analysed simultaneously for each individual sample 
[83, 267-270]. In this respect, the PCR-RFLP experimental technique used during this 
project is similarly unable to resolve the phasing of the separate loci with respect to each 
other, as well as with respect to the separate parental allele(s), during such multi-locus 
analyses. However, in our analysis these ambiguous genotypes did not result in a 
concomitant change in the acetylation status as conferred by the classification 
assignments. Nevertheless, the reliability of this 7-SNP assay and PCR-RFLP 
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methodology has been confirmed in several publications [266, 269, 271, 272] as well as 
via computational analyses [266, 270, 273, 274]. 
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Table 3.3 NAT2 genotypes observed in the local ethnic groups. 
Observed 
Diplotype 
Deduced 
Genotype 
Frequency 
(%) 
Alternative Genotype 
Caucasian Cohort (n = 60) 
Rapid Acetylators (n = 8) 
0000000 2*4/2*4 50 - 
0000010 2*4/2*12A 25 - 
0100000 2*4/2*13 25 - 
Intermediate Acetylators (n = 22) 
0011010 2*4/2*5B 40.9 - 
0100100 2*4/2*6A 18.2 2*13/2*6B 
0100110 2*4/2*6C 18.2 2*12A/2*6A 
0111010 2*4/2*5G 13.6 2*13/2*5B or 2*12B/2*5A 
0010010 2*4/2*5C 4.6 2*12A/2*5D 
0000100 2*4/2*6B 4.6 - 
Slow Acetylators (n= 30) 
0111110 2*5B/2*6A 36.7 2*5G/2*6B 
0022020 2*5B/2*5B 30.0 - 
0200200 2*6A/2*6A 16.7 - 
0111011 2*5B/2*7B 10.0 2*5G/2*7A 
0100200 2*6A/2*6B 3.0 - 
0200101 2*6A/2*7B 3.0 - 
 
Xhosa Cohort (n = 55) 
Rapid Acetylators (n = 15) 
0000020 2*12A/2*12A 33.3 - 
0100010 2*4/2*12B 20.0 2*12A/2*13 
0000000 2*4/2*4 13.3 - 
0000010 2*4/2*12A 6.7 - 
0100000 2*4/2*13 6.7 - 
0100020 2*12A/2*12B 6.7 - 
0001010 2*12A/2*11 6.7 - 
0200000 2*13/2*13 6.7 - 
Intermediate Acetylators (n = 29) 
0111010 2*4/2*5G 24.1 2*13/2*5B or 2*12B/2*5A 
0011020 2*12A/2*5B 17.2 - 
0100110 2*4/2*6C 10.4 2*12A/2*6A or 2*12B/2*6B 
0011010 2*4/2*5B 6.9 2*12A/2*5A 
0100100 2*4/2*6A 6.9 2*13/2*6B 
0000100 2*4/2*6B 6.9 - 
0010020 2*12A/2*5C 6.9 - 
0110010 2*13/2*5C 6.9 2*12B/2*5D 
0010000 2*4/2*5D 3.5 - 
0000110 2*4/2*6F 3.5 2*12A/2*6B 
0101011 2*12C/2*7B 3.5 - 
0200100 2*13/2*6A 3.5 - 
Slow Acetylators (n = 11) 
0111110 2*5B/2*6A 27.3 2*5G/2*6B 
0021020 2*5B/2*5C 18.2 - 
1111010 2*5B/2*14B 18.2 2*5G/2*14A or 2*5A/2*14G 
0022010 2*5B/2*5A 9.1 - 
0111011 2*5B/2*7B 9.1 2*5G/2*7A 
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0100200 2*6A/2*6B 9.1 - 
0200111 2*6C/2*7B 9.1 - 
 
SAC Cohort (n = 108) 
Rapid Acetylators (n = 24) 
0000010 2*4/2*12A 41.7 - 
0000020 2*12A/2*12A 25.0 - 
0000000 2*4/2*4 12.5 - 
0100010 2*4/2*12B 12.5 2*13/2*12A 
0001010 2*4/2*12C 4.2 2*11/2*12A 
0100000 2*4/2*13 4.2 - 
Intermediate Acetylators (n = 55) 
0100110 2*12A/2*6A 23.6 2*4/2*6C 
0011010 2*4/2*5B 20.0 2*12A/2*5A 
0011020 2*12A/2*5B 9.1 - 
0010010 2*4/2*5C 5.5 2*12A/2*5D 
0111010 2*4/2*5G 3.6 2*13/2*5B 
0100100 2*4/2*6A 3.6 2*13/2*6B 
0100001 2*4/2*7B 3.6 2*13/2*7A 
0010020 2*12A/2*5C 3.6  
0100011 2*12A/2*7B 3.6 - 
1000010 2*12A/2*14A 3.6 2*4/2*14E  
1100010 2*12A/2*14B 5.5 - 
0110010 2*12B/2*5D 3.6 2*13/2*5C 
0010000 2*4/2*5D 1.8 - 
1000000 2*4/2*14A 1.8 - 
1100000 2*4/2*14B 1.8 2*13/2*14A 
0000110 2*12A/2*6B 1.8 2*4/2*6F 
0110000 2*13/2*5D 1.8 - 
0200100 2*13/2*6A 1.8 - 
Slow Acetylators (n = 29) 
0022020 2*5B/2*5B 24.1 - 
0111110 2*5B/2*6A 20.7 2*5G/2*6B 
0021020 2*5B/2*5C 17.2 - 
1011010 2*5B/2*14A 6.9 - 
0111011 2*5B/2*7B 6.9 2*5G/2*7A 
0011110 2*5B/2*6B 3.5 2*5C/2*6E or 2*5A/2*6F 
0111100 2*5A/2*6A 3.5 2*11A/2*5J or 2*5K/2*6E 
0010011 2*5C/2*7A 3.5 - 
0111001 2*5A/2*7B 3.5 - 
0100200 2*6A/2*6B 3.5 - 
0200101 2*6A/2*7B 3.5 - 
1100100 2*6B/2*14B 3.5 2*6A/2*14A 
NAT2 genotypes are represented as a 7-digit combinatorial score for positions 
191, 282, 341, 481, 590, 803, and 857 respectively. 
0 = no polymorphism, 1 = heterozygous polymorphism, and 2 = homozygous “mutant” 
polymorphism for each of the polymorphic loci analysed 
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The overall NAT2 acetylation status, as defined by these deduced genotypes is 
summarised in figure 3.2. The Xhosa and SAC cohorts exhibit similar frequencies for the 
RA, IA and SA classes of trimodal acetylation, with the IA status predominating in each 
of these groups. In a study of SAC TB patients, Parkin et al [170] reported frequencies of 
23%, 47% and 30% for RA, IA and SA, respectively. Similar frequencies were found for 
SAC individuals in this study, namely 22.2% (RA), 50.9% (IA) and 26.9% (SA). 
In the Caucasian group, slow acetylators (SA) predominate by a factor of two, when 
compared to the Xhosa and SAC cohorts. In contrast, fast (RA) acetylators are 
approximately twice as prevalent in the Xhosa and SAC cohorts compared to Caucasians. 
These results suggest that the overall rate of metabolism of xenobiotics via NAT2 
acetylation is similar in Xhosa and SAC individuals, and differs significantly from that 
observed for Caucasians. This is supported by the frequency distribution for the rapid (R) 
and slow (S) alleles in these three cohorts (Fig. 3.3). Therefore, anti-TB regimens 
containing INH and standardised for Caucasian individuals may not provide sufficient 
treatment efficacy in the Xhosa and SAC population groups, given the difference in rapid 
and intermediate acetylators observed in these groups. 
 
Figure 3.2 NAT2 acetylation status in ethnic groups of the Western Cape. 
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Figure 3.3 Distribution of the wild type (R) and polymorphic (S) NAT2 
alleles in local cohorts. 
 
 
A comparison of the NAT2 haplotypes, as defined by the seven SNPs investigated is 
depicted in figure 3.4. Frequency distributions for the 2*4, and 2*12 haplotypes are 
similar in the Xhosa and SAC groups, but are significantly different in the 
Caucasians. On the other hand, the frequency distribution of the 2*13 haplotype is 
not significantly different in these three cohorts. Hence the difference in the rapid 
acetylation mechanism between Xhosa and SAC individuals on the one hand and 
Caucasians on the other, would largely be defined by the NAT2*4 and 2*12 
haplotypes. 
The NAT2*5 haplotype is the predominating slow acetylator genotype in all three 
study groups, occurring at a comparable frequency of 55 - 61%. Secondly, the 2*6 
haplotype is 1.5x more frequent in Caucasians than in the other two ethnic groups, 
and together with the 2*5 haplotype accounts for 95% of the slow acetylation 
genotype and phenotype in Caucasians. In contrast, the 2*5 and 2*6 haplotypes 
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contribute only 83% towards the slow acetylation genotype in the SAC ethnic 
group. 
The 2*7 and 2*14 haplotypes are more prevalent in SAC individuals, with a 
combined frequency of approximately 17 %. By comparison, the 2*14 haplotype 
was not found in Caucasians, and occurred at a frequency of only 3.9% in the 
Xhosa group. Therefore the prevalence of these haplotypes (2*7 and 2*14) could 
confer a greater slow acetylation effect in SAC individuals, than Xhosas or 
Caucasians. 
 
 
 
Figure 3.4 Comparison of NAT2 alleles and haplotypes in local 
cohorts. 
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3.4 Conclusion 
INH is the primary drug used in anti-TB treatment regimens, and it is metabolised 
by NAT2, a human liver enzyme. This inactivation of INH would in turn impact upon the 
treatment efficacy and consequently also the control of TB-disease. We investigated the 
NAT2 acetylation status in the three major ethnic groups in a TB endemic area of South 
Africa (Western Cape region). This region has a recorded TB incidence of greater than 
1000 per 100 000 of the population [259]. A panel of NAT2 SNPs, having a well-
characterised genotype-phenotype concordance, were used to assess the overall metabolic 
activity attributable to rapid (RA), Intermediate (IA), or Slow (SA) acetylation in these 
ethnic groups (http://louisville.edu/medschool/pharmacology/consensus-human-
arylamine-n-acetyltransferase-gene-nomenclature/). 
Our results indicate that there is an overall difference in the relative proportions of rapid 
(RA), intermediate (IA) and slow acetylators (SA) between the three study cohorts. The 
significance of this observation warrants further investigation. The SA were found to be 
more prevalent in Caucasians, which is comparable with similar results reported for 
Caucasians in Europe [62, 192, 196] and North America [164]. In Xhosa and SAC 
individuals the IA predominated, occurring at relatively comparable frequencies within 
these two populations. In both populations the RA and SA occurred at similarly low 
frequencies, with the SA being somewhat more prevalent in SAC compared to Xhosa 
individuals. A recent study by Luca et al (2008) [275] has shown that SA and IA 
predominate in a geographic belt from Eastern Africa to North-western Europe, whereas 
RA were more prevalent in Western Africa and Northern Eurasia. In this context, the 
acetylation trend amongst the SAC would appear to correspond more to the East African 
population, whereas the Xhosa group appears similar to Western African populations. 
This result can be explained by the prevailing evidence which suggests that Bantu-
speaking people migrated out of West Africa, initially in an easterly direction, followed 
by a strong southerly migration. These agriculturalists settled as far south as the Fish and 
Kei rivers in South Africa, where intermingling with the Khoisan occurred (hunter-
gatherer/pastoralists) [276]. Thus the Xhosa, as can be detected in their click-language 
dialect, are themselves admixed with the Khoisan. The Bantu origins of the Xhosa would 
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therefore contribute a strong RA input, whilst the admixture with the Khoisan would 
contribute the SA status, essentially leading to a dominance of IA. 
Whilst the significance of these differences is still speculative, it has been proposed that 
acetylation differences between diverse population groups arose as a result of adaptations 
to changes in the environment and diet that occurred during the evolution of humans from 
nomadic hunter-gatherers (such as the Khoisan) to sedentary farmers or agriculturalists 
(such as the Bantu) [275, 277, 278]. Furthermore, these authors found that RA is more 
prevalent in hunter-gatherer populations, such as the Pygmies and the Khoisan, whilst SA 
is more prevalent in populations practising an agricultural lifestyle and existence. The 
current SAC population is also admixed, with genetic input from Khoisan (32-43%), 
Bantu (20-36%), Caucasian (21-28%) and Asian (9-11%) groups respectively [245]. One 
may therefore have expected the Khoisan genetic input into the SAC to have biased the 
NAT2 genotype towards RA. However, the greater contribution of the Bantu and 
Caucasian ancestors to the genetic heritage of the SAC clearly contributes strongly to the 
SA status. Thus the dominance of the IA in the SAC is not surprising, given the strong 
genetic contributions from these respective ancestral groups. 
 
This result suggests that the standardised INH dosage, given in an anti-TB treatment 
regimen to Caucasian individuals, would be subject to a lower rate of acetylation, and 
hence inactivation, compared to the Xhosa and SAC individuals in these local 
populations. Therefore a better treatment efficacy may be attained in Caucasians, than in 
Xhosa or SAC individuals. Given the relatively high numbers of intermediate and rapid 
acetylators in the Xhosa and SAC groups, compared to Caucasians, it is likely that such a 
standardised INH dosage could be less effective in these individuals, due to the increased 
acetylation of INH. Therefore, it is likely that similar acetylation pharmacodynamics exist 
in these groups, which may differ from that for Caucasians, and it may be expedient to 
monitor individuals from these ethnic groups more closely during anti-TB therapy. 
The frequency distribution for the separate NAT2 alleles and haplotypes in the study 
cohorts (Fig. 3.4) depicts a degree of complexity evident in the level of rapid and slow 
acetylation conferred by the 2*12, 2*6, 2*7, and 2*14 haplotypes. NAT2*12 encodes the 
amino acid change lysine to arginine at position 268 in the enzyme, thereby conferring the 
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rapid acetylation phenotype. Earlier studies assessed NAT2 acetylation-capacity by using 
caffeine as the probe drug in human subjects [43, 174], and since caffeine is initially and 
primarily metabolised by CYP1A2 [279-281], it may therefore not undergo a similar 
acetylation rate to INH. In addition, CYP1A2 is subject to both inducible and constitutive 
expression which would have an additional confounding effect on the downstream 
metabolism of caffeine by NAT2. Furthermore, a report by Kawamura et al (2005) [97] 
indicates that NAT2 may have a greater substrate affinity for INH, based on the greater 
acetylation activity of INH compared to caffeine. In this context, it is therefore not yet 
clear what the functional effect of this particular SNP is on enzyme activity, since 
supporting functional experimental data is outstanding [140]. Therefore given the 
differences observed in the study cohorts, it would be expedient to investigate whether the 
NAT2*12 rapid phenotype is equal to or greater than that conferred by NAT2*4. 
In the case of the slow acetylation haplotypes there is no difference between the cohorts 
with respect to the rate of slow acetylation attributable to the 2*5 haplotype. A similar 
observation is seen for the combined effects of the 2*6, 2*7 and 2*14 haplotypes (fig. 
3.4), which collectively contribute between 39 – 45% towards slow acetylation. However, 
in vitro studies have demonstrated that the proteins expressed by the 2*7 and 2*14 
variants were the least stable (compared to NAT2*4) [175], and hence (slow) acetylation 
capacity is significantly reduced when compared to the 2*5 and 2*6 slow acetylators 
[182]. Therefore, the prevalence of these haplotypes in the few SAC individuals identified 
in this study, may reflect even lower acetylation capacity compared to Xhosa and 
Caucasians. SAC individuals harbouring homozygous or heterozygous combinations of 
2*7 and or 2*14 haplotypes may also experience low levels of acetylation, and may 
therefore exhibit a better treatment response, due to the reduced acetylation of INH. 
Altered rates of acetylation have also been shown in in vivo studies using caffeine as 
phenotypic probe substrate [174], where it was demonstrated that some heterozygous 
allele combinations have a lower acetylation activity when compared to homozygous 
allele combinations. This would become more evident in ethnic groups exhibiting a wider 
spectrum of particular genetic haplotypes, since a greater number of allelic permutations 
could arise and thereby constitute a larger spectrum of phenotypes within the group. 
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Our analysis of NAT2 genotypes in three local cohorts in the Western Cape region of 
South Africa has indicated that the spectrum of NAT2 haplotypes differs between these 
groups, with some haplotypes being absent from a particular group, such as 2*14 which 
was not found in Caucasians. In addition, some haplotypes are more prevalent in one 
particular group, such as 2*4 in Caucasians, and 2*7 and 2*14 in SAC, whilst others, 
such as 2*12, are equally prevalent in SAC and Xhosa. In a similar study by Parkin et al 
[63], greater frequency for the 2*12 allele was also observed in SAC TB patients. In 
comparing NAT2 haplotypes between African and non-African populations, Sabbagh et al 
(2011) [278] reported a higher frequency for the 2*12 and 2*13 haplotypes in African 
populations, whereas, the 2*4 haplotype was more prevalent in non-African populations. 
We observed a similarly high prevalence for the 2*12 and 2*13 haplotypes (alleles) in the 
SAC and Xhosa groups, which confirms this observation for African populations. 
 
In past genetic studies the importance of low frequency haplotypes, such as 2*7 and 2*14, 
may have been overlooked, since it was believed that these haplotypes would not have a 
major impact on the manifestation of the disease phenotype. However, recent 
developments in genetic analyses have enabled genome-wide association studies (GWAS) 
to investigate polymorphisms more comprehensively, on a genomic, rather that a genetic 
scale [282-284]. The results from these studies indicate that common (more prevalent) 
polymorphisms only constitute a relatively small contribution to the overall disease 
phenotype. Low frequency polymorphisms on the other hand, having a functional effect 
may constitute better candidates for understanding variations in phenotype. In this regard 
it may be expedient to re-evaluate NAT2 SNPs with respect to their phenotypic 
acetylation of INH. 
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CHAPTER  4 
The analysis of NAT2 Acetylation 
polymorphisms in TB patients 
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4.1 Introduction 
TB surveillance studies conducted in the Ravensmead-Uitsig housing estate (R/U) 
- an urban community in Cape Town - have indicated a consistent increase in the 
notification rate for smear-positive TB since 1994 [260]. Approximately 60% of patients 
from this area are new TB cases [285]. Similarly, a high prevalence of clinical TB has 
also been reported in patients from this area who have previously been treated and 
ostensibly cured of their disease [259], which would indicate that treatment efficacy 
within this community is problematic, thereby arguably worsening the TB epidemic. A 
report by Kritzinger et al [262], noted an annual rate of TB infection in this community of 
greater than 3.5%, which constitutes one of the highest figures reported globally for TB 
disease. 
The R/U housing estate covers an area of 2.4 square km, and has a population of 36 334 
individuals, 98% of whom are of the South African Coloured (SAC) ethnic population 
group (Statistics South Africa: Census 2001 http://www.statssa.gov.za). Given the high 
burden of disease in this area and the singular ethnicity [263], together with a relatively 
uniform set of contributory environmental factors, this community is an ideal study cohort 
for investigating the epidemiology of TB. In this context, it is significant to note that the 
prevalence of HIV infection in the SAC community is lower than for the whole of the 
Western Cape province, which co-incidentally has the lowest HIV prevalence in South 
Africa [286]. Subsequently, several longitudinal research projects have been conducted 
by the Faculty of Health Sciences of Stellenbosch University, along with the assistance 
and active participation of this community since 1992. All projects have been approved 
by the Human Research Ethics Committee of Stellenbosch University. 
 
The South African Coloured (SAC) population is officially recognised as a characteristic 
grouping of individuals, whose genetic ancestry devolves from Africa, Europe, Asia and 
Madagascar [244, 287-289]. In the ensuing generations, since the colonization of the 
southern tip of Africa by the Dutch in 1652, the genetic admixture within this group has 
coalesced into a relatively homogenous ensemble [290], in which the major contributing 
antecedents are Khoi and San (32-43%), Bantu (20-36%), European (21-28%), and Asian 
(9-11%) [245]. The Khoi and San are the considered indigenous groups to the area, and 
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provided the genetic background assimilating the relatively new genetic inputs from 
Europe, Africa (Bantu) and Asia. Hence the SAC are endowed with a genetic similitude, 
which is also evident in the distinctive frequency distribution reported for the human 
leukocyte antigen (HLA) class of alleles. In the case of the HLA-class II alleles, the SAC 
group has a frequency distribution unlike any of the other southern African population 
groupings [291], providing further support for the consolidation of the SAC group-
identity within the Western Cape. 
 
TB patients from the R/U community were enrolled in a longitudinal prospective study 
project, the Surrogate Marker (SM) study, and monitored for a period of twenty-four 
months, from their first diagnosis of clinical disease (enrolment) [292, 293]. A major aim 
of the project was to collect, analyse, and evaluate a range of patient data to identify a 
biomarker (or biomarkers) which could serve as a surrogate to predict the outcome of 
treatment for active TB. Host derived factors, such as malnutrition, BCG vaccination, 
HIV status, age and gender, have been shown to influence the advent of the clinical 
disease [294, 295]. Furthermore there is epidemiological evidence to suggest that host 
derived factors may also be implicated in the individual’s susceptibility to infection and 
disease [296, 297]. 
Pulmonary TB (PTB), the most common form of the disease in South Africa, is usually 
diagnosed on the basis of a number of clinical features, such as persistent cough, loss of 
appetite, night sweats, weight loss, and chest radiography. These clinical features 
however, develop long after the individual has been infected by the causative organism 
Mycobacterium tuberculosis (Mtb), and it is believed that by the time that these clinical 
features become manifest, the infected individual has potentially promoted the disease 
epidemic by facilitating the spread of the disease to casual contacts. Furthermore, these 
clinical features, whilst assisting the clinician in making the final disease diagnosis, are 
not definitive enough, and hence clinicians also rely on the identification of Mtb by 
positive culture via the mycobacteria growth indicator tube (MGIT) system (Beckton-
Dickinson, USA), and Ziehl-Neelsen (ZN) staining, and subsequent examination by light-
microscopy. Thus a substantial amount of time is lost waiting for the results from the 
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laboratory. Therefore, the early detection of TB disease is a major priority in 
counteracting the disease. 
 
 
4.2 The Study Cohort 
Two hundred and twenty-three unrelated individuals from the SM study, ranging 
in age from 18 to 65 years, with a male to female ratio of 1.4:1 (58% versus 42%), were 
screened for NAT2 genotypes in order to assess their acetylation status. The average age 
for males was 37 years and for females 33 years. All patients enrolled in the SM study 
gave their written informed consent of participation, and only individuals experiencing 
their first PTB-disease episode were enrolled. These patients, who were regularly 
monitored, had no indication of any other chronic disease, or pregnancy, and were HIV 
negative. Additional patient data, including smoking and drinking habits, was also 
collected via a questionnaire. All enrollees received directly observed treatment, short 
course (DOTs), for a period of six months, with first line therapy consisting of isoniazid, 
rifampicin, pyrazinamide and ethambutol, as advocated by the World health Organization 
(WHO). 
The infecting Mtb strain from each patient was confirmed by ZN staining and subsequent 
culture (MGIT), and was also subjected to drug sensitivity analysis for susceptibility to 
isoniazid and rifampicin. The strain identity was determined by DNA fingerprinting, 
using the mycobacterial marker IS6110 [298, 299]. 
At enrolment (Day 0), peripheral blood was collected for genetic analyses, for assessing 
the total white blood cell count, as well as absolute neutrophils, monocytes, and 
lymphocyte content to establish the baseline measurements for each patient. Thereafter, 
patients were subjected to regular follow-up assessments at Day1 and 2, then weekly for 
two months (Day 55), and thereafter monthly, for a further period of four months. After 
completion of their DOTs treatment, the patients were followed-up for a further 24 
months for possible subsequent episodes of TB. However, for the purposes of our 
acetylation study, we restricted our analysis to data collected during DOTs treatment 
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focussing on factors that could be predictors of risk for disease and/or possibly diminish 
treatment efficacy. As indicated above, the DOTs treatment period consists of 2 months 
of intensive treatment with a combination of four drugs (the initiation or intensive phase), 
followed by 4 months of treatment with a reduced drug regimen (the continuation phase). 
Isoniazid is an integral part of the drug regimen during both of these treatment phases. 
Efficacy of treatment was assessed by monitoring patient samples for viable Mtb 
organisms via ZN-microscopy and culture to establish a “conversion time” in days, being 
the period from Day 0 (diagnosis) to a point midway between the last positive Mtb culture 
and two consecutive negative Mtb cultures [300]. In keeping with the recommendations 
of the International Union against Tuberculosis and Lung Disease (IUTLD) [301], we 
selected Day 55 as the criterion to establish treatment efficacy on the basis of whether the 
patient had responded to treatment (“responders”) or not (“non-responders”) [300, 302] 
The control cohort, consisting of the 108 unrelated individuals from the same community 
(see chapter 3, section 3.2), had a male to female ratio of 1:1.4 (43% versus 57%). The 
average age for both males and females was 42 years, with an age range from 16 to 96 
years. The annual rate of tuberculosis infection in this community has been reported to be 
greater than 3.5% [262], and whilst a recent study found a positive tuberculin skin test 
(TST) in 76% of those surveyed, these control individuals exhibited no overt signs of TB-
disease. 
 
All statistical analyses were performed in conjunction with the Department for Statistical 
Consultation, (Faculty of Health Sciences, Stellenbosch University), using the Statistical 
Analysis Software (SAS) version 9.1 (www.sas.com) and Stastistica, version 10 
(www.statsoft.com). 
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4.3 Results and Discussion 
4.3.1. NAT2 SNPs in TB patients: case-control analysis 
The NAT2 acetylation status was characterised by the analysis of seven single 
nucleotide polymorphisms (SNPs) in the NAT2 gene, as described in a previous chapter. 
These SNPs occur most frequently in various populations, and have subsequently been 
shown to be the most informative for determining acetylation genotypes [71, 83, 168, 
169]. 
The genotype and allele frequency distribution of these SNPs in the unaffected 
(“controls”) and TB-affected cohorts (“cases”) are indicated in Tables 4.1 and 4.2. The 
Hardy-Weinberg equilibrium (HWE) analysis found six of the seven SNPS analysed to be 
in equilibrium. Only the 803A>G SNP was not in HWE, as shown previously (discussed 
in Chapter 3). Furthermore, an analysis of the allele and genotype frequencies for each of 
the seven SNPs shows no statistically significant difference between the two cohorts (P-
value greater than 0.05). It is interesting to note however, that the genotypes associated 
with the 341T>C SNP exhibit the lowest P-value, exhibiting the best indication of a 
possible trend towards an association with TB-disease. The overall similarity in the 
frequency distributions for these genotypes does not however support an overt association 
between these particular NAT2 polymorphisms and the presence and / or incidence of TB 
disease per se, in the local SAC population group. 
 
This observation is not unexpected, and supports a hypothesis that the inherent acetylation 
status of the individual, as defined by these SNPs, does not play a role in TB disease 
susceptibility or infectivity. However, the NAT enzymes are known to metabolise a 
number of compounds used in anti-TB treatment regimens, such as for example, PAS, 
metabolised by NAT1, and INH, metabolised by NAT2 [28, 44, 46]. Therefore it is likely 
that the impact of these enzymes will be evident in the individual’s response to treatment, 
which may manifest as either a variation in response to treatment, or the manifestation of 
adverse drug reactions (ADR). 
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Table 4.1 Frequency distribution for the NAT2 genotypes between the cohorts 
NAT2 SNP 
 Genotype Frequency 
Cases vs Controls 
Cases (N = 223) Controls (N = 108) 
0  1
 
00
‡
 01
†
 11
‡
 00
‡
 01
†
 11
‡
 P-value
§
 
191 G > A 0.933 0.067 0 0.907 0.093 0 0.4136 
282 C > T 0.484 0.466 0.049 0.574 0.407 0.019 0.1768 
341 T > C 0.422 0.507 0.072 0.509 0.380 0.111 0.078 
481 C > T 0.516 0.435 0.049 0.593 0.343 0.065 0.2657 
590 G > A 0.655 0.314 0.031 0.741 0.250 0.009 0.1943 
803 A > G 0.197 0.574 0.229 0.157 0.611 0.232 0.6696 
857 G > A 0.946 0.054 0 0.917 0.083 0 0.3016 
“0” and “1” represent the major and minor alleles, respectively. 
‡
 - indicates homozygous SNP-genotypes 
†
 - indicates heterozygous SNP-genotypes. 
§
 - determined via Chi-squared (2) analysis. 
 
 
Table 4.2 Frequency distribution for the NAT2 alleles analysed. 
NAT2 
SNP 
Allele Frequency Cases versus Controls 
Cases, n = 446 Controls, n = 216 OR   (95% CI)
$
 P-value
$
 
191 
G
‡
 431   (97) 216   (95) 
1.395 (0.6159 – 3.159) 0.5143 
A 15   (3) 10   (5) 
282 
C
‡
 320   (72) 168   (78) 
0.7256 (0.4955 – 1.063) 0.1096 
T 126   (28) 48   (22) 
341 
T
‡
 301   (68) 151   (70) 
0.8936 (0.6285 – 1.271) 0.5932 
C 145   (32) 65   (30) 
481 
C
‡
 326   (73) 165   (76) 
0.8494 (0.5821 – 1.239) 0.4480 
T 120   (27) 51   (24) 
590 
G
‡
 362   (81) 187   (87) 
0.6683 (0.4229 – 1.056) 0.0982 
A 84   (19) 29   (13) 
803 
A
‡
 216   (48) 100   (46) 
1.089 (0.7866 – 1.509) 0.6094 
G 230   (52) 116   (54) 
857 
G
‡
 434   (97) 207   (97) 
1.572 (0.6521 – 3.792) 0.3463 
A 12   (3) 9   (3) 
‡
 - indicates the Major Allele for each SNP 
$ - Fischer’s exact analysis 
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4.3.2. NAT2 genotypes in TB-patients 
Individual NAT2 genotypes were scored as the summation of the results obtained 
for the 7 SNPs analysed, as described in a preceding chapter. Briefly, this entails the 
assignment of a slow acetylation (SA) status to samples possessing a combination of any 
two of the activity-altering SNPs (namely, 191A, 341C, 590A, and 857A), whilst the 
rapid acetylation (FA) status was assigned to samples without these respective 
polymorphisms. In addition; rapid acetylators were also scored on the basis of the 
presence of the 282C>T and 803A>G SNPs. The intermediate acetylation (IA) status was 
defined by the presence of only one of the activity-altering SNPs (Table 4.3). This 
convention was applied throughout this study to avoid confusion, and possible 
discrepancies in the assignment of the alleles. 
 
Table 4.3 NAT2 genotypes observed between unaffected and TB-affected 
individuals. 
Observed 
Diplotype 
Deduced 
Genotype 
Unaffected 
Cohort 
TB Cohort 
P-value
§
 
N    (%) N     (%) 
Rapid Acetylators (FF) 24    (22.2) 42   (18.8)  
0000010 2*4/2*12A 10     (41.7) 19     (45.2) 
0.5165 
0000020 2*12A/2*12A 6      (25.0) 5      (11.9) 
0000000 2*4/2*4 3     (12.5) 5      (11.9) 
0100010 2*4/2*12B 3     (12.5) 9      (21.4) 
0001010 2*4/2*12C 1      (4.2) n.f. 
0100000 2*4/2*13 1      (4.2) 1     (2.4) 
0200000 2*13/2*13 n.f. 2     (4.8) 
0100020 2*12A/2*12B n.f. 1    (2.4) 
Intermediate Acetylators (FS) 55     (50.9) 106    (47.5)  
0100110 2*4/2*6C 13      (23.6) 15        (14.2) 
0.1074 
0011010 2*4/2*5B 11     (20.0) 22      (20.8) 
0011020 2*12A/2*5B 5       (9.1) 24     (22.6) 
0010010 2*4/2*5C 4       (7.3) 5       (4.7) 
1100010 2*12A/2*14B 3      (5.5) 1     (0.9) 
0111010 2*4/2*5G 2       (3.6) 5      (4.7) 
0100100 2*4/2*6A 2       (3.6) 17    (16.0) 
0100001 2*4/2*7B 2       (3.6) 1      (0.9) 
1000010 2*4/2*14E 2       (3.6) 1      (0.9) 
0010020 2*12A/2*5C 2       (3.6) 5      (4.7) 
0100011 2*12A/2*7B 2       (3.6) 1      (0.9) 
0110010 2*13/2*5C 2       (3.6) 3       (2.8) 
1000000 2*4/2*14A 1       (1.8) 1       (0.9) 
1100000 2*4/2*14B 1       (1.8) 1       (0.9) 
0000110 2*12A/2*6B 1       (1.8) n.f. 
0110000 2*13/2*5D 1       (1.8) n.f 
0200100 2*13/2*6A 1       (1.8) n.f  
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0011000 2*4/2*5A n.f 1     (0.9) 
0000100 2*4/2*6B n.f 1     (0.9) 
0111020 2*12A/2*5G n.f 1     (0.9) 
0110020 2*12B/2*5C n.f 1     (0.9) 
Slow Acetylators (SS) 29      (26.9) 75     (33.6)  
0022020 2*5B/2*5B 7       (24.1) 10     (13.3) 
0.1911 
0111110 2*5B/2*6A 6       (20.7) 28      (37.3) 
0021020 2*5B/2*5C 5       (17.2) 2       (2.7) 
0111011 2*5B/2*7B 2        (6.9) 6       (8.0) 
1011010 2*5B/2*14A 2       (6.9) 2      (2.7) 
0011110 2*5B/2*6B 1       (3.5) 1      (1.3) 
0100200 2*6A/2*6B 1       (3.5) 2      (2.7) 
0200101 2*6A/2*7B 1       (3.5) 2      (2.7) 
0111100 2*5A/2*6A 1       (3.5) n.f. 
0111101 2*5A/2*7B 1       (3.5) n.f. 
0010011 2*5C/2*7A 1       (3.5) n.f. 
1100100 2*6B/2*14B 1       (3.5) n.f. 
0200200 2*6A/2*6A n.f. 5       (6.7) 
1111010 2*5B/2*14B n.f. 4       (5.3) 
0110110 2*5C/2*6A n.f. 3       (4.0) 
0020020 2*5C/2*5C n.f. 2       (2.7) 
0022010 2*5A/2*5B n.f. 1       (1.3) 
0021010 2*5B/2*5D n.f. 1       (1.3) 
1110010 2*5C/2*14B n.f. 1       (1.3) 
1110000 2*5D/2*14B n.f. 1       (1.3) 
0100101 2*6A/2*7A n.f. 1       (1.3) 
1200100 2*6A/2*14B n.f. 1       (1.3) 
1200001 2*7B/2*14B n.f. 1       (1.3) 
Table 4.3 continued….. 
§
 - global P-value determined by the Chi-squared (2) analysis. 
n.f. = not found. 
 
 
The frequency distribution for the FA, IA and SA genotypes is comparable between the 
cohorts, and the small differences between them does not correlate significantly with 
either the controls or cases (see Table 4.3). It is likely however, that these differences 
failed to achieve a significant correlation due to the relatively small sample set employed 
in this experiment. However, a number of interesting features are evident between the 
cohorts, such as a slightly greater frequency with respect to FA and IA groups in the 
control cohort, whilst the SA status prevails amongst the cases. 
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In the FA group, the NAT2*4/2*12A and NAT2*4/2*4 genotypes are equally distributed 
between the controls and the cases. Secondly, the NAT2*4/2*12A genotype was the most 
common genotype in both cohorts. In contrast to this, the NAT2*12A/2*12A and the 
NAT2*4/2*12B genotypes represent a greater proportion amongst the control and TB-
affected individuals respectively (an approximately 2x difference between the cohorts). 
This is interesting, since the polymorphisms classifying these NAT2*12 haplotypes, 
namely, 803G (for NAT2*12A), and 282T plus 803G (for NAT2*12B), do not confer a 
reduced acetylation activity [177, 303]. In effect, the 803 polymorphism changes the 
amino acid lysine (K) to arginine (R) at position 268 (K268R), whilst the 282C>T 
polymorphism is a synonymous variant, maintaining the amino acid identity at position 
94, which is tyrosine (Y). In this respect, there may be some significance in the 
observation of an approximately two-fold difference in the prevalence of these particular 
NAT2*12 alleles between the two cohorts. 
Given the well-known redundancy in the genetic code, synonymous polymorphisms are 
generally regarded as being equivalent to one another, since they do not alter the amino 
acid identity in the protein. However, it has been shown that the use of the alternative 
codon in these so-called “silent” polymorphisms is not a random event in biological 
systems [304-306]. A definite correlation has for example been reported between the 
extent of bias in codon usage, and the level of gene expression [304, 307, 308]. This type 
of codon bias has also been shown in different tissues [309, 310]. More recently, ‘silent” 
polymorphisms have also been found to influence the activity of proteins even at the level 
substrate specificity [265]. 
The prevalence of the NAT2*4/2*12B rapid acetylator genotype in the TB cohort may 
therefore indicate a potential reduction in the treatment efficacy in these individuals, 
possibly due to an increased rate of INH metabolism, thereby causing individuals with 
this genotype to require a relatively longer period of time to be cured, due to the relatively 
rapid removal of the drug (INH). Consequently, these individuals may be at risk of 
developing multi-drug resistance in the infecting Mtb strain, due to the impairment of the 
efficacy of INH in the standard treatment regimen. Whilst it may be advisable to 
administer an increased dosage of INH to individuals with this genotype to achieve the 
required treatment efficacy, the specific acetylation effect of this genotype on the 
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metabolism of INH, still needs to be determined empirically, since the relative merits of 
each of these codons in influencing the level of NAT2 gene expression, and hence protein 
activity, is unknown. 
 
In the case of the IA group, there are several genotypes that occur more frequently 
amongst the control samples than amongst TB-affected individuals. These differences 
generally range from approximately 2-fold (for NAT2*4/2*6C (1.7x), to as much as 6-
fold (for NAT2*12A/2*14B). Furthermore, the NAT2*12A/2*14B and NAT2*4/2*14B 
genotypes respectively, have a 6-fold and 2-fold greater occurrence between the cohorts. 
Hence it would appear that the presence of the 803G variant (in NAT2*12A) may afford a 
3-fold greater acetylation advantage in combination with the NAT2*14B allele, than 
would the wild type NAT2*4 allele. However, in the case of the analogous 
NAT2*12A/2*7B and NAT2*4/2*7B genotypes, the difference in the frequency 
distribution of these particular genotypes remain unchanged between the cohorts (at 4-
fold greater in the controls). This latter observation may indicate that the apparent 
advantageous effect of the 803G polymorphism is counteracted by different SA alleles. 
Alternatively, it is likely that the acetylation effect conferred by the NAT2*14B allele may 
be more pronounced, since it has been shown that the 857A SNP variant, present in the 
NAT2*7 alleles, exhibits a decreased binding affinity for the cofactor acetylCoA [176, 
177]. This interaction is an overriding step in the acetylation reaction, and its retardation 
or inhibition would preclude the subsequent acetylation of the substrate (INH). Hence the 
overall acetylation rate for the NAT2*7 allele may be slower relative to that of the 
NAT2*14 alleles. 
Of equal interest within the IA group, particularly in the context of factors that may 
reduce anti-TB treatment, is the observation that the NAT2*12A/2*5B and NAT2*4/2*6A 
genotypes occur more frequently amongst the cases than the controls, at 2.5-fold and 4.4-
fold, respectively. These genotypes may therefore have an effect on the efficacy of anti-
TB treatment, and predispose individuals to a relatively longer treatment episode. 
Furthermore, of the 14 IA genotypes commonly observed among the cohorts, 
approximately 43% (6/14) occurred at a frequency of less than 1% in the TB-affected 
cohort. However, the Chi-squared analysis for the IA group (P-value = 0.1074) indicates 
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that there is no significant differences in the genotypes between the two cohorts, whilst 
some of the genotypes, such as for example, NAT2*4/2*12A, and NAT2*4/2*5B are 
equally distributed between them. 
 
The most prevalent acetylation genotypes in the SA group are NAT2*5B/2*5B (24.1% in 
controls versus 13.3% in cases), and NAT2*5B/2*6A (20.7% in controls versus 37.3% in 
cases). This 2-fold difference between the cohorts with respect to these genotypes may 
only have a slight impact upon the difference in treatment efficacy, in those individuals 
harbouring the NAT2*5B/2*6A genotype. On the other hand, the NAT2*5B/2*14A and 
NAT2*5B/2*5C genotypes, being less prevalent among the cases, at approximately 3-fold 
and 6-fold, respectively, could be indicative of a better prognosis with respect to the 
treatment efficacy, and for this reason may be more effective in improving the overall 
disease epidemiology, by improving the rate of cure of the disease. In this respect, the 
trend for the SA group is similar to that observed for the FA and IA acetylation groups, in 
that several of the commonly occurring NAT2 genotypes are found more frequently 
amongst the individuals unaffected by TB disease (controls). 
Equally interesting in the SA group, is the difference in number of unique NAT2 
genotypes that occurred between the cohorts, with 28% (21/75) observed amongst the 
cases and only 14% (4/29) in the controls. In the case of the FA and IA groups, the 
number of unique genotypes are relatively small, and not that different between the 
cohorts, being 4.2% and 4.8% (controls versus cases) in the FA group, and 5.5% and 
5.3% (controls versus cases) in the IA group. The importance of these differences among 
the SA group should be investigated further, on the basis of a dual genotype-phenotype 
assay to determine the significance of these unique genotypes with respect to anti-TB 
treatment efficacy. 
 
The chi-squared analyses indicate that there are no significant differences in the FA, IA 
and SA states between the cohorts, and no obvious trend can be observed in the different 
cohort groups, beyond the general differences apparent in the frequency distribution of 
some genotypes between the cohorts. Nevertheless the differences observed for these 
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particular genotypes in the FA, IA and SA states, may warrant further investigation in 
those individuals to assess the role of NAT2 acetylation underlying TB disease. 
A possible confounding factor may reside in the alternative allele assignments that can be 
deduced from observed diplotypes (Table 4.4). These assignments could not be resolved 
unambiguously by the experimental methodologies generally used in the NAT2 
genotyping assays [170, 173, 311]. However, we found that in most situations of such 
ambiguity, the alternative allele and genotype assignment(s) did not alter the overall 
acetylation status of the individual sample. Furthermore, this 7-SNP assay for determining 
NAT2 genotypes has also been used successfully by several other authors [272, 312]. 
 
Table 4.4 Alternative NAT2 genotypes deduced from observed diplotypes 
 
Observed 
Diplotype 
Deduced 
Genotype 
Proposed Alternative 
Genotype 
Acetylation Change 
Fast Acetylation 
0001010 2*4/2*12C 2*11/2*12A - 
Intermediate Acetylation 
0100110 2*4/2*6C 2*12A/B/2*6A/B - 
0011010 2*4/2*5B 2*12A/2*5A  
0010010 2*4/2*5C 2*12A/2*5D  - 
1100010 2*12A/2*14B 2*12B/2*14A - 
0111010 2*4/2*5G 2*13/2*5B or 2*12B/2*5C  - 
0100100 2*4/2*6A 2*13/2*6B  
0100001 2*4/2*7B 2*13/2*7A - 
1000010 2*4/2*14E 2*12A/2*14A - 
0100011 2*12A/2*7B 2*12B/2*7A - 
0110010 2*13/2*5C 2*12B/2*5D - 
1100000 2*4/2*14B 2*13/2*14A - 
0000110 2*12A/2*6B 2*4/2*6F - 
Slow Acetylation 
0111110 2*5B/2*6A 2*5G/2*6B or 2*5C/2*6N - 
0111011 2*5B/2*7B 2*5G/2*7A or 2*7C/2*5A - 
1011010 2*5B/2*14A 2*4/2*14C Intermediate (IA) 
0011110 2*5B/2*6B 2*5C/2*6E or 2*5A/2*6F  
1100100 2*6B/2*14B 2*4/2*14D Intermediate (IA) 
0111100 2*5A/2*6A 2*5D/2*6N - 
1111010 2*5B/2*14B 2*13/2*14C Intermediate (IA) 
0110110 2*5C/2*6A 2*12B/2*5E Intermediate (IA) 
0021010 2*5B/2*5D 2*5A/2*5C - 
1110010 2*5C/2*14B 2*13/2*14F Intermediate (IA) 
0100101 2*6A/2*7A 2*4/2*6J Intermediate (IA) 
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Some of these alternative assignments, particularly among SA individuals, did alter the 
proposed genotype to IA. In all of these latter instances the change in genotype is due to 
the assignment of more than one of the activity-altering SNPs to a particular haplotype. 
For example, the observed diplotype 1011010, can be resolved as either the 
NAT2*5B/2*14A genotype (SA), or the alternative, NAT2*4/2*14C genotype (IA) (table 
4.4). In the latter genotype, all four of the observed polymorphic SNPs (191A, 341C, 
481T, and 803G) are assigned to one allele, namely NAT2*14C. Similar haplotype 
combinations (to that for NAT2*14C) have been reported by other authors [313-315], but 
the effect of these particular alleles (haplotypes) on the overall acetylation status of the 
enzyme has, to our knowledge, not yet been elucidated. The current practise in the 
acetylation research field assigns the activity-altering polymorphisms to separate alleles 
(see table 4.5), a protocol that we have also followed, since the experimental techniques 
are unable to rapidly determine the phasing of these SNPs in particular genotypes. 
 
Comparisons using pair-wise linkage disequilibrium (LD) analyses (Haploview version 
4.2, http://www.broad.mit.edu/mpg/haploview) [316] to align these 7 SNPs were unable 
to indicate an over-riding pattern of associations between particular SNPs. Some authors 
have attempted to resolve this question by using a computer programme (PHASE version 
2.1.1, http://www.stat.washington.edu/stephens/software.html) for the reconstruction of 
haplotypes from population data [317]. These authors found that while these haplotype 
prediction techniques cannot fully determine the actual NAT2 genotype, the ambiguity in 
prediction only varies between 0.1% to 1.2% [266, 270]. Furthermore, Agúndez (2003) 
[271] reported that the 282 polymorphism has not been found on the same NAT2 allele 
(haplotype) as the 341 polymorphism, thereby providing some support for the argument 
against the generalised assignment of SNP variants to one haplotype. 
Thus whilst ambiguities in NAT2 genotyping may prevail in studies using the current 
methodologies, the degree of discordance may be small and may not be significantly 
relevant across populations due to the variation in the NAT2 SNP frequencies between 
populations. The inclusion of additional, known activity-altering SNPs, such as for 
example 364G>A, 411A>T, 434A>C, and 845A>C, may become a major factor in 
reducing this ambiguity or discordance. 
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Table 4.5 Nucleotide alterations defining various NAT2 alleles. 
NAT 
Allele 
Nucleotide Change Amino Acid Change 
Defining Acetylation 
Phenotype 
Phenotype 
191 282 341 481 590 803 857 
          
2*4
‡
 G C T C G A G None Rapid 
2*5A   C T     Slow 
2*5B   C T  G   Slow 
2*5C   C   G   Slow 
2*5D   C     I
114→T Slow 
2*5E   C  A    Slow 
2*5G  T C T  G   Slow 
2*6A  T   A    Slow 
2*6B     A   R
197→Q Slow 
2*6C  T   A G   Slow 
2*6J  T   A  A  Slow 
2*7A       A G
286→E Slow 
2*7B  T     A  Slow 
2*12A      G  K
268→R Rapid 
2*12B  T    G   Rapid 
2*12C    T  G    
2*13  T      Y
94→Y (None) Rapid 
2*14A A       R
64→Q Slow 
2*14B A T       Slow 
2*14C A  C T  G   Slow 
2*14D A T   A    Slow 
2*14E A     G   Slow 
2*14F A  C   G   Slow 
‡
 - indicates the wild type (reference) allele. 
Blocked text indicates the defining polymorphisms for the various allele classes. 
Amino acid Abbreviations:- Glutamate (E); Glycine (G); Isoleucine (I); Lysine (K); 
Glutamine (Q); Arginine (R); Threonine (T); Tyrosine (Y). 
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4.3.3 NAT2 alleles and haplotypes in TB-patients 
An analysis of the NAT2 acetylation distribution with respect to the rapid and 
slow alleles reflects the general trend observed in the genotype analyses, in that no 
significant correlations were found in the overall allele frequencies between the cohorts 
(Table 4.6). This trend was also reflected in the allele subclasses, such as for example, the 
NAT2*12 rapid alleles, and the NAT2*5 slow alleles. 
 
Table 4.6 Distribution of the NAT2 alleles within the cohorts 
Deduced 
Genotype 
Unaffected 
Cohort 
TB Cohort 
P-Value
†
 
N        (%) N        (%) 
Fast Alleles 103   (47.7) 190  (42.6) 0.9306 
NAT2*4 57   (57.3) 109    (57.4)  
2*12A 37     (34.0) 62      (32.6) 
0.5672 
2*12B 3      (2.9) 11      (5.8) 
2*12C 1      (1.0) n.f. 
NAT2*12 41     (37.9) 73     (38.4) 
NAT2*13 5     (4.9) 8   (4.2)  
Slow Alleles 113    (52.3) 256   (57.4) 0.2801 
2*5A 2       (1.8) 3    (1.2) 
0.4661 
2*5B 46     (40.7) 114    (44.5) 
2*5C 14     (12.4) 23     (9.0) 
2*5D 1      (0.9) 2      (0.8) 
2*5G 2      (1.8) 3    (1.2) 
NAT2*5 65      (57.5) 145     (56.6) 
2*6A 12       (10.6) 64      (25.0) 
0.0026* 
2*6B 4       (3.5) 5      (2.0) 
2*6C 13       (11.5) 15      (5.9) 
NAT2*6 29       (25.6) 84     (32.9) 
2*7A 1       (0.9) 1       (0.4) 
1.000 2*7B 8       (7.1) 11       (4.3) 
NAT2*7 9       (8.0) 12       (4.7) 
2*14A 5       (4.4) 4      (2.0) 
0.4422 
2*14B 5       (4.4) 10    (3.9) 
2*14E n.f 1     (0.4) 
NAT2*14 10       (8.8) 15    (6.3) 
†
 indicates the global P-value determined by Chi-squared analysis 
or Fischer’s exact analysis. 
* - P-value < 0.05 represents a statistically significant association. 
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However, a significant association was observed for the NAT2*6 class of alleles (P-value 
= 0.0026) which indicates that these particular slow alleles may have a potential impact 
on TB epidemiology. We also tested this association between particular NAT2*6 alleles, 
namely NAT2*6A versus NAT2*6C, since these two haplotypes only differ on the basis of 
the 803G SNP, present in NAT2*6C. In the latter instance, the significance of the 
correlation was confirmed (P-value = 0.0035). In contrast, the frequency of the NAT2*6B 
allele did not differ substantially between the cohorts. Therefore, the significant 
correlation observed for the NAT2*6 alleles between controls and cases is associated with 
differences in the NAT2*6A and NAT2*6C alleles. 
As indicated in table 4.5, NAT2*6 alleles share the 590A polymorphism, which imparts a 
slow acetylation activity to the enzyme. However, the greater prevalence of particular 
haplotypes in controls compared to cases (NAT2*6C) and vice versa (NAT2*6A) would 
appear to indicate that these additional NAT2 SNPs may afford differing acetylation 
capacities to the individuals in these groups. Hence the NAT2*6A allele (haplotype) may 
have a greater confounding effect on TB treatment efficacy, than NAT2*6C, due to the 
synonymous SNP at 282. Alternatively, the rapid acetylation status conferred by the 803G 
SNP variant may impart a beneficial affect with respect to the overall acetylation activity. 
In this context it may be interesting that the NAT2*6C allele occurred among IA 
individuals and not among SA individuals in the SAC cohorts. Among the IA individuals 
the NAT2*4/2*6C genotype was associated with the control cohort more than the TB-
affected cohort. On the other hand, the NAT2*4/2*6A genotype showed a greater 
association with TB-affected IA individuals. Furthermore, in the SA group, the 
NAT2*6A/2*6A genotype was not found among control individuals, while the 
NAT2*6A/2*6B genotype occurred equally among control and TB-affected SA 
individuals. 
 
 
4.4 The Surrogate Marker surveillance study 
The surrogate marker surveillance study has the added advantage of providing 
specific demographic data pertaining to TB disease, since the patients were strictly 
monitored during their DOTs treatment episode. In this respect this study has the potential 
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to broaden the understanding of the impact of the acetylation status on the epidemiology 
of this very complex disease. Table 4.7 and 4.8 list some of the demographic data 
collected to promote an understanding of the ramifications implicit to the disease. It is 
envisaged that this information may facilitate the attainment of certain goals which may 
assist in the curtailment of the disease epidemic. 
Table 4.7 Demographic data for the SM cohort
§
 
Demographic 
Count 
(n = 223) 
Frequency 
(%) 
Gender 
Male 130 58.3 
Female 93 41.7 
Age (years) 
<20 8 3.6 
21-30 83 37.2 
31-40 63 28.3 
41-50 44 19.7 
>51 25 11.21 
INH
S
 
Yes 23 10.3 
No 197 88.3 
Unknown 3 1.4 
Education 
None 5 2.2 
Primary level 160 71.8 
Secondary level 48 21.5 
Tertiary level 2 <1 
Unknown 8 3.6 
Monthly 
Income 
None 16 7.2 
<R250 22 9.9 
R251-1000 28 12.6 
R1001-2000 22 9.9 
> R2000 6 2.3 
Unknown 129 57.9 
Consume 
Alcohol 
Yes 171 76.7 
No 36 16.1 
Unknown 16 7.2 
Smoke 
Yes 199 89.2 
No 12 5.4 
Unknown 12 5.4 
BMI
†
 
Male average 18.34
†
  
Female average 18.32
†
  
Height
*
 
Male average 1.654  
Female average 1.653  
INH
s
 = Indicates Mtb strains sensitive to isoniazid. 
†
 = body mass index. 
* = Height measured in metres. 
§
 = adapted from Babb, C.L. (2007) Ph.D. Dissertation. 
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Table 4.8 Mtb strain families identified the SM study cohort 
Strain 
Family
Δ
 
Distribution 
frequency 
N     (%) 
Median Sputum Smear 
Conversion Day 
Median Culture 
Conversion Day 
0 6 2.7 21.5 67.5 
2 8 3.6 42 60 
4 4 1.8 72.5 65.5 
6 6 2.7 21 42.8 
7 7 3.1 23 58.5 
8 1 0.4 21 41.5 
9 5 2.2 41 56 
11 47 20.9 42 72 
12 1 0.4 139 42.5 
13 3 1.3 21 42 
14 6 2.7 23 31.5 
16 4 1.8 31 66.5 
17 1 0.4 10 73.5 
18 4 1.8 27.5 57.8 
19 1 0.4 73 59 
21 2 0.9 23 47.2 
23 2 0.9 41 21 
24 2 0.9 42.5 42 
25 1 0.4 2 20.5 
27 2 0.9 57.5 57.3 
28 6 2.7 20.5 41.3 
29 69 30.7 41 72 
30 1 0.4 212 116 
31 1 0.4 72 72 
110 5 2.2 22.5 43.5 
120 8 3.6 42 56.8 
130 2 0.9 57 72 
140 18 8.0 38 43 
150 2 0.9 16 42.3 
Δ
 = Mtb strain family nomenclature according to Richardson et al [318] 
Bold type indicates the most frequently occurring Mtb strains. 
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4.4.1 Assessing strain prevalence in the cohort  
As indicated in table 4.8, DNA fingerprinting analysis identified 29 different Mtb 
strains among the 223 SM cases, of which 45% (13/29) occurred at a frequency less than 
1%. The most prevalent Mtb strains were identified as belonging to family 29 (Beijing 
clade), family 11 (LAM clade) and family 140 (Low copy-number clade), which co-
incidentally are also the most prevalent infecting strains in the Western Cape Province of 
South Africa [298, 319]. This may be an indication of “strain success” for family 29 and 
11 which together cause 51.6% of the disease burden in this community, whereas family 
140, the next most prevalent Mtb strain, only accounts for 8.0% of the disease prevalence 
in this cohort. Alternatively, the most dominant Mtb strains may have become 
“established” in this community due to their relatively longer association with it. 
 
 
 
Figure 4.1 Sixty percent of the identified Mtb strains belong to only three strain 
families. The x-axis represents the NAT2 acetylation genotypes, whilst the y-axis 
represents the number of individuals harbouring a specific strain family. No 
significant association was observed between the strains and the rapid (FA, IA) or 
slow acetylation (SA) activity groups. (P value = 0.0777) 
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A chi-squared analysis to investigate a possible correlation between the presence of the 
most prevalent infecting strains and acetylation status as described by the rapid (FA and 
IA) versus slow (SA) acetylation found an association of borderline significance only (P-
value = 0.0777) (Fig. 4.1). 
It is probable that this association may be due to the fact that these strains are over-
represented in this community, yet this in itself is significant, since Mtb strains appear to 
have a niche host-population relationship [6, 7, 320]. The significance of this relationship 
is also evident in a report which found that a particular Mtb strain can be an independent 
risk factor for treatment failure in some populations [321]. Moreover the Beijing strain 
has been found to associate with TB-susceptible host genetic polymorphisms in the 
SCL11A1/NRAMP (natural resistance-associated macrophage protein 1) gene in the local 
SAC population [322], as well as in an Indonesian population [323]. Therefore, it would 
be interesting to investigate the associative trend observed in this study, between rapid 
acetylation and the Mtb strain families 11 and 29, in a future investigation, given that 
family 29 also belongs to the Beijing clade. 
 
 
4.4.2 Assessing treatment outcomes via sputum conversion 
The SM patients were also investigated for various host-derived factors that could 
predict treatment outcome based on the comparison of ZN-microscopy (smear) and 
culture analysis of patient sputa at enrolment and after 2 months of DOTs treatment, 
according to the National Treatment Programme of South Africa. Early data from the SM 
cohort indicated a difference in the sputum results for some patients after 8 weeks of 
treatment, in that the majority of these patients (91) recorded a negative sputum result, 
and were labelled as the responder group (R), whilst 21 patients recorded a positive 
sputum result after 8 weeks of treatment. These latter patients were referred to as the 
delayed or Non-responder (NR) group. 
A cohort of 36 patients (18 responders and 18 non-responders), matched for age, gender, 
extent of disease (number of cavities as well as the extent of disease-affected alveolar), 
sputum smear grade (bacterial load in sputum sample) and good adherence to treatment 
(completed 32 of the required 40 treatment doses (DOTs)) were subsequently selected 
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and investigated for their NAT2 acetylation status as well as for differences in 
immunological biomarkers. The results of the latter analysis was reported by Brahmbhatt 
et al [293], who observed differences in several immune markers, such as soluble tumour 
necrosis factor alpha receptors 1 and 2 (sTNF-R1and sTNF-R2), soluble interleukin-2 
receptor alpha (sIL-2R), and the absolute counts of selected white blood cells (such as 
monocytes and neutrophils) which could be used to predict whether a patient would 
exhibit a delayed response to treatment (be a NR) or not. 
Only 34 patients of this matched SM group were assessed for their acetylation, since the 
DNA from one sample of the responder group could not be amplified. This sample pair 
was therefore removed from the analysis. Table 4.9 summarises the acetylation results 
observed for this group of patients. 
 
Table 4.9 NAT2 acetylation polymorphisms for the matched group of SM patients 
Observed 
Diplotype 
Deduced 
Genotype 
Sputum ZN-smear Conversion 
Responders 
N        (%) 
Non-responder 
N         (%) 
Rapid Acetylators (FF) 6    (35.3) 2      (11.8) 
0200000 2*13/2*13 2    (11.8) n.f. 
0000010 2*4/2*12A 1     (5.9) 1      (5.9) 
0100010 2*4/2*12B 1     (5.9) 1      (5.9) 
0100000 2*4/2*13 1     (5.9) n.f. 
0000020 2*12A/2*12A 1     (5.9) n.f. 
Intermediate Acetylators (FS) 2    (11.8) 14      (82.4) 
0011020 2*12A/2*5B n.f. 6     (35.3) 
0100100 2*4/2*6A n.f. 3     (17.6) 
0011020 2*4/2*6C n.f. 2     (11.8) 
0011010 2*4/2*5B 1     (5.9) 1      (5.9) 
0010010 2*4/2*5C 1     (5.9) n.f. 
1000000 2*4/2*14A n.f 1      (5.9) 
0010020 2*12A/2*5C n.f. 1      (5.9) 
Slow Acetylators (SS) 9    (52.9) 1     (5.9) 
0111110 2*5B/2*6A 3     (17.6 n.f 
0200200 2*6A/2*6A 2    (11.8) n.f. 
0111011 2*5B/2*7B 2    (11.8) n.f. 
0111011 2*5C/2*5C 1     (5.9) n.f. 
0100200 2*6A/2*6B 1     (5.9) n.f. 
0020020 2*5B/2*5C n.f. 1      (5.9) 
n.f. = not found 
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A highly significant association was observed between the acetylation status (FA, IA and 
SA) and the observed difference in the sputum ZN-smear conversion response between 
the responders (R) and Non-responders (NR) (P-value = 0.0002, (chi-square analysis)). 
The majority of the responders (88%) belonged to the SA and the FA classes respectively. 
These results indicate that SA and FA responded to the DOTs treatment, with a better 
treatment efficacy evident amongst the slow (53%) than rapid (35%) acetylators. On the 
other hand the observed delay in treatment efficacy, as measured by sputum response 
after 8 weeks of treatment, could be attributed to the effect of the IA status in the NR 
patients. 
Given these initial results for this matched cohort, we extended our acetylation analysis to 
include all patients from the SM study cohort who had completed the initiation phase of 
treatment, and for whom both ZN-smear and culture results were available. The median 
conversion time for ZN-smear was 41 days (range 1-231days), and for culture 71.5 days 
(range 0.5-268.5days) respectively. At Day 55, the data for 213 patients was audited for 
treatment efficacy only, and the patients were classified as either Responders or Non-
responders, as delineated by ZN-smear and culture conversion results. For this analysis 
we defined the Non-responders as those individuals who exhibited a positive ZN-smear 
and culture result at Day 55. Of these patients 213 patients, 190 were sensitive to 
isoniazid (INH
S
), and 21 were resistant (INH
R
), whilst 2 were of unknown drug 
sensitivity. However all of the patients with INH
R
 Mtb strains returned negative culture 
and ZN-smear results at Day 55 (hence classified as responders), were included in the 
analysis. The overall acetylation results for this cohort of samples is summarised in Table 
4.10. 
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Table 4.10 NAT2 acetylation in Responder and Non-responder patients. 
Acetylation 
ZN-Smear Conversion
§
 Culture Conversion
§
 
Responder Non-Responder Responder Non-responder 
Rapid (FA) 30 19.2 11 19.3 20 22.2 21 17.1 
Intermediate (IA) 77 49.4 26 45.6 43 47.8 60 48.8 
Slow (SA) 49 31.4 20 35.1 27 30.0 42 34.1 
Total 156 100% 57 100% 90 100% 123 100% 
§
 = no significant association found for either ZN-Smear (P-Value = 0.863) nor Culture 
conversion (P-Value = 0.606). 
 
As indicated in the table 4.10 the acetylation status does not differ between the cohorts. 
However, upon assessing the prevalence of the individual NAT2 SNPs in the responder 
versus the non-responder groups several differences become evident (Tables 4.11 and 
4.12). 
 
 
Table 4.11 NAT2 genotypes in the responder and non-responder patient groups 
NAT2 
SNPs 
ZN-Smear Conversion (n = 213) Culture Conversion (n = 213) 
R 
n = 156 (%) 
NR 
n = 57 (%) 
P-value
‡
 
R 
n = 90 (%) 
NR 
n = 123 (%) 
P-value
‡
 
191 
GG 149 (95.5) 49 (86) 
0.0298 
86 (95.6) 120 (97.6) 
0.4592 
GA 7 (4.5) 8 (14) 4 (4.4) 3 (2.4) 
282 
CC 81 (51.9) 24 (42.1) 
0.2771 
51 (56.7) 87 (70.7) 
0.1023 CT 66 (42.3) 31 (54.4) 34 (37.8) 32 (26.0) 
TT 9 (5.8) 2 (3.5) 5 (5.6) 4 (3.3) 
341 
TT 65 (41.7) 26 (45.6) 
0.5314 
39 (43.3) 83 (67.5) 
0.0015 TC 79 (50.6) 29 (50.9) 43 (47.8) 36 (29.3) 
CC 12 (7.7) 2 (3.5) 8 (8.9) 4 (3.3) 
481 
CC 81 (51.9) 31 (54.4) 
0.4712 
48 (53.3) 90 (73.2) 
0.0089 CT 66 (42.3) 25 (43.9) 36 (40.0) 30 (24.4) 
TT 9 (5.8) 1 (1.8) 6 (6.7) 3 (2.4) 
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590 
GG 102 (65.4) 38 (66.7) 
0.7501 
62 (68.9) 97 (78.9) 
0.1588 GA 48 (30.8) 18 (31.6) 26 (28.9) 22 (17.9) 
AA 6 (3.8) 1 (1.7) 2 (2.2) 4 (3.3) 
803 
AA 30 (19.2) 11 (19.3) 
0.9782 
18 (20.0) 12 (9.8) 
0.0094 AG 90 (57.7) 32 (56.1) 52 (57.8) 95 (77.2) 
GG 36 (23.1) 14 (24.6) 20 (22.2) 16 (13.0) 
857 
GG 151 (96.8) 52 (91.2) 
0.1362 
86 (95.6) 122 (99.2) 
0.1648 
GA 5 (3.2) 5 (8.8) 4 (4.4) 1 (0.8) 
Table 4.11 continued… 
R = Responder; NR = Non-responder. 
‡
 = Statistical results obtained by Fischer’s exact or Chi-Squared (2) analyses (Results in 
bold indicate statistically significant observations). 
 
Table 4.12  NAT2 SNP genotypes associated with Culture conversion 
NAT2 
SNP 
Genotype Frequency  
Responders Non-responders OR   (95% CI)
$
 P-value
$
 
341 
TT 39 83 
0.3934   (0.2194 – 0.7054) 0.0020 
TC 43 36 
TC 43 36 
0.5972   (0.1661 – 2.147) 0.5394 
CC 8 4 
TT 39 83 
0.2349   (0.0667 – 0.8278) 0.0247 
CC 8 4 
481 
CC 48 90 
0.444   (0.244 – 0.808) 0.0096 
CT 36 30 
CT 36 30 
0.6000   (0.1382 – 2.606) 0.7228 
TT 6 3 
CC 48 90 
0.2667   (0.0638 – 1.114) 0.0752 
TT 6 3 
803 
AA 18 12 
2.740   (1.225 – 6.130) 0.0145 
AG 52 95 
AG 52 95 
0.43790   (0.2090 – 0.9173) 0.0357 
GG 20 16 
AA 18 12 
1.200   (0.4490 – 3.207) 0.8047 
GG 20 16 
$
 = Fischer’s exact analysis. Bold type indicates significant association (P-value less than 
0.05). 
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In the case of the ZN-smear conversion (table 4.10), the heterozygous GA genotype at 
SNP 191 is significantly associated with non-responders (NR) rather than responders 
thereby indicating that this genotype may have a confounding effect on the treatment 
efficacy in the NR group. None of the genotypes of the other 6 SNPs investigated show 
any correlation with either of these groups in the ZN-smear conversion cohort. 
In the culture conversion assessment, a significant correlation was observed for the NAT2 
genotypes delineated at positions 341, 481 and 803 respectively. In the case of the 341-
and 481-SNPs the wild-type genotypes (341TT and 481CC, respectively) are significantly 
associated with NR, whereas in the case of the 803-SNP, the heterozygous variant 
(803AG) is significantly associated with the NR group. 
 
Approximately 58% (123/213) of patients were classified as Non-responders by their 
culture conversion result at Day 55, despite the observation that the majority of the Mtb 
strains (89.4%) in this group were sensitive to isoniazid. This would indicate that the 
response to treatment involves a greater complexity with several other factors, such as the 
interplay between the host’s immune response and the virulence of the mycobacterium, 
playing an equally important role [324]. Another factor concerns the viability of the 
mycobacteria in lung lesions, which ranges from actively growing, - hence conducive to 
the antibacterial activity of the drugs - to fully dormant and intractable to drugs [325, 
326]. Since INH is known to exert its anti-mycobacterial activity against actively growing 
organisms, the viability of the bacteria in the lung lesions would play an important role in 
the actual survival of the organism in the presence of INH. 
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4.5 Conclusion 
The effect of NAT2 gene polymorphisms was investigated as a possible 
confounding factor to anti-TB treatment efficacy in South African Coloured (SAC) 
individuals from a high TB-incidence community. A seven single nucleotide 
polymorphism (SNP) assay was used to delineated the enzyme activity on the basis of 
rapid (FA), intermediate (IA), and slow (SA) acetylation, and in the initial case-control 
association analysis no acetylation differences were observed between cases and controls 
with respect to the above activity classifications. However, a number of interesting trends 
were observed with respect to particular NAT2 genotypes and alleles, which may merit 
further investigation. 
 
In the FA class the NAT2*4/2*12B genotypes appear to associate more with the cases 
rather than controls, whilst in the IA class, a similar trend is observed for the 
NAT2*12A/2*5B and NAT2*4/2*6A genotypes. It is interesting that one of the common 
features associated with these above genotypes involves synonymous SNPs (282C>T and 
481C>T), which are generally not considered to affect the acetylation activity of the 
enzyme. Various publications have however, reported that synonymous variants can exert 
significant effects on protein activity by influencing the expression level of genes [265, 
304-306], possibly via ribosome stalling [327]. This would result in aberrantly folded 
proteins which, are removed via the proteasome-ubiquitin pathway [112], thereby 
depleting the pool of active protein. This aspect of synonymous polymorphisms has not as 
yet been investigated with respect to the various known haplotype combinations present 
in NAT2. Whilst the results observed for the FA, IA, and SA groups were not significant, 
possibly due to the relatively small cohort sample, some of the trends observed among 
particular allele subclasses, may become significant in a larger study cohort. This may 
constitute an interesting avenue for future research. 
In the case of the SA alleles, the NAT2*6A allele was significantly associated with TB-
affected individuals. This allele results in an impaired acetylation activity, which may be 
further compounded by the 282C>T synonymous polymorphism, and may be a 
confounding factor with respect to anti-TB treatment efficacy. A recent publication by 
Higuchi et al (2007) [243] found a significance association between the NAT2*6A 
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haplotype and the development of drug-induced hepatotoxicity (DIH) in Japanese 
individuals. In this respect, DIH would have an important negative effect on TB-treatment 
efficacy, since its appearance in TB patients is idiosyncratic, and necessitates the 
suspension of treatment [328, 329]. Given the genetic ancestry of the local SAC 
community, particularly with respect to their oriental antecedents [245], the NAT2*6A 
allele (haplotype) may be an important biomarker in TB-affected individuals. 
 
Our experimental analysis also investigated the acetylation genotype or status in a well 
defined group of TB patients from the SM cohort. These individuals were strictly 
monitored and assessed for environmental and host-derived demographic factors that 
could affect the treatment efficacy during the intensive phase of treatment (Day 55, month 
2), as recommended by the International Union against Tuberculosis and Lung Disease 
(IUTLD) [301]. On the basis of their treatment results at this time point, these patients 
were classified as either responders, who gave a negative result, or non-responders, who 
scored positive for Mtb, as assessed by both ZN-smear and culture analyses. 
Our results indicated that FA, IA and SA activity did not differ between responders and 
non-responders, which imply that the acetylation activity per se does not influence the 
treatment efficacy during the intensive phase of treatment (Day 55). However, a number 
of significant correlations were observed for certain NAT2 SNPs and the observed 
treatment response in the ZN-smear conversion and culture conversion groups, 
respectively. The 191GA NAT2 genotype was significantly associated with the non-
responders in the Zn-smear conversion group, yet did not show a similar correlation in the 
culture conversion assessment. Furthermore, none of the other NAT2 SNPs showed any 
correlation in the ZN-smear conversion group. On the other hand, in the culture 
conversion group, only the genotypes delineated by the 341,- 481,- and 803-SNPs were 
significantly associated with non-responders. These results indicate that only certain 
particular NAT2 genotypes may have a confounding effect on treatment efficacy as 
assessed by ZN-smear or culture conversion. 
Individually, these SNPs define the separate NAT2*14 (191), NAT2*5 (341), NAT2*11 
(481) and NAT2*12 (803) alleles or haplotypes, which exhibit disparate effects on the 
acetylation activity of the enzyme as explained in an earlier chapter. In this context, these 
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individual effects may underlie the singularity of the observations in the ZN-smear and 
culture conversion assessments. Alternatively, these SNPs collectively define the 
NAT2*14C allele, or the NAT2*5/2*14 SA genotype. Given the technology currently 
available for genotypic analysis, it is not yet possible to delineate the effects of the 
separate SNPs as observed for the ZN-smear and culture conversion assessments. 
The majority of the patients assessed by culture conversion were non-responders, who 
exhibited a delay in converting to culture negative, indicating that there are factors other 
than acetylation activity affecting the response to treatment. Interestingly, we were able to 
show a slight borderline association between the infecting Mtb strain (family 29 and 
family 11) and the rapid acetylation genotype. However this associative trend warrants 
further investigation to establish its significance. 
 
In an analogous genetic study of the SM cohort, Babb et al [300] reported several factors 
that could be correlated with treatment efficacy. These authors found that the extent of 
disease (as measured by degree of the lung affected by TB disease and number of 
cavities) and the total number and type of white blood cells at diagnosis were predictive 
of the ZN-smear and culture conversion times in the responder / non-responder patients. 
Furthermore smoking and SNPs in the Vitamin D receptor also predicted treatment 
response, as measured by ZN-smear conversion time. These factors did not show a similar 
association with culture conversion time. Similarly, Brahmbhatt et al [293] indicated that 
the differences in certain serum biomarkers and white blood cell counts, as measured at 
diagnosis (Day 0) and after 4 weeks of treatment could predict sputum ZN-smear status 
after 8 weeks of treatment. Carroll et al [330] and Hesseling et al [302] also found that 
the delay in ZN-smear conversion was linked to a higher bacterial load in the sputum 
sample at diagnosis, which in turn may be indicative of more extensive TB-disease, or 
greater virulence of the infecting mycobacterial strain. These results indicate that the 
extent of disease may be a major indicator of treatment response during the initiation 
phase of DOTs treatment. 
These reports indicate that several host derived factors, such as the immunological 
response to the mycobacterial infection, as well as mycobacterial “virulence” may 
contribute to the extent of the disease manifestation. Secondly, this may be exacerbated 
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by individual habits (such as smoking, and delays in seeking medical treatment) and 
social stigma, which may contribute to the disease becoming established in the host. 
Given that the DOTs treatment regimen is standardised on the basis of milligram drug per 
kilogram body weight of the patient [301], coupled to inherent, yet largely neglected 
acetylation activity if the individual’s NAT2 enzyme, the above factors may collectively 
facilitate the observed delay in the curative treatment response. However, given the 
proven effectiveness of INH against active, drug sensitive Mtb strains (as found in the SM 
study cohort), a better treatment efficacy could be facilitated by adjustments to the 
standardised DOTs treatment regimen, given a prior knowledge of the individual’s 
acetylation status. 
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CHAPTER  5 
An investigation of NAT1 Polymorphisms 
in South African populations 
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5.1 Introduction 
The action of drug metabolising enzymes in response to environmental insults is 
important, particularly given their involvement in the biotransformation of therapeutic 
drugs and xenobiotics. From a health perspective, there is a mounting interest in 
understanding the action of these enzymes due to the increased burden of iatrogenic 
illnesses stemming from therapeutic drug usage [331, 332]. In this context, the study of 
arylamine N-acetyltransferases (NAT1 and NAT2) set a historic precedent. These 
conjugating enzymes are responsible for the N-acetylation, O-acetylation, and N, O-
acetylation of various amine-containing aromatic compounds [68, 80, 182], via a complex 
series of reactions, in metabolic pathways that result in the detoxification or activation of 
these substrates (Fig. 5.1) 
 
Figure 5.1. Proposed pathways for the metabolic biotransformation of amine-
containing aromatic substrates, from Grant et al, 1997 [182]. The enzyme 
abbreviations are: UGT, UDP-glucuronosyltransferase; NAT, arylamine N-
acetyltransferase; DAC, microsomal deacetylase; SULT, sulphotransferase; 
CYP1A2, cytochrome P4501A2; PHS, prostaglandin H synthase; OAT, O-
acetyltransferase; NOAT, intramolecular N,O-acetyltransferase (OAT and NOAT 
reactions are catalysed by the NATs).  
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The NAT enzymes play an important part in these metabolic pathways, therefore are 
potentially linked to sources of toxicological susceptibility [333]. Whilst it is well-known 
that these enzymes have separate substrate specificities [28, 66-68], there is tantalising 
evidence to suggest that there is an inter-dependence between these enzymes during 
acetylation. Mark et al [206] has shown that para-aminobenzoic acid (pABA), a known 
NAT1 substrate, is formed as a by-product of the metabolism of procainamide (PRO), a 
known NAT2-substrate, thereby suggesting that these enzymes may act sequentially. 
Furthermore, studies by Du Souich et al [45], and Dutcher et al [334], have indicated that 
PRO and acetyl-PRO, a subsequent by-product, are metabolised independently of each 
other, whilst Cribb et al [335] has implicated both NAT2 and NAT1 in the metabolism of 
caffeine. More recently, studies by Kawamura et al [97] have shown that certain 
substrates that are metabolised via acetylation, such as, 4-ethoxyaniline (EOA), 5-
aminosalicyclic acid (5AS), and 4-iodoaniline (IOA) are equally acetylated by both 
NAT1 and NAT2. 
A recent study high-lighted the importance of detailing the genetic characterization of 
African populations in order to adapt treatment regimens for these patients [167]. This 
becomes all the more significant given the high burden of diseases, such as tuberculosis 
(TB) (World Health Organization (WHO) Factsheet No. 104, November 2010, 
http://www.who.int/mediacentre/factsheets/fs104/en/), and the distinctive ethnic and 
genetic diversities on the African continent, where extensive genetic variation exists even 
amongst populations located geographically close to one another [336]. More recently, 
micro-array based comparative genome hybridization studies indicate that population 
differences in expressed genetic phenotypes can be correlated with population clustering 
[337, 338]. Hence it is important for countries, particularly developing countries, to 
research the genetic challenges underpinning local disease epidemiology. It is within this 
context that we investigated NAT1 genetic polymorphisms within local populations, given 
that 4-aminosalicyclic acid (4AS or PAS), a well-known component of treatment 
regimens of multi-drug resistant (MDR) Mtb, is metabolised by NAT1 [44]. 
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5.2 The Sample Sources 
DNA samples from the unrelated healthy, Caucasian and SAC individuals 
described in chapter 3 (section 3.2) were also investigated for polymorphisms in the 19 
exonic and 3 intronic NAT1 SNPs, as detailed previously (Table 1.1, Chapter 1). 
Secondly, we also tested the samples from the Surrogate Marker study cohort (chapter 4 
section 4.2) for these NAT1 SNPs, because of the overlapping substrate specificity and 
inter-dependence in metabolism between the NAT isoenzymes. 
 
 
5.3 Results and Discussion 
The NAT1 gene sequence was initially amplified by a PCR assay using primers 1 
and 2 (Table 5.1) to yield the 1492 bp sequence domain of interest. This amplified 
domain was then sequenced at the Central Analytical Facility, Stellenbosch University, 
using primers 2, 3 and 4. 
 
Table 5.1 Primers used in the analysis of the NAT1 gene 
Primer DNA Sequence Tm* 
1. NAT1/117 5’-117AGGATACCAGTTGGAATCTCTCT 54.8°C 
2. NAT1/1609 5’-1609AACAATAAACCAACATTAAAAGCTT 50.5°C 
3. NAT1/409 5-409GCTTTCGTTTTGTTTTCC 47.6°C 
4. NAT1/899 5’-899GTGTCTTCCGTTTGAC 47.4°C 
Tm
*
 = Annealing temperature, as determined by supplier (http://www.idtdna.com) 
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Table 5.2 summarises the 22 NAT1 single nucleotide polymorphisms (SNPs) investigated 
in the sample cohorts. We obtained sequencing results for 349 samples (of 359 sent for 
analysis), consisting of 50 Caucasian, 109 SAC, and 190 SM individuals.  
 
Table 5.2 List of the NAT1 nucleotides analysed for genetic polymorphisms. 
NAT1 SNP 
Nucleotide 
Position in 
gene
‡
 
Rs Identifier 
Amino acid 
Change 
Phenotype 
21T>G
†
 461 4986992 L7L Wild-Type
§
 
97C>T 537 56318881 R33Stop None
*
 
190C>T 630 56379106 R64W Slow 
350G>C 790 
72554606 
R117T Unknown 
351G>C 791 R117T Unknown 
402T>C
†
 842 - P134P Wild-Type
§
 
445G>A 885 4987076 V149I Rapid 
459G>A
†
 899 4986990 T153T Wild-Type
§
 
497G>C 937 
72554608 
R166T Unknown 
498G>C 938 R166T Unknown 
499G>C 939 R167Q Unknown 
559C>T 999 5030839 R187Stop Slow 
560G>A 1000 4986782 R187Q Slow 
613A>G 1053 72554609 M205V Wild-Type
§
 
640T>G 1080 4986783 S214A Unknown 
752A>T 1192 56172717 D251V Slow 
777T>C
†
 1217 4986991 S259S Wild-Type
§
 
781G>A 1221 72554610 E261K Wild-Type
§
 
787A>G 1227 72554611 I263V Wild-Type
§
 
884A>G 1324 55793712 None Unknown 
1088T>A 1528 1057126 None Unknown 
1095C>A 1535 15561 None Unknown 
Information for the table was derived from the NAT consensus website. 
(http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-
acetyltransferase-gene-nomenclature/) 
§ = refers to the reference NAT1*4 allele. 
† = SNPs coding for a synonymous amino acid change. 
* = truncated protein, no enzyme activity. 
‡ = nucleotides numbered in accordance with the reference sequence (Genbank Accession 
Number AJ307007). 
Amino acid Abbreviations define - Aspartate (D), Glutamate (E), Isoleucine (I), Lysine 
(K), Leucine (L), Methionine (M), Proline (P), Glutamine (Q), Arginine (R), Serine (S), 
Threonine (T), Valine (V) and Tryptophan (W). 
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The Caucasian group had a median age of 74 years (range 51 to 86) and consisted of 18 
males and 32 females, whilst the SAC group had a median age of 30 years (range 17 to 
59) of whom 22 were male and 80 female. In the SM group the median age was 33 years 
(range 18 to 64) with 112 males and 78 females. 
The results of the sequencing reactions were compared to the NAT1 reference sequence 
AJ307007 (Genbank Accession Number), and DNA sequence analysis was performed 
using the computer programme Sequencher, version 4.10.1 (Gene Codes Corporation, 
USA (http://www.genecodes.com)). 
 
 
5.3.1 NAT1 polymorphisms in Caucasians 
No polymorphisms were observed in 15 of the 22 exonic SNP positions analysed 
in this group. Furthermore, only the homozygous wild-type (WT) genotype (allele) was 
observed at these SNP positions. Single nucleotide polymorphisms were however 
observed for the exonic positions at 190C>T, 445G>A, 459G>A, 560G>A and 640T>G, 
respectively, where only the heterozygous genotype (allele) was observed (Table 5.3). 
 
Table 5.3 NAT1 polymorphisms in Caucasian individuals 
Sample 
No. 
Age Sex 
1
9
0
C
>
T
 
4
4
5
G
>
A
 
4
5
9
G
>
A
 
5
6
0
G
>
A
 
6
4
0
T
>
G
 
1
0
8
8
T
>
A
 
1
0
9
5
C
>
A
 NAT1 
Genotype 
C1 75 F C/T     T/T C/C 1*4/1*17 
C2 80 F C/T     T/T C/C 1*4/1*17 
C3 70 M  G/A G/A  T/G T/T C/C 1*4/1*11 
C4 77 M  G/A G/A  T/G T/T A/A 1*3/1*11 
C5 57 M  G/A G/A  T/G A/A A/A n.d. 
C6 79 F    G/A  T/A C/A 1*4/1*14A 
C7 85 F    G/A  A/A A/A 1*10/1*14A 
C8 72 F    G/A  T/A C/A 1*10/1*14B 
C9 78 F      T/A A/A 1*3/1*10 
C10 76 F      T/T A/A 1*3/1*3 
n.d.= “not defined”, indicating a SNP combination that could not be given a 
NAT1 allele classification. 
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Interestingly, these results were obtained in only 8 individuals of the group (16%), 5 of 
whom only possessed a single polymorphism in the NAT1 exonic region. These SNPs 
confer the slow acetylation activity on the enzyme, and classify the NAT1*17 (190C>T) 
and NAT1*14 (560G>A) alleles respectively [74, 110, 339]. The NAT1*11 alleles, 
classified by the 445G>A SNP, is observed in two of the remaining 3 samples, whilst in 
the remaining sample the observed SNP combination could not be classified as a NAT1 
allele according to the NAT consensus database. The effect of the NAT1*11 alleles on the 
acetylation activity of this enzyme has yet to be characterised [340, 341]. In addition to 
the above 8 samples, a further 2 samples showed intronic SNPs only. Whilst both of these 
samples have the homozygous 1095AA polymorphism, which represents the NAT1*3/1*3 
genotype, the other sample, classified as NAT1*3/1*10, has the additional 1088CA 
heterozygous genotype. These 10 samples account for 20% of the NAT1 genotypes 
observed in the Caucasian group. 
The highest frequency distributions were observed for the 1088T>A and 1095C>A 
intronic SNPs, with their wild-type alleles, 1088T and 1095C respectively, being the most 
prevalent in the group (71% and 70% respectively). These SNPs together define the 
NAT1*10 allele, which was previously considered to be a gain of function allele, 
exhibiting a more enhanced acetylation capacity than the reference NAT1*4 allele [148, 
158]. However, according to the NAT consensus website, the phenotypic activity of these 
alleles is currently listed as “unknown”. Nevertheless, in addition to the reference allele 
(NAT1*4), these SNPs account for 80% of the NAT1 alleles observed in this group 
(discussed later). 
 
 
5.3.2 NAT1 polymorphisms in SAC individuals 
In the case of the SAC group, a similar pattern was observed to that described 
above for the Caucasian group, in that the greatest frequency distribution for polymorphic 
variants was again observed for the 1088T>A and 1095C>A SNPs. However, in this 
group the 1088T and 1095C alleles occurred at a relative frequency of only 0.53. 
Table 5.4 summarises the exonic SNP variants observed in the SAC group. Despite 
showing polymorphic variants at 7 SNP positions, two more than was observed in the 
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Caucasian group, only one of the SNPs, namely 560G>A, (which defines the NAT1*14 
allele), has been characterised as a loss of function allele, and exhibits an acetylation 
activity lower than the reference allele NAT1*4 [341]. Of the 6 remaining SNPs, the 
459G>A (NAT1*11) and 777T>C (NAT1*23 and NAT1*27) SNPs are synonymous 
variants [342], whilst the acetylation activity conferred the other 4 SNPs has yet to be 
determined empirically (NAT consensus website). We also observed a number of samples 
containing SNP combinations that could not be classified as NAT1 alleles according to the 
information in the NAT website. These alleles (“not defined”) would require further 
investigation and characterisation, particularly since they have SNPs (459G>A and 
640T>G) which encode amino acid changes that could potentially alter the activity of the 
enzyme. 
 
Table 5.4 NAT1 polymorphisms in SAC individuals 
Sample 
No. 
Age Sex 
4
4
5
G
>
A
 
4
5
9
G
>
A
 
4
9
7
G
>
C
 
4
9
8
G
>
C
 
5
6
0
G
>
A
 
6
4
0
T
>
G
 
7
7
7
T
>
C
 
1
0
8
8
T
>
A
 
1
0
9
5
C
>
A
 
NAT1 
Genotype 
SAC1 30 F A/A A/A    T/G  T/A C/A n.d. 
SAC2 28 M  G/A      T/T C/C 1*4/1*11 
SAC3 46 F   G/C     A/A C/A n.d. 
SAC4 39 F    C/C A/A   T/T C/C n.d. 
SAC5 41 F       T/C T/A C/A 1*10/1*23 
SAC6 41 M       T/C T/T C/A 1*4/1*23 
SAC7 28 F        T/A C/C n.d. 
SAC8 32 F        A/A C/A n.d. 
SAC9 31 F        A/A C/A n.d. 
SAC10 27 F        T/A A/A 1*3/1*10 
SAC11 22 F        T/A A/A 1*3/1*10 
SAC12 32 M        T/T C/T 1*4/1*3 
SAC13 29 F        T/T C/T 1*4/1*3 
SAC14 40 M        T/T C/T 1*4/1*3 
n.d. = “not defined”, indicating SNP combinations that could not be given a NAT1 allele 
classification. 
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5.3.3 NAT1 polymorphisms in SM individuals  
NAT1 analysis of samples from the SM group, exhibited polymorphic variants at 
13 of the 22 SNPs investigated, 10 exonic and 3 intronic SNPs (Table 5.5). Five NAT1 
SNPs occurred exclusively in this group, namely 21T>G (NAT1*27), 350G>C, 351G>C 
(NAT1*5), 781G>A (NAT1*24), 787A>G (NAT1*25), and 884A>G (NAT1*5). The 
NAT1*24, 1*25 and 1*27 alleles encode an acetylation activity equivalent to NAT1*4 
[339, 341], whilst the activity of the NAT1*5 allele has yet to be characterised [70]. 
As in the previous groups the NAT1*14 allele (560G>A) was the only loss of function 
allele observed in this group that could have an effect on the NAT1 acetylation activity 
[341, 343]. Furthermore, as indicated before, there are several SNPs whose effect on the 
acetylation activity has yet to be determined. Interestingly, some of these SNPs and 
alleles also occurred in the Caucasian group. The significance of this observation needs 
further investigation, since some of these alleles, such as for example, NAT1*5 (35G>C, 
351G>C) and NAT1*11 (640T>G) encode amino acid changes that could have some 
potential significance on NAT1 acetylation activity (see Table 5.2). 
It was not possible to classify several of the SNPs to particular NAT1 alleles, mainly 
because these observed SNP combinations are not described in the NAT consensus 
database (http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-
acetyltransferase-gene-nomenclature/). As indicated in Table 5.5, several of these 
assignments involve homozygous allele variants for the SNPs at positions 1088 and 1095 
in combination with one or more of the exonic SNPs. For example, in the case of samples 
SM12 and SM13, which possess the 781AA (NAT1*24 allele) and 787GG (NAT1*25 
allele) homozygous SNPs respectively, these alleles have not been described in 
combination with SNPs at positions 1088 and 1095 (in the NAT consensus database). 
Therefore, these SNP combinations which we observed in this population represent 
previously undescribed alleles and haplotypes. These SNPs account for 12.9% (14/109) of 
the NAT1 genotypes in this group, and a significant proportion of this group (6/14 
(42.9%)) could not be assigned to a known NAT1 haplotype (alleles), and would therefore 
constitute an interesting avenue for future research. 
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As in the previous groups, the most frequent polymorphisms were again observed for the 
intronic SNPs at NAT 1088 and 1095 respectively, with an observed frequency for the 
1088T allele equal to 0.505, whilst the 1095C allele occurred at a frequency of 0.457. 
These frequencies were lower than observed in the Caucasian group, and may indicate a 
potential activity difference between these ethnic groups, since the NAT1*10 allele 
(1088A plus 1095A polymorphisms) has previously been found to be a rapid acetylator 
using para-aminobenzoic acid as a probe drug [76, 158]. However, Hein et al [344] and 
Zhu and Hein [341] have shown that the NAT enzymes exhibit differing acetylation 
activities towards different substrates, and in this context, the activity of these NAT1*10 
alleles would need to be re-evaluated. 
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Table 5.5 NAT1 polymorphisms in SAC individuals from the SM study group 
Sample 
No. 
Age Sex 
2
1
T
>
G
 
3
5
0
G
>
C
 
3
5
1
G
>
C
 
4
4
5
G
>
A
 
4
5
9
G
>
A
 
5
6
0
G
>
A
 
6
4
0
T
>
G
 
7
7
7
T
>
C
 
7
8
1
G
>
A
 
7
8
7
A
>
G
 
8
8
4
A
>
G
 
1
0
8
8
T
>
A
 
1
0
9
5
C
>
A
 NAT1 
Genotype 
SM1 24 M T/G           T/A C/A n.d. 
SM2 36 F T/G           T/T C/C n.d. 
SM3 28 F  C/C G/G         A/A A/A n.d. 
SM4 60 M  G/C    G/A  T/C    T/T C/C n.d 
SM5 53 M     G/A       T/T C/C 1*4/1*30 
SM6 61 M    A/A A/A  T/G     A/A A/A n.d. 
SM7 21 F    G/A G/A  T/G     A/A A/A n.d 
SM8 37 M    G/A G/A  T/G     A/A A/A n.d 
SM9 25 M    A/A A/A  G/G  A/A   T/T A/A n.d 
SM10 28 M T/G       T/C    T/T C/C 1*4/1*27 
SM11 32 M        T/C    T/A C/A
/A 
n.d. 
SM12 33 F          G/G  A/A A/A n.d 
SM13 25 F         A/A   A/A A/A n.d. 
SM14 33 M        T/C    T/T C/C 1*4/1*23 
SM15 63 M        T/C    T/T C/C 1*4/1*23 
SM16 39 M        T/C    T/A C/A 1*10/1*23 
SM17 25 F           G/G T/A
/ 
C/A n.d. 
SM18 31 M            T/A A/A 1*3/1*10 
SM19 38 MN            A/A
/ 
C/C n.d. 
SM20 42 F            A/A C/A n.d. 
SM21 34 M            A/A C/C n.d. 
SM22 36 M            A/A C/A n.d. 
SM23 31 M          G/G G/G T/A C/A n.d. 
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SM24 33 F            T/T C/A 1*4/1*3 
SM25 59 M            T/T C/A 1*4/1*3 
SM26 26 F            T/T C/A 1*4/1*3 
SM27 46 F T/G       T/C    T/A C/A 1*10/1*27 
SM28 24 M            T/A A/A 1*3/1*10 
                 
…. Table 5.5 continued.. 
n.d. = “not defined”, indicating SNP combinations that could not be classified as known NAT1 alleles. 
Underlined nucleotides represent novel bases observed at the respective SNP position(s). 
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The most prevalent genotypes observed in the three study groups were NAT1*4/1*4, 
NAT1*4/1*10, and NAT1*10/1*10, and together these account for between 80 and 87% 
of the acetylator alleles (genotypes) described in these groups. The relative frequency 
distribution for these genotypes is summarised in Tables 5.6 and 5.7. 
 
Table 5.6 Frequency distribution for the NAT1 genotypes in the study groups 
NAT1 Genotype 
Genotype Frequency 
Caucasian SAC SM group 
1*4/1*4 27            (54%) 29             (26.6%) 50              (26.3%) 
1*4/1*10 8              (16%) 42             (38.5%) 65             (34.2%) 
1*10/1*10 5               (10%) 24              (22.0%) 47             (24.7%) 
‡
NAT1* 10              (20%) 14              (12.8%) 28             (14.7%) 
TOTAL 50            (100%) 109              (100%) 190            (100%) 
%)  
 
 
Table 5.7 Comparison of NAT1 genotype frequency between Caucasian and SAC 
individuals 
NAT1 Genotype 
Genotype Frequency 
Caucasian group SAC group
§
 P-value       OR (CI)
 †
 
1*4/1*4 27            (54%) 79                (26.4%) 
<0.0001      3.236 (1.862-5.625) 1*4/1*10 8              (16%) 107              (35.8%) 
1*10/1*10 5               (10%) 71                (23.7%) 
‡
NAT1* 10              (20%) 42                (14.1%)  
TOTAL 50            (1000%) 299              (100%) 
† = statistical analysis via Fischer’s exact test 
‡ = NAT1 genotypes that do not contain the 1*4 or 1*10 alleles 
§ = combined group consisting of individuals from both the healthy and TB-affected 
groups (SAC and SM). 
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The results in table 5.6 indicate that the different NAT1 genotypes have a comparable 
frequency distribution between the healthy SAC individuals and the TB-affected 
individuals from the SM study group. Since these individuals all belong to the South 
African Coloured ethnic group, these observations indicate that these NAT1 genotypes are 
not correlated with TB disease in this ethnic group. On the other hand, the frequency of 
these genotypes were very different in the Caucasian group, where the NAT1*4/1*4 
genotype occurred at a relative frequency of 54%. The NAT1*4 confers rapid NAT1 
acetylation activity, and this allele is classified as the reference allele. The acetylation 
activity of NAT1*10 on the other hand is controversial, since the SNPs defining this 
haplotype occur in the 3’-untranslated region of the gene, and hence it is thought that 
these SNPs would not have an effect on NAT1 enzyme activity. 
 
Table 5.8 shows the allele distribution observed in this study for the Caucasian and SAC 
individuals in comparison to similar results reported for different ethnic group. It is 
evident from the table that the NAT1 allele frequencies observed for the South African 
Caucasian group is comparable to that observed for Caucasians in Europe. In the case of 
the SAC individuals the overall pattern is quite similar to that previous reported for South 
African Blacks [155]. On the other hand the relative frequency for the NAT1*10 allele is 
similar to that previously reported for Thai and Japanese individuals. Hence these NAT1 
results lends support to the idea that the SAC community has received genetic 
contributions from Oriental antecedents [245]. 
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Table 5.8 NAT1 allele distribution as reported for different ethnic groups 
Ethnic Group 
No. of 
Alleles 
tested 
(n) 
Allele frequency expressed as a percentage (%) 
1*4 1*3 1*10 1*11 Other
*
 
Caucasian       
British
[155]
 224 73.7 3.6 18.7 3.1 0.9 
German
[76]
 628 70.9 3.0 20.1 3.3 2.7 
African       
Lebonese
[156]
 84 56 3.6 10.7 - 29.8 
S.A. Black
[155]
 202 48.5 1.0 50.5 - - 
Asian       
Indian
[154]
 280 51 30 17 2 - 
Thai
[201]
 466 50.4 3.4 43.8 2.4 - 
Japanese
[161]
 98 52.6 1.0 40.6 - 5.7 
RSA
‡
       
Caucasian 100 62 4 18 3 13 
SAC 598 44.3 1.7 41.6 0.2 12.2 
‡ = Results observed in this study of local ethnic groups. 
Other
*
 = NAT1*14, NAT1*15, NAT1*18, and Unassigned alleles, not yet listed on the 
NAT1 website. 
 
 
5.5 Conclusion 
We have investigated NAT1 polymorphisms in ethnic populations in Cape Town 
South Africa in order to characterise the prevalent genetic variants that may influence the 
NAT1 acetylation activity. Twenty-two NAT1 SNPs and alleles, described in the NAT 
consensus database, were analysed via automated DNA sequencing. Our results indicate 
SNP variants for 16% of Caucasian samples, 6% of SAC and 9% of the SM group 
samples analysed. Furthermore, in the majority of these samples only a single exonic 
locus was observed to be polymorphic. 
The commonly occurring SNPs in all three groups were at positions 445, 459, 560 and 
640, and of these, only the 560G>A SNP has been characterised as a loss of function 
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allele (slow acetylator). However, this SNP occurs rarely in the SAC individuals, being 
observed at a frequency of less than 1% and hence would not be considered to make an 
appreciable contribution to the change in the overall NAT1 acetylation activity in this 
population. In the Caucasian group, this SNP had a frequency of occurrence of 6%. 
The highest level of polymorphic variation involved the 1088T>A and 1095C>A intronic 
SNPs, and these observations are similar to results recently reported by Mortensen et al 
(2011) [345] for diverse groups of African and non-African populations. The effect of 
these SNPs and hence their relevance to NAT1 acetylation is somewhat controversial at 
present. The NAT1*10 allele is defined by the 1088T>A and 1095C>A SNP combination, 
and various studies have reported an association between the NAT1*10 allele and the 
occurrence of various cancers [76, 147, 148]. Furthermore, this NAT1*10 allele has been 
associated with rapid acetylation activity in several cancer studies, such as gastric [149], 
larynx [346], prostate [148], pancreas [347] and colorectal cancer [348]. However, since 
these polymorphisms occur in the 3’-untranslated region of the gene it is considered by 
popular convention that these polymorphisms would not alter the structure, and 
subsequently the activity function of the NAT1 protein. Therefore this feature is currently 
an area for future research. 
 
In this context it is perhaps more interesting to note that no polymorphisms were observed 
for the 97C>T, 402T>C, 499G>C, 559C>T, 613A>G and 752A>T SNPs in any of the 
groups studied, which could indicate that these SNPs may possibly be omitted from the 
NAT1 genotypic analysis in these ethnic groups. Two of these SNPs, namely, 402T>C 
(NAT1*20) and 613A>G (NAT1*21) confer rapid acetylation activity, whilst 559C>T 
(NAT1*15) and 752A>T (NAT1*22) are loss of function alleles, conferring slow 
acetylation activity. Similarly, the 97C>T SNP (NAT1*19) encodes a truncated NAT1 
protein, which could also be considered to be a loss of function allele. Hence, given the 
result that several of the polymorphic alleles observed in our study are currently of 
unknown phenotypic status, the characterisation of these allelic variants would be an 
important avenue for future research since these alleles could have a substantial effect on 
overall NAT1 acetylation activity in our local populations. 
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CHAPTER  6 
Rapid Detection of NAT2 polymorphisms 
by the SNaPshot
®
 technique 
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Précis 
Several NAT2 genetic polymorphisms have been validated for assessing the phenotype of 
the enzyme. This analysis is frequently done via a restriction enzyme - gel electrophoresis 
technique (RFLP analysis), which is relatively inexpensive and easy to perform, yet has 
the disadvantage of being laborious and time-consuming. Hence there is a need to 
investigate other more rapid techniques, which may be of particular relevance in a 
resource-limited setting, such as in most of Africa, where access to DNA sequencing or 
TaqMan
®
 technology is limited or non-existent. 
We therefore investigated the suitability of the SNaPshot
®
 assay. This method enables the 
simultaneous analysis of multiple genetic sites, via a relatively simple yet specific primer 
extension assay. Using SNaPshot
®
 we were able to discriminate both homozygous and 
heterozygous nucleotide alterations (alleles) at each of the genetic targets (loci), via a 
simple two-tube multiplex reaction assay. A significant saving in time compared to the 
RFLP assay was realised. Furthermore, the technique facilitated the rapid classification of 
the acetylation status for individual samples, in a higher throughput setup. 
Our experimental design used a dual-tube multiplex assay, which obviated primer cross-
reactivity during the SNaPshot
®
 assay. We found this primer cross reactivity to be a major 
limitation in a single-tube assay format, using the NAT2 gene-specific primers of 
relatively short lengths (less than 30 nucleotides). Increasing the length of the primers 
would improve primer-annealing and may solve this problem. However longer primers 
are more prone to forming secondary structures (hairpin loops) and/or annealing to non-
specific loci, thereby generating no primer extension results or non-specific results. These 
factors would reduce the specificity of the assay, which is ultimately more significant 
than the advantage in time-saving. These limitations notwithstanding, this dual-tube 
SNaPshot
®
 assay may have some advantages over the RFLP technique in a resource-
limited setting, despite its limitations. 
Sample Source:- Adult samples obtained from the TB clinics in the Boland-Overberg 
region of the Western Cape Province. Sample cohort used in this study only. 
 
All authors contributed to the experimental design; MB and CJW contributed equally to 
the experimentation and analysis of results (SNaPshot
®
 and RFLP); MB and CJW co-
wrote the initial manuscript; MB and CJW are listed alphabetically.  
Stellenbosch University  http://scholar.sun.ac.za
 - 134 - 
6.1 Abstract 
Background The human NAT2 gene metabolises isoniazid, an important therapeutic drug 
used in anti-TB treatment regimens. Numerous NAT2 genetic polymorphisms alter the 
activity of the enzyme, and can be used to classify individuals into fast, intermediate, and 
slow acetylators. 
Design The SNaPshot
®
 technique enables multiple single nucleotide polymorphisms to be 
assayed simultaneously via a primer extension assay. We used this assay to facilitates the 
accurate detect of the major phenotype-altering polymorphisms in the NAT2 gene, to 
facilitate the characterisation of the individual’s acetylation status. 
Results Both homozygous and heterozygous nucleotide changes were easily discriminated 
at each individual locus analysed. The technique facilitated the rapid analysis of multiple 
targets in the gene, in a high throughput setup. 
Conclusion The accurate classification of the acetylator status for individuals on anti-TB 
treatment regimens can reduce the incidence of adverse drug effects and promote better 
patient compliance, thereby improving the treatment efficacy. 
 
 
 
Key words Primer extension, N-acetyltransferase, polymorphisms, pharmacogenetics, 
SNaPshot
®
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6.2 Introduction 
The arylamine N-acetyltransferases (NAT1 and NAT2; E.C. 2.3.1.5) are important 
enzymes in the bio-transformational processes in the liver. These phase II drug 
metabolizing enzymes (DMEs), catalyse the acetyl-Coenzyme A mediated conversion of 
important therapeutic xenobiotics, via their reactive oxygen and nitrogen substituent 
atoms [68, 80, 349]. Numerous single nucleotide polymorphisms (SNPs) have been 
described in both the NAT1 and NAT2 genes, and certain SNPs within each of these genes 
have been associated with a reduced enzyme activity [168, 181, 342, 350]. This facilitates 
the speedy classification of the individual’s acetylation status without the constraints of 
using of different probe drugs specific for NAT1 and NAT2 [68, 80]. These 
polymorphisms contribute to the individual’s predisposition to developing certain 
environmentally associated diseases and various cancers [351-353]. Furthermore, 
acetylation studies in different population groups indicate that some of these SNPs exhibit 
an ethnic bias in their frequency of occurrence [63, 185], and may therefore confer alleles 
responsible for the inter-ethnic and inter-individual variability in acetylation. 
Previous studies have shown that the NAT2 genotyping assays accurately reflects the 
phenotype of individuals, and also facilitates the sub-classification of individuals into 
rapid, intermediate and slow acetylators [62, 170, 174]. As such, the human NAT2 gene 
has been shown to be the enzyme responsible for the inactivation of INH, the primary 
drug used to treat TB patients. A significant number of patients on anti-TB treatment 
experience INH-related adverse drug reactions (ADR), which are often life-threatening 
[173, 213, 354]. Therefore, an a priori knowledge of the patient’s NAT2 acetylation 
status could facilitate the individualisation of the INH dosages used in therapeutic anti-TB 
regimens, ensuring a better rate of treatment compliance, as well as reducing the 
incidence of drug-induced liver injury (DILI) [211]. 
Currently, more than 50 different alleles have been described in the NAT2 gene 
(http://www.louisville.edu/medschool/pharmacology/NAT.hmt). The majority of these 
alleles possess combinations of only a few specific SNPs, namely, 191G>A, 282C>T, 
341T>C, 481C>T, 590G>A, 803A>G, and 857G>A (Figure 4.1). Some of these SNPs 
encode synonymous amino acids (282C>T, and 481C>T), or conserved amino acids 
(803A>G), and do not reduce the activity of the enzyme. However, reduced acetylation is 
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conferred by the 191G>A, 341T>C, 590G>A, and 857G>A SNPs, which respectively 
designate the NAT2*14, 2*5, 2*6, and 2*7 allele classes. Consequently, these particular 
SNPs have become the ones most often investigated with respect to NAT2 genotyping 
studies. 
 
 
 
 
 
 
Figure 6.1 Schematic illustration of the NAT2 gene showing the analysed 
SNPs. The relative SNP positions within the NAT2 gene are indicated above 
the schematic, whilst their deduced amino acid changes are indicated below 
(http://www.louisville.edu/medschool/pharmacology/NAT2.html). 
Asterisk (*) indicates alleles conferring a reduced acetylation activity. 
 
 
Most of the NAT2 genotyping assays utilise a Polymerase Chain Reaction-Restriction 
Fragment Length Polymorphism (PCR-RFLP) technique [355], because of the simplicity, 
ease, and relatively low cost of this analysis. However, this methodology is time 
consuming and relatively labour intensive. Subsequently a number of faster genotyping 
methods have been evaluated, including fluorescence resonance energy transfer (FRET) 
[356], WAVE DNA fragment analysis [357], and the use of Taqman Fluorogenic probes 
[358]. In addition, the 341T>C SNP has been genotyped using Nested PCR and Reverse 
Line Blot Hybridization methodologies.[359, 360]. All these methods have their inherent 
advantages and disadvantages, and often certain important SNPs are omitted from the 
genotypic analysis [171, 172]. This obviates comparisons of the SNP allele frequencies in 
different ethnic populations, which may be particularly significant in some populations in 
the context of the increasing worldwide TB epidemic, since the greatest burden of disease 
occurs in some geographic populations and sub strata of these groupings 
(http://www.who.int/mediacentre/factsheet/fs104/en/index.html). 
Arg 64  Gln 
G191A 
Gly 286  Glu 
G857A* 
Lys 268  Arg 
A803G 
Arg 197  Gln 
G590A* 
None 
C481T 
Ile 114  Thr 
T341C 
None 
C282T *  * 
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The peculiarities of TB disease epidemiology are currently under renewed scrutiny, with 
greater emphasis being placed upon understanding the reasons behind issues of disease 
latency, re-infection, and patient non-compliance to treatment [214, 216]. In this context, 
it would be important to invest in a rapid NAT2 genotyping technique, which would have 
the capability of analyzing the significant activity altering SNPs in a high throughput 
setup. This knowledge would enable the treatment regimen, particularly with respect to 
the INH dosage, to be adjusted for individual patients, to ensure optimal efficacy, as well 
as reduce the incidence of treatment interruption due to DILI. We therefore assessed the 
SNaPshot
®
 technique as a means to facilitate the rapid, high throughput classification of 
the acetylation status of individuals, by characterising the major phenotype-altering SNPs 
in the NAT2. 
 
 
6.3 Materials and methods 
This study forms part of a longitudinal research project undertaken in the Western 
Cape Province of South Africa, amongst patients attending the TB clinics outside of the 
Cape Town Metropole. The project was reviewed and sanctioned by the Institutional 
Review Committee of Stellenbosch University (registered under the project code 
2000/C061). Blood samples from randomly selected patients attending these clinics were 
processed for DNA via our standard laboratory protocol, as previously described [361]. 
All subjects who participated gave their informed consent for inclusion in the study. 
PCR-Amplification A 1000 bp domain of the NAT2 gene was initially amplified by PCR 
using gene specific primers previously described by Hickman et al [62] (Table 6.1). The 
100 l PCR reactions were carried out on a Gene Amp® System 9700 temperature cycling 
platform (Applied Biosystems, USA), consisting of 100 ng template DNA, 1x PCR 
reaction buffer (Qiagen, Germany), 3.5 mM MgCl2, 4.0 mM of each of dATP, dCTP, 
dGTP and dTTP, 25 pmol of each primer, and 0.5 units HotStar Taq DNA polymerase I 
(Qiagen, Germany). The PCR amplification conditions consisted of an initial incubation 
at 95C for 15 min., followed by 45 cycles of 94C for 1 min., 53C for 1 min., and 72°C 
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for 1 min., followed by a final polymerisation at 72C for 10 min. PCR amplification 
products were verified in 1.5% agarose, using 1x TBE (pH 8·3) running buffer, a current 
of 100 v/cm for 1 hour, and visualized by ethidium bromide staining (Chapter 2). 
SNaPshot
®
 Analysis This technique (Applied Biosystems, USA) utilises individual 
primers to bind to the sequence-specific DNA domain, immediately 5’to the SNP in 
question. Subsequently, the primer is extended by the incorporation of a sequence-
specific fluorescently-tagged ddNTP complementary base. Seven primers, varying 
between 17 to 22 bp in length, were designed for the primer extension (PE) analysis of the 
most frequently genotyped polymorphisms in the NAT2 gene (Table 6.1). 
 
Table 6.1 NAT2 Primers used in the genotype analysis. 
 
a
 = NAT2 PCR primers, according to Hickman et al [62]. 
nt = nucleotide. 
Tm = Melting point temperature (primer annealing). 
NAT2 
Primers 
Primer Sequence (5’-3’) 
Primer 
Length 
(nt) 
NAT2 
Allele 
Tm 
PCR Primers
a
     
Nat-Hu14 (F) 5' GACATTGAAGCATATTTTGAAAG-3' 23  60ºC 
Nat-Hu16 (R) 5' GATGAAAGTATTTGATGTTTAGG-3' 23  60ºC 
Multiplex 1 
Primers     
Msp191 5’-TCACATTGTAAGAAGAAACC-3’ 20 G/A 48.9ºC 
Mb341 5’-CACCTTCTCCTGCAGGTGACCA-3’ 22 T/C 61.2ºC 
BamH 857 5’-CTCGTGCCCAAACCTGGTGATG-3’ 22 G/A 60.7ºC 
Multiplex 2 
Primers     
Fok282 5’-CAATGTTAGGAGGGTATTTTTA-3’ 22 C/T 48ºC 
Kpn481 5’-AAGAGAGAGGAATCTGGTAC-3’ 20 C/T 50.5ºC 
Taq590 5’-ATTTACGCTTGAACCTC-3’ 17 G/A 46.6ºC 
Dde803 5’-GGTTGAAGAAGTGCTGA-3’ 17 A/G 49.2ºC 
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The primers were designed using the software programme Primer Premier v5.00 (Premier 
Biosoft International, USA), and assessed for suitability in a multiplex reaction format, 
using Autodimer v1.0 [362], and Oligo Analyser software v3.0 
(http://www.idtdna.com/analyzer/applications/oligoanalyzer/). 
Each PE reaction contained 3 µl (0.30 ng/µl) of purified NAT2 gene product, 5 µl of the 
SNaPshot ready mix, consisting of fluorescently labelled ddNTPs, Amplitaq DNA 
polymerase, and 1x reaction buffer, provided in the (ABI PRISM
®
 SNaPshot
®
 Kit, Applied 
Biosystems, USA), and 1 µl of the primer mix (Table 6.1), to a total volume of 10 µl. 
These mini-sequencing reactions were executed by 27 cycles of denaturation at 96C for 
10 sec., annealing at 50C for 5 sec., and polymerisation at 60C for 30 sec. 
In this study two separate multiplex PE reactions were employed, consisting of the 
following primer combinations: primer set 1: Taq 590, Fok 282, Kpn 481 and Dde 803, 
and primer set 2: Msp 191, Mb 341 and Bam H 857 (Table 1). Unincorporated ddNTPs 
were removed by enzymatic degradation with 1unit of Shrimp Alkaline Phosphatase 
(SAP) (1 U/µl) at 37C for 60 min, followed by the heat inactivation of the SAP enzyme 
at 75°C for 30 min. The fluorescently labelled PE products were fractionated in a single 
capillary system on an ABI PRISM
®
 3100-AVANT Genetic Analyzer, and the data was 
scored with the Genotyper
®
 Software v3.7 NT, according to the manufacturers 
instructions. An internal size-standard (LIZ-120, Applied Biosystems) was included in 
every lane to ensure accurate sizing of the PE fragments. 
 
We also analyzed these samples via our standard PCR-RFLP methodology for 
comparison [361]. Briefly, this entailed the specific restriction of aliquots of the NAT2 
PCR product with MspI, FokI, KpnI, TaqI, DdeI, and BamHI according to the 
manufacturer’s recommendations.  These enzymes analyse the 191G>A, 282C>T, 
481C>T, 590G>A, 803A>G, and 857G>A SNPs respectively. The MspI, KpnI and 
BamHI restriction profiles were subjected to a further round of digestion with PstI to 
facilitate the analysis of these restriction enzyme profiles via 5% polyacrylamide gel 
electrophoresis (mini PROTEAN II apparatus, BioRad, USA) with silver staining [250]. 
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The 341T>C SNP was detected by AS-PCR, using the confronting two-pair primer 
method [251]. 
 
 
6.4 Results and Discussion 
The SNaPshot
®
 analysis clearly discriminated between homozygous and 
heterozygous nucleotide bases at the targeted SNP position (Fig.6.2). Ease of 
classification is facilitated by the incorporation of the specific complementary ddNTP 
base, as well as the differential migration of the SNaPshot
®
 primer products. This is 
largely determined by the secondary structure of the primer, which is a property of the 
specific primer sequence. Hence primers of the same length are easily discriminated in 
the electrophoretograms. Representative electrophoretograms of the two multiplex 
reactions for a single patient are illustrated in Figure 6.2. 
We observed complete concordance in the genotyping results obtained via the SNaPshot
®
 
and PCR-RFLP methodologies. Table 6.2 depicts the typical results observed for a few 
individual samples. The latter method is however more time-consuming and relatively 
labour intensive. Furthermore, we found that despite analysing the SNP RFLP profiles via 
polyacrylamide gel electrophoresis, the 191G>A SNP was sometimes prone to 
misclassification, since the homozygous-and heterozygous “mutant” alleles could not be 
assigned unambiguously. It thus became necessary to re-analyse this particular SNP via 
bidirectional sequencing, adding additional costs and a further delay in determining the 
individual’s acetylation status. 
We determined the NAT2 acetylation genotype via a dual multiplex SNaPshot
®
 reaction 
assay to assess the 7 informative SNPs. This was necessary to obviate primer cross-
reactivity during the SNaPshot
®
 reaction, which, could not be avoided due to the nature of 
the gene-specific sequences in primers of these relatively short lengths. It may be possible 
to overcome this problem by designing longer SNaPshot
®
 primers greater than 30 bases in 
length. This would improve the target specificity of the primers by annealing to a larger 
region of the gene sequence, and hence may enable one to assay the different SNPs in a 
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single multiplex reaction. However, cross reactivity between primers, as well as the 
formation of secondary structures (hairpin loops), which are a property of the specific 
sequences, would inhibit the SNaPshot
®
 PE reaction, and therefore should be determined 
empirically to assess the viability of the single multiplex reaction assay. Other studies 
have reported analysing as many as 14 different SNPs using the SNaPshot
®
 multiplex 
reaction format [363], which confirms the viability and robustness of the technique. 
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Figure 6.2 Representative electrophoretogram of the SnapShot analysis using 
multiplex PCR reaction mixes 1 (A) and 2 (B) 
Homozygous alleles at position 191 (G/G) and 857 (G/G) are shown as single peaks; 
double peaks represent heterozygous alleles. Primer marker size standards (LIZ-120) 
ar indicated by orange peaks. Fluorescent ddNTPs are colour-coded as follows:- G = 
Blue, C = Black, T = red and A = green 
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Table 6.2 Comparison between the primer extension (SnapShot
®
) and PCR-RFLP 
analyses. 
 
Sample Method G191A C282T T341C C481T G590A A803G G857A NAT2 Alleles Genotype 
1 
RFLP G/G C/C  C/T G/G G/G G/G 
2*12A/2*5B Intermediate ASPCR   T/C     
PExt. G/G C/C T/C C/T G/G G/G G/G 
2 
RFLP G/G C/C  C/C G/G A/G G/G 
2*4/2*5C Intermediate ASPCR   T/C     
PExt. G/G C/C T/C C/C G/G A/G G/G 
3 
RFLP G/G C/C  C/T G/G A/G G/G 
2*4/2*5B Intermediate ASPCR   T/C     
PExt. G/G/ C/C T/C C/T G/G A/G G/G 
4 
RFLP G/G C/C  C/T G/G G/G G/G 
2*12A/2*5B Intermediate ASPCR   T/C     
PExt G/G C/C T/C C/T G/G G/G G/G 
5 
RFLP G/G C/T  C/C G/G A/G G/G 
2*4/2*12B Fast ASPCR   T/T     
PExt. G/ C/T T/T C/C G/G A/G G/G 
6 
RFLP G/G C/C  C/T G/G G/G G/G 
2*12A/2*5B Intermediate ASPCR   T/C     
PExt G/G C/C T/C C/T G/G G/G G/G 
7 
RFLP G/G C/C  C/C G/G A/G G/G 
2*4/2*12A Fast ASPCR   T/T     
PExt. G/G C/C T/T C/C G/G A/G G/G 
8 
RFLP G/G C/C  C/T G/G G/G G/G 
2*12A/2*5B Intermediate ASPCR   T/C     
PExt. G/G C/C T/C C/T G/G G/G G/G 
9 
RFLP G/G C/T  C/C G/A A/G G/G 
2*12A/2*6A Intermediate ASPCR   T/T     
PExt. G/G C/T T/T C/C G/A A/G G/G 
10 
RFLP G/G C/C  T/T G/G G/G G/G  
Slow ASPCR   C/C     2*5B/2*5B 
PExt. G/G C/C C/C T/T G/G G/G G/G  
11 
RFLP G/G C/C  C/T G/G G/G G/G 
2*12A/2*5B Intermediate ASPCR   T/C     
PExt. G/G C/C T/C C/T G/G G/G G/G 
12 
RFLP G/G C/C  C/C G/G G/G G/G 
2*12A/2*12A Fast ASPCR   T/T     
PExt. G/G C/C T/T C/C G/G G/G G/G 
 
RFLP = restriction fragment length polymorphism 
ASPCR = allele-specific polymerase chain reaction 
PExt. = primer extension reaction 
 
NAT2 alleles are classified into their respective haplotype clusters according to the NAT 
website (http://www.louisville.edu/medschool/pharmacology/NAT2.html) 
 
 
Furthermore, this PE-based technique has also been used with equal success in studies of 
Alzheimer’s disease [364], and for the forensic detection of SNPs in the human 
mitochondrial genome [365]. 
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We subsequently validated the SNaPshot
® 
technique by genotyping these NAT2 
polymorphisms in an additional 290 TB patients and typical results are depicted in table 
6.2. This kit-based method is an efficient and simple technique, which can easily be 
extended to include other activity-altering NAT2 SNPs. Several such SNPs, have also 
been delineated in the human NAT2 gene, but their purported effect(s) on NAT2 
acetylation still need to be validated by in vitro analysis.  Moreover, there is a dearth of 
epidemiological information on these SNPs in different populations groups, and therefore, 
it is difficult to ascertain their significance in the overall acetylation status of individuals. 
Recently, it was demonstrated that the 364G>A (D122N) and A411T (L137F) SNPs also 
confer a reduced acetylation activity [180]. However, the significance of these SNPs, as 
judged by their frequency of occurrence in different population groups has not as yet been 
reported, to our knowledge. This limitation could easily be addressed using the 
SNaPshot
®
 technique, by the simple addition of specific primers targeting these SNPs. 
 
 
 
6.5 Conclusion 
This study describes the use of a simple primer extension methodology which 
accurately determines the acetylator status in individuals, by characterisation of their 
NAT2 genotype. Furthermore, a more encompassing acetylation classification can be 
achieved by simply including other phenotype-altering SNPs, such as, 364G>A (D122N), 
411A>T (L137F), and 434A>C (Q145P), into the overall analysis of NAT2 acetylation via 
SNaPshot
®
. This simple and easy technique enables the high throughput screening of 
multiple targets in multiple samples, thereby substantially improving the practical 
application of genotyping in pharmacogenetic studies. Secondly, the genotyping results 
can easily be converted into a binary code for the purposes of SNP data analyses (1 = 
homozygous wild-type; 0 = homozygous mutant = 0). This practise could facilitate the 
automated scoring of the acetylation status. 
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Précis 
GST and NAT2 are two drug metabolising enzymes involved in the metabolism of many 
environmental compounds and chemotherapeutic drugs, and as a result may influence an 
individual’s response to treatment or susceptibility to disease. The Xhosa and SAC ethnic 
groups of South Africa have a high incidence of Oesophageal Cancer (OC) and 
Tuberculosis (TB) disease respectively. As a first step towards the case-control 
investigation of GST and NAT2 polymorphisms as potential markers for OC risk and TB 
treatment response respectively, we undertook preliminary genotyping analyses of these 
two genes to establish the baseline frequencies for their allelic variants in healthy 
individuals from the Xhosa and SAC populations. 
We observed a range of frequencies for GST and NAT2 alleles, which may indicate that 
the metabolic activity of the two enzymes in these groups may be quite different 
compared to other ethnic groups. For example, we observed a higher frequency with 
respect to the NAT2 fast genotype (wild type) in the SAC population than has been 
reported for Caucasians. NAT2 fast alleles are believed to reduce the efficacy of the TB 
treatment regimen due to their rapid clearance of isoniazid from the body. Hence the 
higher incidence of the fast genotype in SAC individuals could be a factor influencing the 
response to TB treatment in patients with this ethnic background. 
The frequency of the null genotype for GSTM1 was the lowest thus far reported, whilst 
the frequency for the GSTT1 null genotype was considerably higher in the Xhosa group 
than has been reported for other Africans. The frequency distribution of the GSTT1 null 
genotype in the Xhosa population was similar to that reported for Chinese individuals, 
who incidently also have a very high incidence of OC. 
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Although further (case-control) studies are required to validate any potential associations 
between NAT2 and TB treatment response, or GSTT1 and OC risk in the populations 
studied, the allelic frequencies observed for these two genes might be interesting from a 
clinical perspective, and warrant further investigation. 
Sample Source:- Adult samples obtained from the Eastern Cape (Xhosa) and Western 
Cape Provinces (SAC). Sample cohort used in this study only.  
 
The experimental work was performed by CA (GST) and CJW (NAT2). Both CA and CJW 
contributed equally to the manuscript preparation. CA and CJW listed alphabetically. 
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Précis 
Cataract disease is a progressive, degenerative ocular condition, and various 
environmental and genetic factors, as well as certain clinical conditions have been 
implicated in cataract formation. Advancing age appears to be the most significant factor 
associated with the disease globally. We therefore hypothesized that increasing levels of 
toxicants from environmental insults, coupled to a reduced metabolic turnover of these 
substances may contribute to cataract formation. 
We investigated the NAT2 acetylation status in cataract disease in SAC individuals in a 
case control association study. We observed complete concordance between the NAT2 
phenotype and genotype results. Furthermore, the NAT2 Slow allele (S) was significantly 
associated with cases rather than control samples, which indicated that the slow allele was 
a significant risk factor in cataract disease. Similarly a comparison of the fast (FF), 
intermediate (FS), and slow (SS) acetylators also showed that the greatest risk for cataract 
disease was associated with individuals having the Slow (SS) genotype. Individuals 
having the intermediate genotype are also at risk for cataract disease, albeit at a lower risk 
level than for the Slow genotype. 
Unfortunately, NAT2 acetylation activity has not as yet been reported inside the human 
eye, and therefore the acetylation activity in loco is uncertain at this stage. However, it is 
interesting to note that acetylation activity has been found in the bovine lens as well as in 
the rabbit eye. These results indicate that there may well be a role for NAT acetylation in 
the eye. Further studies investigating the contribution(s) of the NAT enzymes inside the 
eye would be a valuable addition to the already published work. 
Sample Source:- Samples were case-control matched SAC adults from the Western Cape 
Province. Sample cohort used in this study only. 
 
All the NAT2 genotypic analysis was performed by CJW and the original draft manuscript 
was prepared by CJW and PDvH. 
  
Stellenbosch University  http://scholar.sun.ac.za
 - 158 - 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 - 159 - 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 - 160 - 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 - 161 - 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 - 162 - 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
 - 163 - 
 
CHAPTER  9 
Isoniazid Pharmacokinetics in children 
treated for Respiratory Tuberculosis 
  
Stellenbosch University  http://scholar.sun.ac.za
 - 164 - 
 
Isoniazid pharmacokinetics in children treated for respiratory 
tuberculosis 
 
H.S. Schaaf
1‡
, D.P. Parkin
2
, H.I. Seifart
2
, C.J. Werely
3
, P.B. Hesseling
1
, P.D. van 
Helden
3
, J.S. Maritz
4
, and P.R. Donald
1
 
 
Departments of 
1
Paediatrics and Child Health, 
2
Pharmacology, and 
3
Medical 
Biochemistry, Medical Faculty, Stellenbosch University, P.O. Box 19063 Tygerberg 
7505, South Africa. 
 
4
Biostatistical Unit of the South African Medical Research Council, Francie van Zijl 
Drive, Tygerberg, South Africa. 
 
 
‡
Author for correspondence (email: hss@sun.ac.za) 
 
 
 
 
 
 
Archives of Diseases in Childhood (2005) 90(6):614-618. 
  
Stellenbosch University  http://scholar.sun.ac.za
 - 165 - 
Précis 
Isoniazid (INH) is currently the only recommended prophylactic treatment for children 
with latent TB. However, there is a lack of data on the pharmacokinetics of INH in 
children, and it has been suggested that adhering to the dosing guidelines recommended 
for adults (based on body weight) may not be suitable, due to the larger liver-to-body 
mass ratio in children. We therefore investigated the pharmacokinetics of INH in children 
with respect to their NAT2 genotype. 
Our results showed that the metabolism of INH in children follows the expected trimodal 
pattern, according to the fast (FF), Intermediate (FS), and slow (SS) genotype-classes. 
Secondly, the rate of INH metabolism in children was also faster compared to adults. 
Furthermore, the highest rate of INH elimination was observed in children less than 5 
years of age, with older children having a slower rate of elimination by comparison. More 
importantly, the metabolism of INH was not related to the weight of the child. This study 
investigated the pharmacology of INH elimination in children based upon a once-off dose 
of INH (of 10 mg/kg body weight), which proved to be sub-optimal in the FF acetylators, 
who achieved a peak serum concentration of less than 2 mg/l. These observations support 
the hypothesis that the rate of INH metabolism may be ascribed to the higher (total) 
metabolic activity of the relatively large liver in children compared to adults. Hence the 
proposed optimal dosing for children should be based on a calculation of the surface area 
of the body, rather than the mass. These results also provide support for the 
recommendation that generally children should receive a higher dose of INH than adults. 
It would therefore be interesting to test a range of INH doses in children (of known 
acetylator status) to determine the INH dose for optimum efficacy, as well as validate 
these results in children receiving co-administered antibiotics, as recommended by the 
DOTs regimen for TB treatment. 
Sample Source:- Adolescent samples were sourced from the Tygerberg Hospital, Western 
Cape Province. Sample cohort used in this study only. 
 
All NAT2 genotyping was performed by CJW, who wrote the experimental methodology in 
the manuscript, and contributed to the writing of the manuscript. 
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Précis 
The elimination of isoniazid has previously been shown to be faster in children compared 
to adults, and yet the dosage guidelines for children have not been widely established. 
Here we investigated the effect of a range of INH doses in children, to determine the 
optimum dose range that would yield efficacies similar to that found in adults. 
Pre-adolescent children, being treated for TB were enrolled in the study, and the NAT2 
genotypes in a group of 48 children were observed as 14% fast, 46% intermediate and 
40% slow acetylators. Thirty-four children in the group were given a dose of 4-6 mg/kg 
of INH, whilst the remaining 14 received 8-12 mg/kg INH. In the first group, 76% of 
children [7/14 slow, 13/14 intermediate and 6/6 fast acetylators) recorded a minimum 
peak concentration below 3 mg/l (In adults a minimum INH peak concentration of 3 mg/l 
correlated with good treatment efficacy). In contrast, all of the children in the second 
group achieved this INH concentration level, irrespective of their NAT2 genotype.  
These results indicate that children given the standard 4-6 mg/kg dose of INH are at 
greater risk of exhibiting a sub-optimal treatment efficacy. Interestingly, the risk of INH-
related hepatitis was not significantly different between these groups, indicating that the 
use of the higher INH dosage in children was relatively safe. 
Sample Source:- Adolescent samples were obtained from the Brooklyn Hospital for Chest 
Diseases, Western Cape Province. Sample cohort used in this study only. 
 
All NAT2 genotyping was done by CJW, who also contributed to the interpretation of 
results and writing of the manuscript. 
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Précis 
INH is still one of the most effective agents used in anti-tuberculosis treatment despite 
being one of the oldest. It targets actively growing mycobacterial cells, reducing their 
numbers within a very short time period, referred to as its “early bactericidal activity” 
(EBA). It has previously been shown that the NAT2 genotype has a significant effect on 
the EBA of INH, and therefore we assayed INH dosage to investigate an optimal EBA, in 
which a “killing power” of 90% or greater (EBA90) could be obtained. 
A cohort of TB patients, the majority of whom were from the South African Coloured 
(SAC) group, were given a range of INH doses, from 0.2 mg/kg to 12 mg/kg body 
weight. The acetylation status of the patients was assessed via NAT2 genotype analysis, as 
well as the optimum EBA at each INH dose. We found that the optimum EBA (EBA90) 
was attained at different doses of INH in the fast (FF), intermediate (FS) and slow (SS) 
acetylation groups. These results indicated that, whereas a low dose of INH in slow 
acetylators would be sufficient to attain optimum treatment efficacy, this level of INH 
would be sub-optimal in intermediate and fast acetylators. Furthermore, the percentage of 
patients that attained the EBA90 increased proportionately, in all three acetylation groups, 
with increasing INH dosage, such that at a dose of 10-12 mg/kg INH, all of the patients 
attained the EBA90. 
The results of this study, whilst promising, only relate to the early effects of INH in the 
different acetylator groups, and it would be interesting to determine if this early effect of 
INH also applies to the end of therapy (treatment outcome). Clearly these results for INH 
have to be interpreted in conjunction with co-administered drugs under standardised TB 
therapy. Since the 10-12 mg/kg dose is a higher dose of INH than generally used, it is 
likely that more cases of hepatotoxicity (especially among SS acetylators) may occur, and 
this will need to be investigated in future. 
Sample Source:- Adult patient samples were obtained from Tygerberg Hospital and the 
Brooklyn Hospital for Chest Diseases. Sample cohort used in this study only. 
 
All NAT2 genotyping was done by CJW, who also contributed the interpretation and 
writing of the manuscript. 
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Drug metabolising enzymes (DMEs) are important determinants of individual-specific 
variations observed in the metabolism of xenobiotics and therapeutic drugs introduced 
into the human body. In this respect the study of Arylamine N-acetyltransferases (NAT1 
and NAT2), is of particular importance, since these enzymes have the capacity to 
metabolise therapeutic drugs, such as p-amino-salicylate (PAS) [44], and isoniazid (INH) 
[18], respectively. Both of these compounds are important in the treatment of tuberculosis 
(TB) [18, 35, 39, 75]. Due to the increasing incidence of TB world-wide, the World 
Health Organisation (WHO) has declared TB a global health emergency (WHO Report 
2006, and WHO TB Factsheet No.104) which clearly makes TB treatment a high priority. 
Effective TB treatment entails the elimination of the infecting organism, Mycobacterium 
tuberculosis (Mtb) from the human host [14], which in theory may be compromised by 
the activity of the NATs. Therefore it may be expedient to administer and monitor the 
anti-TB treatment in conjunction with individual’s inherent acetylation capacity so as to 
maximise the treatment efficacy. 
Previous studies have indicated that NAT2 enzyme activity can be correlated with 
specific single nucleotide polymorphisms (SNPs) in the gene [37, 161, 165, 168], and as 
such these SNPs can be used to rapidly screen for NAT2 acetylation activity in 
individuals. Similarly, numerous SNPs have been described for NAT1 [76, 140], and the 
effect of these SNPs on NAT1 acetylation activity may be important for TB treatment 
since this enzyme acetylates PAS [44], which is used in the treatment of drug resistant 
TB. However, there is limited information available on NAT1 alleles in African 
populations, and the effect of these NAT1 SNPs has, to our knowledge, not been 
investigated in local South African communities. 
Apart from the metabolism of compounds used for treating infectious diseases (such as 
INH for TB), the acetyltransferase enzymes also metabolise environmental compounds or 
xenobiotics. These xenobiotics or their metabolites may be risk factors for disease. In this 
context we investigated NAT2 alleles as potential risk factors for the development of eye 
disease (cataract formation), as well as in a pilot study for high risk of cancer in our 
population. Clearly, the risk for the development of a chronic disease is unlikely to be 
linked to one single gene only, and thus in the cancer study we also investigated other 
genes as potential protection against xenobiotic damage. 
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If we wish to use the knowledge about the individual’s acetylation status to decide on TB 
treatment, we would require a rapid acetylation assay to determine individual-specific 
acetylation. Currently, a relatively slow 7-SNP analysis method is widely used to 
determine the NAT2 acetylation status in individuals. We developed a rapid screening 
assay using the SNaPshot
®
 technique to facilitate NAT2 genotype analysis. Using this 
technique we were able to unambiguously analyse all 7 SNPs in a two tube multiplex 
assay. We were however unable to utilise a single tube multiplex protocol due to cross 
reactivity between the primers, which inhibited the analysis. The method realised a 
significant saving in time and labour, but requires more costly reagents, sophisticated 
laboratory equipment (DNA-sequencer) and technical expertise than the easier restriction 
enzyme based method (PCR-RFLP assay). Therefore in its current format, it may not be 
suitable for use in developing countries, where the need for the best treatment efficacy is 
greatest because of the high burden of TB disease. 
Nevertheless, as a consequence of the Human Genome Project, DNA sequencing analysis 
is subject to ongoing optimisation, thereby becoming more affordable and user friendly 
[366, 367]. Currently sequencing costs are estimated at less than fifty American cents 
[368], and the technology is also able to achieve single molecule sequencing, using 
nanotechnology [369]. This may enable DNA sequencing centres to be set up in 
developing countries, which would facilitate the DNA sequencing analysis from remote 
and rural areas. 
The SNaPshot
®
 technique enables the high throughput screening of multiple sequence 
targets in the NAT2 gene in multiple samples, which would improve the practical 
application of genotyping studies in pharmacogenetic studies. In addition, these results 
could be converted into a binary code for the purpose of SNP analysis (1 for the reference 
allele, and 0 for the polymorphic variant) which would facilitate the automation of the 
process. However, the methodology is very dependant upon primer sequence 
characteristics, and we were unable to adapt this technology to the genetic analysis of the 
NAT1 SNPs, due to primer cross reactivity, as a result of the NAT1 gene sequence 
characteristics (nucleotide order). In this respect, the technology may have a restricted 
application. 
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Genetic studies may often extrapolate findings in African American individuals to be 
applicable to Africans per se, despite the observation that the people on the African 
continent are the most genetically diverse group on earth [370, 371], and genetic results 
from one group would not necessarily be the same in other Africans. Unexpected 
phenotypes have been noted for different individuals and ethnic groups, and the source of 
these phenotypic variations have been linked to genetic polymorphisms [37, 48, 372, 
373]. Furthermore, several reports support the hypothesis that disease susceptibility risk 
in diverse populations may be due to the relative proportions of certain alleles of DMEs 
[136, 374]. To test this hypothesis we investigated polymorphisms in two DMEs, namely 
Glutathione S-transferase (GST) T1, M1, P1 and Pi, which has been associated with 
cancer risk, and NAT2. Previous studies have established that the South African Black 
African (Xhosa) individuals have a high incidence of oesophageal cancer (OC) [375]. 
The analysis of GST polymorphism in the black and SAC groups returned interesting 
results. For example, the GSTM1*0 (null) allele occurred at a frequency of 20% in both 
SAC and Xhosa groups, whilst the GSTT1*0 allele was observed at a frequency of 41% 
and 57 % in the Xhosa and SAC groups respectively. The observed frequency for the 
GSTM1*0 allele was similar in other African groups but statistically different in 
Caucasians and Chinese, where GSTM1*0 occurred at a frequency of 40-60%. In the case 
of the GSTT1*0 allele the frequency in Caucasian and Chinese was 10-24% and 64%, 
respectively. Moreover the combined GSTM1*0/GSTT1*0 genotype was approximately 
2-fold higher in Xhosa and SAC (at 11-13%) than in other African groups (at 
approximately 5%). 
Similar observations were made for the GSTP1Ile
105
/Val
105
 polymorphism, in which 
homozygous GSTP1Ile
105
/Ile
105
 and GSTP1Va1
105
l/Val
105
 occurred at a low frequency of 
22 -28% respectively, whilst the heterozygous variant GSTP1Ile/Val occurred at a 
frequency of 51% in Xhosa individuals. By comparison, South African Venda had 
frequencies of 77%, 1% and 22% respectively. 
The incidence of OC shows large disparities between Caucasians and Blacks, with a 2-
fold greater survival rate in Caucasians than Blacks in North America [376]. OC is also 
prevalent amongst the Chinese, particularly in the north east of the country [377]. In 
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South Africa, the highest incidence of oesophageal cancer occurs in the Transkei, the 
cultural home land of the Xhosa [378]. These disparities in OC between ethnic groups has 
been an ongoing topic of research, and various genetic and environmental factors, such as 
dietary proclivities have been suggested to be risk factors in these ethnic groups. 
In our investigation, we observed significant differences for specific NAT alleles between 
Caucasian, SAC and Xhosa ethnic groups. A similar finding was also evident in the 
frequency for GST alleles, in which differences are even evident amongst individuals 
belonging to the Venda and Xhosa Black African groups. Thus these results tend to 
support our idea of the inadmissibility of extrapolating the incidence of genetic 
polymorphisms in African populations. However, given that GST enzymes are involved 
in detoxification reactions, it may be that variations in GST alleles may play a role in 
increasing the risk oesophageal cancer in the Xhosa group. 
 
 
Cataract formation and macular degeneration of the eye are major causes of visual 
impairment with which advancing age has been significantly associated. The aetiology of 
these conditions is multi-factorial and various “environmental” factors have been 
associated with cataract formation [379]. Drug metabolising enzymes such as NAT2, 
provide an important interface between environmental factors and the individual’s 
inherent metabolism of chemical compounds introduced or made in the body, and these 
alleles were investigated to provide a better understanding of the aetiology of cataracts. 
We were able to show that individuals belonging to the South African Coloured (SAC) 
group, harbouring the NAT2 slow acetylator (S) allele, had a significantly higher risk for 
cataract formation [380]. Furthermore, this association was observed in both the 
homozygous slow (SS) and heterozygous intermediate (FS) genotypes, which represent 
the slow (SA) and intermediate (IA) acetylation phenotypes, respectively. NAT2 slow 
acetylation has also been indicated as a risk factor for cataract formation in a group of 
Turkish individuals [381]. Moreover, these authors also report that only the NAT2*6A 
allele was significantly associated with the condition in this population. Whilst a link 
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between cataract formation and NAT2 slow acetylation in particular is not intuitive, the 
NAT acetylation pathway is involved in the metabolism and subsequent detoxification of 
xenobiotic compounds containing amine and hydrazine moieties [46, 48], such as 4-
aminobiphenyl, which is a constituent of tobacco smoke. In this context, it is interesting 
to note that smoking has been indicated as a risk factor for cataract formation [382]. 
However, it is not clear from the literature whether 4-aminobiphenyl is metabolised by 
NAT2 or NAT1 or both. This point may be moot, since it has been reported that both 
NAT1 and NAT2 genes are expressed in human lens epithelial cells [383]. Furthermore 
these authors indicate that the NAT genes can be inactivated by ultra-violet irradiation 
(UVB), which would further confirm the importance of the NAT enzymes in playing a 
protective role in the eye via the acetylation detoxification reactions. 
 
 
The pharmacokinetic and pharmacodynamic characteristics of INH have been well 
established in studies of adult TB patients [384]. Similar data concerning children is 
generally lacking. In a high TB-incidence country like South Africa, an increasing 
number of children are affected with TB, and therefore a study was undertaken to 
facilitate a better understanding of INH metabolism in children. In a cohort of 64 
children, with a median age of 3.8 years (range 1.8 – 7.8 years), we observed a trimodal 
model of INH elimination in children by both phenotype and genotype analyses [361]. 
These results are similar to earlier findings reported by our research group in adult 
individuals [63, 170]. More significantly, these recent results indicate a clear difference in 
the metabolism of INH between children and adults, as well as a faster elimination of 
INH in younger compared to older children. Furthermore, 23% were FA, 38% were IA, 
and SA was observed in 39% of the children. In this context it was also observed that in 
the FA group, 45% did not attain the recommended post-dose INH concentration of 1.5 
mg/l, as required to facilitate treatment efficacy. 
Given that the recommended treatment dosage range is based upon a measure of 
milligrams INH per kilogram body weight [301], it is believed that the faster INH 
elimination in children may be due to the greater proportion in liver mass with respect to 
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their body weight. Whilst this increased acetylation of INH in children has been shown in 
earlier phenotype studies, this study represents the first report to include the NAT2 
genotype analysis as confirmation of this earlier observation. 
 
 
In the subsequent study of INH acetylation in children (chapter 10) we investigated the 
pharmacokinetics of INH in children given the dose of 4-6mg of INH per kg body weight 
as recommended by the World health Organization. In this latter we investigated the 
efficacy of this WHO recommended dosage, given the findings of the previous study 
(chapter 9) which indicated that children may have a greater INH elimination capacity 
when compared to adults. Our results indicate that children given this standard treatment 
regimen attained a peak concentration 58% lower than children given 8-10 mg/kg body 
weight. Furthermore, the majority of children (70%) on the standardised treatment 
regimen achieved a peak serum INH concentration of less than 3 mg/l which may be 
ineffective in the elimination of the Mtb organism and /or achieving treatment efficacy. 
This level of peak serum INH has been shown to be reached in adults given 300 mg of 
INH daily, which is effective in achieving the maximum cure rate. Hence it has been 
recommended that in children should be given a 8-10 mg/kg dose of INH in order to 
achieve peak serum concentrations comparable to that reached in adults. Furthermore, at 
the standard dose regimen infants may beat a greater risk of achieving o low peak serum 
concentration of INH than older children due to the increased rate of INH elimination 
reported by Schaaf et al [361]. 
 
 
The early bactericidal activity (EBA) of INH achieves a log10 reduction in the number of 
Mtb colony forming units during the first two days of treatment [173]. However, despite 
this characteristic, these authors showed that the individual-specific acetylation capacity 
has a significant influenced on the EBA of INH, and FA (bearing the homozygous RR 
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genotype ) were deficient in achieving a INH peak serum concentration of 2-3 mg/ml to 
effect an optimal EBA. For this reason it has been advocated that FA should be treated 
with an increased INH dosage to off-set this apparent limitation, but that the most 
appropriate dose for treatment efficacy should be balanced against the well-known 
possibility of INH toxicity [18, 222, 385] due to the differing acetylation capacities 
inherent in FA, IA and SA. We therefore evaluated different doses of INH, ranging from 
0.2 mg/kg to 12 mg/kg against the individual-specific NAT2 acetylation activity that 
would result in an optimal EBA in a group of SAC individuals. 
The Pharmacokinetic results indicted that a 90% killing capacity (optimal EBA) occurred 
at an INH peak serum concentration of 2.19 µg/ml at 2 hours post-dose. This serum 
concentration was obtained in all individuals treated with an INH dose of 10-12 mg/kg 
body weight. At the 6 mg/kg dose 20% of FA failed to achieve this serum concentration, 
and at the lower dose of 5 mg/kg, 75% of FA did not exhibit the optimal EBA. On the 
other hand SA could be treated effectively with a 3 mg/kg INH dosage, with a minimal 
probability of drug toxicity. Similarly, no overt drug toxicity was observed among FA 
treated with INH at a dose of 6 mg/kg. Therefore in a population with a high incidence of 
FA such as the SAC, the 6 mg/kg dose would be appropriate, whereas in a population 
with predominantly SA, 5 mg/kg would be sufficient to achieve an optimal EBA, and 
hence would be more appropriate. This study presents data from a range of INH doses, 
and samples were only assayed over a short time period to assess the EBA, and hence no 
data on longer term outcomes were available However our results indicate that prior 
determination of the acetylation status in individuals would enable physicians to 
administer differing doses of INH in FA and SA to achieve the same optimal EBA. 
 
 
In the TB case-control analysis of SAC individuals from a high TB-incidence area, the 
overall acetylation activity, as described by rapid (FA), intermediate (IA) and slow (SA) 
status, was similar in these groups. However, differences in NAT2 allele (haplotype) 
frequencies were also observed between these groups. In the TB cases the 
NAT2*4/2*12B, NAT2*12A/2*5B, and NAT2*4/2*6 IA genotypes were more prevalent 
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than in the TB-unaffected cohort. Here the common feature amongst these genotypes was 
the presence of the synonymous SNPs, 282C>T and 481C>T. In the case of the SA 
individuals the NAT2*6A haplotype was significantly associated with cases rather than 
with controls (table 10.6). However, the overall slow acetylation attributed by the 
NAT2*6 class of alleles, did not differ between cases and controls, and hence it is unlikely 
that the NAT2*6A allele contributes to disease epidemiology. In this context, this 
observation remains without explanation, and may be merely a chance association. It is 
however curious that the same allele was also associated with cataract formation in SAC 
individuals. 
 
 
We next extended our investigation of NAT2 SNPs and their impact upon the acetylation 
status to SAC TB cases, treated with the standard regimen of first-line drugs, and 
intensively followed up. In contrast to the EBA study (chapter 11) the data for this study 
consisted of multiple samplings from individual patients, followed-up for two years after 
completion of the standard drug therapy. Our results show that the frequency distribution 
of the FA, IA and SA classes did not differ amongst responder (R) and non-responder 
(NR) individuals, as classified by their sputum smear microscopy (ZN-smear) and culture 
results after two months of the anti-TB treatment (standard directly observed treatment, 
sort course, (DOTs)). However, we observed a relatively low overall treatment 
conversion rate in our population, which can speculatively be ascribed to the relatively 
high proportion of rapid acetylators (homozygous (FA) and heterozygous (IA)) in this 
ethnic group compared to Caucasians, for example (table 1.6). Previous studies by our 
group have indicated that these rapid acetylators are unable to attain the optimum INH 
peak serum concentration required for maximum treatment efficacy, using the 
standardised DOTs dosing regimen of 5 mg of INH per kg body weight, because of the 
increased elimination of INH by this class of acetylators [173]. Hence the studies in 
chapters 4 and 11 are very different, and do not constitute follow-up studies as such. 
However, all information in science is interconnected and hence useful. 
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The NAT1 study represents the first analysis of NAT1 genotypes in local ethnic groups to 
our knowledge. We therefore focussed our investigation upon the analysis of the 22 NAT1 
SNPs described in the NAT consensus database. Our initial results reflected a difference 
in the NAT1 SNPs and alleles observed between the Caucasian and SAC cohorts, such 
that 16% of Caucasian and approximately 8% of SAC individuals had NAT1 variants in 
exonic SNPs. The significance of this observation requires further investigation, 
particularly since many of these exonic variants, such as for example, SNP 350, 351G>C 
(rs 72554606), have yet to be characterised phenotypically, whilst others, such as the 
777T>C (rs 4986991) SNP, encodes synonymous amino acids, which have been shown to 
have a definite effect on protein activity [305, 306, 327]. 
Interestingly, the 560G>A SNP, (which defines the loss of function allele NAT1*14), was 
observed in both ethnic groups, albeit at a frequency of less than 1% in the SAC cohort 
and 6% in Caucasians. These rare variants are often overlooked or ignored in genetic 
analyses, because they are supposed to have no appreciable effect on the disease 
phenotype due to their very low frequency of occurrence. However, recent genetic 
studies, employing whole genome sequencing (GWAS), have shown that common (more 
frequently occurring) polymorphisms may only constitute a relatively small contribution 
to the disease phenotype [282-284, 386]. In the context of these results it would be 
premature to overlook the contribution of rare variants to genetic studies since they may 
define episodes of phenotypic variation which are observed clinically. It is these low 
frequency variants which may turn out to be better candidates to elucidate subtle 
phenotypic variations. 
The most prevalent genotypes in the Caucasian and SAC cohorts were observed to be 
NAT1*4/1*4, NAT1*4/1*10, and NAT1*1/1*10, with the homozygous NAT1*4/1*4 
genotype predominating in Caucasians (54%), whilst the heterozygous NAT1*4/1*10 
genotype was the most prevalent in the SAC cohort (36%) (table 11.7). Furthermore, 
these genotype differences were statistically significant, indicating that their respective 
acetylation effects would make an important contribution to the overall NAT1 phenotype 
difference in these ethnic groups. By convention, the NAT1*4 allele is the reference 
allele, encoding a rapid acetylation activity [339, 387], whilst the NAT1*10 allele is 
presently considered to represent somewhat of an enigma. It has variously been described 
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as exhibiting an elevated acetylation activity in some studies, whilst in others it is 
assigned an acetylation status equivalent to that of the reference NAT1*4 allele [75, 110, 
159, 339, 340, 343, 387]. 
The NAT1*10 allele (genotype) is defined by intronic SNPs (1088T>A and 1095C>A) 
that are located in the 3’-untranslated region (UTR) of the gene. Similarly, the 1095C>A 
SNP defines the NAT1*3 allele. Whilst the functional effects of genetic polymorphisms in 
this domain of the gene are poorly understood [388], it has been shown that NAT1 mRNA 
undergoes differential polyadenylation, initiated in the 3’-UTR of the gene [116]. It is 
further supposed that this may facilitate differential regulation of gene expression in 
different tissues [133-135]. Therefore, given the relatively high frequency of variants 
involving the 1088T>A and 1095C>A SNPs, as observed in both the Caucasian and SAC 
cohorts, and in the light of the reports just cited, these polymorphisms would constitute an 
important area for future research. 
 
 
The investigation of the acetylation status in healthy individuals from the Caucasian, 
South African Coloured (SAC) and Black African (Xhosa) ethnic groups, from a 
tuberculosis (TB) endemic area, has shown that NAT2 slow acetylation (SA) 
predominates in Caucasian individuals, whilst intermediate acetylators (IA) were more 
prevalent in SAC and Xhosa individuals. The prevalence of IA in the SAC group may be 
particularly significant for TB treatment efficacy, since the outcome of the overall NAT2 
acetylation activity in IA would be determined by the individual rapid and slow acetylator 
alleles inherent in the individual. Whilst the effects of individual NAT2 slow alleles have 
been well characterised, the different NAT2 rapid acetylator alleles may require further 
study, particularly with regard to the contribution (s) of synonymous SNPs present in the 
allele (haplotype). In view of the high burden of TB disease in SAC individuals [259], 
and because anti-TB treatment regimens are generally standardised based upon studies of 
Caucasian individuals, it is possible that the standard TB-treatment regimen would be less 
effective in SAC individuals, due to the increased acetylation (inactivation) of INH, by 
the relatively higher proportion of rapid acetylators in the latter population group, 
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compared to Caucasians. Furthermore, in light of the high burden of TB-disease in the 
SAC community, and the association reported between the NAT2*6A allele (haplotype) 
and drug induced hepatotoxicity in an Asian population [243], it may be important to 
closely monitor SAC TB-patients harbouring this genotype. 
 
Our analysis of the NAT gene polymorphisms has highlighted the importance of 
individual SNPs and SNP-combinations (or haplotypes) in the acetylation activity of 
NAT2 in SAC individuals in particular, in South Africa. Similarly, the NAT1 analysis has 
also reflected a prevalence of certain NAT1 alleles in this ethnic group, compared to 
Caucasians. Whilst the functional effects of several of these NAT SNPs require further 
investigation, we have shown that the relative SNP and allele frequencies appear to be 
associated with certain ethnic groups, which could subsequently have an effect on the 
variation in acetylation activity in individuals from different ethnic groups, thereby 
affecting their response to certain therapeutic treatments, and/or their response to 
environmental insults. 
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